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A B S T R A C T
'1Ï
j
The 2A region of the foot-and-mouth disease virus (FMDV) polyprotein is only 16 ^
amino acids in length. During synthesis of the FMDV polyprotein, a primary 
proteolytic processing event occurs between the 2A and 2B regions of the polyprotein 
at a Gly-Pro junction. Since the 2A region is too small to be an enzyme, and there is 
evidence to rule out host protease involvement, it is proposed that the 2A segment 
represents a self-cleaving system.
Synthetic oligopeptides containing the 2A sequence have been prepared using solid 
phase peptide synthesis and their three-dimensional structures in different solvents have 
been investigated, using NMR and CD techniques. Computer modelling studies of the 
2A region have been carried out and have indicated the presence of a cis prolyl bond.
Short peptide fragments containing the sequence of the 2A region around the scissile 
bond have also been prepared by solution phase peptide synthesis and their 
conform ations examined, using NMR spectroscopy. In particular, the NPGP 
tetrapeptide, which is alleged to possess cleavage activity was prepared and its 
reactivity investigated.
The influence of prolyl cis/trans isomerism on the stmcture of polypeptides is poorly 
understood and a synthetic approach has been used to prepare cis X-Pro peptides. The 
strategy involved the formation of bicyclic compounds containing a hydrazide linkage 
with a view to breaking the N-N bond under mild conditions to give the natural cis 
X-Pro peptide. The design, synthesis and reactivity of various novel, bicyclic cis 
X-Pro dipeptides is described. These compounds represent a new class of type VI 
p-turn mimetics and as it has been shown that they can be easily extended at the amino 
and carboxy termini for incorporation into larger peptides. X-ray crystal structures for 
some of the compounds and intermediates are presented. Investigations into the 
reductive cleavage of these compounds were carried out and some were found to 
display unusual reactivity with the chosen reduction method. In particular, a novel 
intram olecular transam idation reaction is reported and its mechanism has been 
investigated by the use of various substituted derivatives.
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CHAPTER 1: INTRODUCTION
1.1 Viruses
1.1.1 Introduction
A virus is an infectious agent of small size and simple composition which can 
multiply only in the living cells of animals, plants, or bacteria. Outside a living cell a 
virus is a dormant particle, but within an appropriate host cell it becomes an active 
entity, capable of subverting the cell’s metabolic machinery for the production of new 
virus particles. Historical descriptions of viral diseases date as far back as the 10th 
century BC. The concept of the virus, however, was not established until the last 
decade of the 19th century, when several researchers gained evidence that agents far 
smaller than bacteria were capable of causing infectious diseases.
The question of whether viruses are actually micro-organisms (similar to very tiny 
bacteria) was resolved in 1935, when the virus responsible for causing mosaic disease 
in tobacco was isolated and crystallized; the fact that it could be crystallized proved I
that the virus was not a cellular organism. A virus consists of a single or double I
stranded nucleic acid core surrounded by a protein capsid. The capsid protects the 
nucleic acid from enzymic attack and mechanical breakage, delivering it intact to a 
susceptible host. In some of the more complex vimses, the capsid is surrounded by 
an envelope that contains fatty material (lipids) and glycoprotein. The complete 
extracellulai* product of vims multiplication is called a virion or vims particle.
As well as the importance of understanding the viral infections of animals and man, 
there is much current interest in viruses for several other reasons. First, vimses are 
capable of adapting themselves over time and are therefore sources of insight into 
evolutionaiy processes as well as the molecular aspects of host-parasite relations.
Second, some viruses cause cancers in animals and the possible role of viruses in 
human cancers is being intensively studied.  ^ Third, viral multiplication is a model for 
cellular development because it requires the sequential expression of genes and the 
assembly of macromolecules to form highly ordered stmctures.
Viruses are classified according to the host that they infect: plant, animal or bacteria.
W ithin these three main classes, viruses are grouped according to their chemical 
composition (type of nucleic acid, presence or absence of a lipid envelope) and their 
size and shape.
1.1.2 RNA viruses
One of the most striking discoveries made by virologists this century was that the 
extreme volatility and rapid evolution of some viruses results from the storage of their 
genetic codes in RNA rather than DNA - a phenomenon not found in any other living 
organisms.
Because their genetic material is RNA instead of DNA, RNA viruses are of great 
biological interest. Clearly, their replication must involve radically different 
mechanisms from those involved in DNA vims replication. For example, the use of 
RNA as a template instead of the usual DNA means that enzymes are required which 
are unlikely to be found in the uninfected cells of the host. Such enzymes therefore 
have to be virus-encoded.^ Like DNA viruses, the crucial factor in the successful 
infection of a cell is the production of viral mRNA.
RNA viruses are divided into two groups depending on the nature of their RNA 
genome:
1. Positive-strand viruses in which the input RNA genome acts as mRNA; these 
RNA genomes are infectious and, when applied to cells, the purified RNA can 
initiate a complete infectious cycle of vims replication.
2. Negative-strand viruses in which the input virus RNA genome is transcribed 
into mRNA. RNA viruses o f this sort contain a transcrip tase of 
RN A -dependent RNA polym erase within their particle and since the 
transcriptase is essential for infectivity, the purified RNA genome is not 
infectious.
Foot-and-m outh disease virus (FMDV) is an example of a positive-strand RNA 
vims. 3 In order to replicate, this type of virus particle has to enter a cell, uncoat and 
deliver its genome intact to the cellular translation machinery where it behaves as 
mRNA and protein is produced. A complex pathway of proteolytic processing 
follows to produce the mature virus particles. The genome also has to act as the 
template for replication by the vims encoded RNA polymerase so that both viral RNA 
and virus proteins are produced. New virus particles assemble and are released on 
cell lysis. FMDV is able to complete this cycle of events in about four hours in tissue 
culture and in the process may produce 100 000 particles from a single cell.
The principal steps in the replication of positive-strand RNA vimses once inside a 
host cell aie illustrated in Scheme 1.1 and described overleaf.
After uncoating, the RNA genome of the infecting particle functions as virus mRNA 
and attaches to host cell ribosomes for translation into virus-specified proteins; 
FMDV RNA is polycistronic, i.e. it codes for a single very large polyprotein,3
Translation: The viral mRNA is translated into a single very large polyprotein which 
is divided into structural and non-structural proteins. These are produced from the 
large protein by cleavage due to the action of virus-encoded proteolytic enzymes. 
The cleavage is a complex process and takes place in several stages.4 The proteins 
finally produced include RNA-dependent RNA polymerase and four capsid proteins.
Virus RNA synthesis: New RNA molecules are replicated by a virus-encoded 
enzyme: RNA-dependent RNA polymerase. This enzyme is produced by cleavage 
from the large polypeptide which is the primary product of translation. Virus RNA 
synthesis takes place in the following stages:
1. A second (negative) RNA strand, which is complementary to the input positive 
RNA genome, is produced with formation of a double-stranded RNA stmcture 
known as the replicative form.
2. New positive RNA strands are synthesized, using as a tem plate the 
complementary negative RNA strand of the double-stranded replicative form.
The new (positive strand) RNA molecules have three functions:
1. Templates for the manufacture of more replicative forms for further synthesis of 
RNA genomes.
2. Genomes for new virus particles: RNA molecules which become genomes in 
new vims particles have a small protein linked to their 5 ' terminal.
3. Virus mRNA: the newly synthesized RNA which acts as mRNA does not 
become encapsidated as the genomes of new particles.
Assem bly: After replication, the new virus particles are assembled on clusters of 
ribosomes in the cytoplasm. The new particles are released by sudden mpture of the 
cell.
+  +
>. translationrelease
CDassembly
viral protein
cleavage
RNA-dependent 
RNA polymerase
structural
proteins
Scheme 1.1: Life cycle o f a positive strand RNA virus
1.1.3 Picomaviruses
One of the lai*gest groups of animal viruses is the picomaviruses which lists among its 
members a diverse variety of pathogenic agents. The name comes from the Greek 
pico which means tiny and RNA which is the form in which the viruses store their 
genetic information.
Picom aviruses are non-enveloped and have a 25-30 nm capsid o f icosahedral 
symmetry. They have been subdivided, on the basis of chemical properties such as 
pH stability and buoyant density, into four main genera: entero-, rhino-, cardio- and 
aphthoviruses. The known picomaviruses are listed below, grouped into the four 
main classes.
Table 1,1: Classification o f pircornaviruses
Genera Virus
□  Aphthovimses
□  Cardiovimses
FMDV (foot-and-mouth disease virus)
EMCV (encephalomyocarditis virus)
Mengovims
TMEV (Theiler’s murine encephalomyelitis vims)
□  Enteroviruses Poliovims
Coxsackievirus
Echovims
Enterovims 70
Swine vesicular disease vims
Bovine enterovims
Hepatitis A vims
□  Rhinoviruses Human rhinovims
Each type of vims has a number of different strains or serotypes - for example, there 
are seven serotypes of FMDV which constitute the aphthoviruses and there are over 
100 serotypes of the human rhinovims (the major cause of the common cold). 
Altogether, there are over 230 picornavims serotypes. ^
In spite of the disparate afflictions caused by these agents, all picornavimses share 
remarkable similarity in their genome and capsid organisation.^ Complete or partial 
nucleotide sequences are now available for more than 90 strains of picornavimses, 
including representative members from all classification groups.3 Also, the three- 
dimensional crystal structures have been solved for several of the most interesting 
types - that of FMDV was published in 1989 (Fig. 1.1). &
D espite the m odest protein capsid structures and small RNA genom es that 
characterize this family, picornavirus-caused diseases are of enormous medical and 
agricultural importance. Infection with rhinovims for example, better known as the 
common cold, is among the most prevalent and acute of human upper-respiratory 
illnesses. Each year, this virus exacts a high toll from every economic and social 
institution, as cold-related absenteeism is the single largest cause of lost work days 
for schools and businesses,
Poliovims, another well known member of the picornavirus family, has likewise 
afflicted human population for as long as recorded history. Even today, in the 
presence of modern vaccines and sanitation technology, many thousands of new cases 
are chronicled annually, especially in developing countries. The unfortunate results 
produce economic hardships from loss of productive m anpower and from the 
obviously difficult medical burdens incurred in patient care.
mFigure 1.1: Crystal structure o f FMDV^
1.1.4 Foot-and-mouth disease virus
Animal populations are also susceptible to picornavirus infections. Foot-and-mouth 
disease virus (FMDV) is one of the most virulent pathogens ever described. It affects 
practically all cloven-footed mammals, including many varieties o f commercial 
livestock, namely pigs, sheep, goats and cattle. The disease is characterized by the 
formation of painful fluid-filled blisters on the tongue, lips, and on other parts of the 
body where the skin is thin, such as between the two toes of the feet.
The losses caused by foot-and-mouth disease are tremendous. Malignant forms of the 
disease have led to losses of up to 50 percent and in those animals that survive, great 
losses in weight occur because the animals cannot eat. The virus can survive for 
relatively long periods of time in the air, in food, and even in hides, hair and wool, so 
measures for controlling the disease are necessarily rigorous.
1.1.5 Control of foot-and-mouth disease
In countries such as Great Britain, where the disease arises only as a result of 
imported infection, the accepted policy is to stamp it out by slaughtering all affected 
stock and any other animals which have been exposed to the risk of infection. 
Slaughtered carcasses, plus bedding and other infected material must either be burnt 
or buried under six feet of earth. The farm must be thoroughly disinfected and cannot 
be restocked for a further six weeks. In addition to this, restrictions are placed on the 
movement of all livestock within a ten mile radius, known as the infected area.
Following the disastrous epidemic of 1967-8, which involved 2397 outbreaks and 
payments in compensation to owners of slaughtered animals of about £27 million, a 
committee was appointed under the chairmanship of the Duke of Northumberland to 
review  the policy and arrangem ents for dealing with the disease. The 
Northumberland committee recommended continuation of the slaughter policy. It 
further advised reinforcement by a ring vaccination scheme if meat import restrictions 
were not implemented.
There are several reasons why it is hoped that these measures will never be used. 
First, once Britain becomes an infected country, it will lose many of its export 
markets. Second, because there are a variety of different strains of FMDV, the 
vaccine in use may not be totally effective. Third, vaccinated animals can become
carriers, shedding infection to other stock. Finally, to give full protection, vaccination 
would have to be carried out each year and in the long term, this would be much more 
expensive than the current slaughter policy.
Considerable attention is being paid to methods of preventative inoculation and 
vaccines are widely used on the European mainland, in South America and Africa. 
Up to the present day, however, no method has been used in Europe which will give 
an animal immunity to more than one or two of the several strains of virus which can 
cause the disease. Another disadvantage is that generally, immunity lasts only six 
months. In countries where the disease is endemic and its incidence high, such as 
Ai*gentina, Germany, Italy and Spain, comprehensive vaccination is seldom practical 
for reasons of cost. Instead, ring vaccination of all susceptible animals within a given 
radius is usually practised. Other countries such as Denmark, Sweden, Switzerland, 
Holland and Mexico adopt a combined slaughter and vaccination policy.
1.1.6 Vaccines
There is no general useful therapy for viral infections in any way similar to antibiotic 
therapy for bacterial disease. The vaccines that aie currently employed are produced 
from chemically inactivated forms of the virus. There are several problems with the 
use of such vaccines.
1. There are a variety of different strains of FMDV and several of these are 
difficult to grow in sufficient abundance to provide enough material for 
effective vaccination.
2. The virus particle is unstable, especially under acidic conditions and at warm 
temperatures. Thus it is necessary to refrigerate vaccines to retain their 
potency which is clearly a major limitation, particularly in tropical climates.
3. There have been several cases of outbreaks of disease due to improperly 
inactivated virus.
The concept of using a peptide vaccine stems from work on the tobacco mosaic virus 
which showed that a segment of the coat protein would elicit an antibody which 
reacts with the virus particle.^ Clearly, the use of synthetic peptides as therapeutic 
agents would circumvent the hazards of working with large scale production o f the 
infectious virus.
Of the four capsid proteins of FMDV, (VP1-VP4), only V Pl has been shown to have 
an important antigenic role.^ V Pl was found to be the only capsid protein which 
induced neutralizing antibody responses against FMDV.^^ Treatment of the virus 
particle with trypsin, which causes the cleavage of V Pl only, results in a drastic 
reduction of the infectivity of the virusJhi2  Several trypsin-sensitive regions within 
V P l have antigenic activity, the most significant being the region bounded by 
residues 130 and 160 with a minor contribution from residues 200 to 213 at the 
extreme carboxyl terminus. The major immunogenic site on V Pl (130-160) has been 
structurally characterized in detail using X-ray c r y s t a l l o g r a p h y  and consists of a 
mobile surface loop connecting two p-strands (Fig. 1.2). The residues Arg-Gly-Asp 
(145-147) are known to be particularly im portant as a recognition site for cell 
attachment and in V Pl, the RGD sequence is highly conserved and centrally placed in 
the loop as shown in the diagram below. The same triplet has been located in an 
external loop of the coat protein V Pl of the human rhinovirus^ and it has been 
proposed that this unit is involved in the binding of the virus particle to the cellular 
r e c e p t o r .  ^ 4 ,1 5  Further work is required to establish the identity of the cellular receptor 
for FMDV and to ascertain the nature of the interaction of the virus particle with it.
155,
CYS134
148 ,
0 1 4 7
0 1 4 6
Figure 1.2: Major immunogenic loop o f FM DV
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1Chemically synthesized peptides corresponding to two different regions of the V Pl 
protein (Y130-P160 and R200-L213) produced significant levels of serotype-specific 
vims neutralizing antibodies in cattle, guinea pigs and rabbits. Protection of cattle 
against FMDV was achieved after a single immunization with a 40 residue peptide 
which consisted essentially of the two previously identified immunogenic regions 
connected by a diproline spacer. Various experiments were carried out with a range 
of peptides containing either or both of the two significant s e q u e n c e s .   ^7 These 
experiments showed that the most effective structure, in terms of protection is one in 
which both sequences are present with no additional amino acids. Although the 
sequence Y 130 to P I 60 appears to be the major site for generation of neutralizing 4
antibodies, the additional presence of the sequence R200-L213 significantly increases 
the potency of the peptides.
One of the disappointing aspects of FMDV peptide vaccines has been their relatively 
poor performance in cattle compared with the high promise shown in guinea pigs. It 
has been suggested that to realise their potential as vaccines, the peptides must 
contain domains which react with helper T-cell receptors in addition to binding sites 
for anti-protein antibodies. Preliminary experiments have shown that genetically 
controlled non-responsiveness to a peptide can be overcome by adding an additional f
helper T-cell epitope from a different protein. Mice, which are non-responders to - 
immunogenic peptides of FMDV will respond to the same sequences when they are 
linked to helper T-cell determinants from sperm whale myoglobin.
Two very recent studies have used novel approaches, which do not focus on V Pl as a 
therapeutic target, to try to disable the virus. Lewis et a l  have demonstrated that 
empty virus capsids isolated from  infected cells antigenically resem ble virus 
particles. They have constructed FMDV clones which can express, in an 
appropriate host, conformationally correct immunogens which lack nucleic acid and 
could make effective and safe vaccines. Plasmids containing the FMDV structural 
protein precursor PI and the 3C proteinase genes were expressed in E, coli. This 
resulted in the efficient synthesis and processing of P I and assembly of the resultant 
proteins into empty capsids. This material elicited a significant neutralizing antibody 
response in vaccinated guinea pigs but has yet to be tested in cattle.
The FMDV leader proteinase L, possesses considerable potential as a target of 
antiviral drug th e r a p y .K le in a  and Grubman have shown that the thiol proteinase 
inh ib ito r E -64  (S - rm nj-epoxysuccinyl-leucylamido-(4-guanidino)-butane) (1) 
specifically blocks autocatalytic activity of the proteinase L and interferes with the 
cleavage of the structural protein precursor P l.^ i L proteinase activity is specifically
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and irreversibly inhibited by E-64 and its analogues, and inhibition of the L 
proteinase initiates a cascade of events that affect the replication o f FMDV. 
Processing of the structural protein precursor PI is blocked, leading to improper 
assembly of the viral capsid .22 The L proteinase is an ideal candidate molecule for 
antiviral compounds as among the serotypes of FMDV, L proteinases share greater 
than 90% homology at their amino acid level. E-64 blocks the autocatalytic activity 
of the L proteinase in all serotypes tested. Thus, an antiviral agent that attacks L 
w ould circum vent the problem s of serotype-specific reactions observed with 
conventional FMDV vaccines.
NH
U
N NHo HHN
(1): Thiol proteinase inhibitor E-64
1.1.7 Structure of FMDV
The virus particle (25-30 nm in diameter) consists of a single copy of the genome 
packaged in an icosahedrally symmetric protein capsid composed of 60 copies of the 
four structural proteins, VPl-4.^ The primary functions of the viral capsid are:
1. To interact with specific cellular receptors on susceptible host cells in a manner 
that results in the internalization of the genome.
2. To selectively package the newly synthesized genome.
3. To facilitate the eventual exit of the new virus particle.
The icosahedral capsid is assembled from pentameric intermediates, each composed 
of five copies of V Pl, VP3 and a precursor protein, VPO, in which VP4 and VP2 are 
covalently linked (Scheme 1.2).23 Cleavage of VPO, one of the final steps of capsid 
assembly, may be related to encapsulation of the nucleic acid and stabilization of the 
mature p a r t i c l e . 2^ .25 the surface of the vims, the area surrounding the fivefold axis
of the pentamer is composed of the main capsid proteins, VP 1-3. VP4 is much
smaller, has an extended conformation and is located internally underneath the other 
proteins.
1 2
One or two copies of VPO remain uncleaved in each capsid, the functional 
significance of this observation being u n c le a r .  26 The pentam ers appear to be 
stabilized by interactions between the N and C termini of V Pl and VP3 together with 
VP4. Adjacent pentamers are held together by hydrogen bonds between parts of VP2 
and VP3 and it is thought that the weakness of these interactions may be important in 
the uncoating of the viruses. ^  The icosahedral shell surrounds the RNA genome 
which is linked covalently to a small virus-encoded protein, VPg.27 Upon entry into 
the cell and following uncoating, this RNA is translated into one long polyprotein 
which is cleaved by at least two viral proteinases to give the structural and non-
structural p r o t e i n s .  ^ > 2 8
i
Pentamer
Immature virus
V P O
P I
V P 3
;■H
V P 4  V P 2  V P 3
V P l
V P l
Mature virus
Scheme 1.2: Assembly and maturation o f the FMDV virion
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The major portion of the virus genome is a single very large open reading frame of 
6996 nucleotides encoding a polyprotein of 2332 amino a c i d s . 2 9 ,3 0  The polyprotein 
may be considered as four different components, termed L, P1-2A, P2 and P3. The 
P1-2A section is the precursor of the capsid proteins while the P2 and P3 precursors 
are processed to non-structural proteins involved in virus RNA replication and protein 
processing.
The structure of the foot-and-mouth disease virus has been determined at close to 
atomic resolution by X-ray diffraction (Fig. 1.1).6 Unlike other picornaviruses, 
FMDV does not possess any major depressions or pits on its surface and as VP 1-3 are 
substantially smaller, the protein shell is generally thinner.^ The smoothness of the 
surface has important implications for cell attachment and it is thought that FMDV 
binds to cellular receptors via a small, flexible exterior loop on V Pl (Fig. 1.2). 
Another unique property of FMDV, which is not demonstrated by any of the other 
picornaviruses is extreme susceptibility to acid induced dissociation. It has been 
suggested that the high number of histidine residues lining the pentamer interfaces is 
responsible for the instability of the virus below pH 7J5 It may be that the acid 
sensitivity of the virus is a necessary prerequisite for rapid and efficient uncoating 
within the cell.
The structural proteins VP 1-3 consist of eight strands of p-sheet arranged as a 
sandwich of two four-stranded sheets. The tertiary structure is formed by a p-hairpin 
bend which results in a wedge shaped molecule which fits well around the five-fold 
axes of the icosahedral capsid (Fig. 1.3).
Figure 1.3: Structure exhibited by the three external capsid proteins
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1.1.8 Polyprotein processing
In the life-cycle of all picornaviruses, the RNA genome is translated into a very long 
polyprotein which undergoes a complicated series of proteolytic processing events to 
produce the mature virus particles. Several excellent reviews have been published on 
picornaviral polyprotein processing.^’^ -^^ b^ a The complete polyprotein is never 
observed within infected cells since some of the processing events occur extremely 
rapidly, probably while the translation process is still occurring.
A three-tiered cascade of primary, secondary and maturation cleavages efficiently 
produces the spectrum of viral proteins necessary for a productive infection. All the 
active proteins associated with picornaviral processing (2A, L, 3C and VPO) are 
encoded by viral genomes and no cellular components are required. Enzymic self- 
sufficiency must clearly be an advantage to a highly mobile pathogen and may 
explain in part why the picornaviruses can efficiently infect a diverse variety of hosts 
with such virulence and obvious success.
The three phases of viral processing are described below.
1. P rim ary  cleavage.
These processing events are cotranslational, occurring as the ribosome moves 
along the genome. In FMDV, the polyprotein is rapidly processed into four 
primary cleavage products: L, P1-2A, 2BC and P3 as shown in Fig. 1.4, These 
primary cleavages involve all three viral proteinases: L, 2A and 3C.
2. Secondary cleavage.
This phase involves the subsequent processing of the primaiy cleavage products 
into all the mature viral proteins necessary for establishment and completion of 
a successful infectious cycle. An example is the processing of the precursor 
protein PI by the viral proteinase 3C to give the capsid proteins (VP1-VP4 or 
lA -lD ). The details of 2BC and P3 secondary processing have not been fully 
characterized in FMDV or other picornaviruses but it is known that 3C is solely 
responsible for all secondary processing r e a c t i o n s .  2 0 ,3 3 ,3 4
3. M atu ration  cleavage.
This is the final cleavage within picornaviral polyproteins and involves the 
processing of the VPO structural protein into VP2 and VP4. The cleavage only 
occurs on encapsulation of viral RNA to produce virus particles (Scheme 1.2) 
and the mechanism is so far u n k n o w n . 2 3 , 2 4
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PRIMARY POLYPROTEIN CLEAVAGES
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Figure 1.4: Picornavirus primary polyprotein cleavages
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1.1.9 Primary polyprotein cleavages
There are three primary processing events which occur w ithin in the FMDV 
polyprotein to produce the primary cleavage products: L, P I, P2 and P3.
1. The L /P l cleavage
The FMDV L protein is located at the N-terminus of the polyprotein and is the first 
gene product released from the nascent polyprotein.^s Thus, in FMDV, the first 
processing event is uniquely the L /P l cleavage. In cardioviruses, the only other 
picornaviruses which have an L protein, the L /Pl junction is cleaved by the 3C
proteinase. 14
2. The 2A/2B cleavage
The second very rapid cleavage event within the FMDV polyprotein occurs at the 
2A/2B junction. In contrast to entero- and rhinovimses, the cleavage in cardio- 
and aphthovirus polyproteins occurs at the carboxy terminus of their 2A regions, 
releasing a P I -2A precursor by autocatalytic cleavage. This junction always 
appears completely cleaved, even using in vitro translation assays^^.se and the 
cleavage has been shown to be independent of both L and 3C.36 In cardioviruses, 
the 2A/2B cleavage is attributed to the 2A proteinase which contains 143 amino 
acids. 32 In FMDV, a similar cleavage occurs but the 2A region is only 16 amino 
acids in length.30 Studies on cardioviruses have shown the 2A/2B cleavage to 
possess characteristics of a cotranslational intramolecular cleavage: insensitivity to 
dilution and resistance to a range of proteinase inhibitors. 3?
3. The 2C/3A cleavage
The P3 region of the polyprotein contains the 3C proteinase which mediates not 
only the 2C/3A primary cleavage but all subsequent secondary cleavages. The 
mechanism of the 2C/3A cleavage is not fully understood but it is known to be an 
intramolecular cleavage for which the 3C proteinase is solely responsible.
1.1.10 Viral proteinases
Proteinases play a key role in the replication cycles of many v i r u s e s .  2  One or more 
proteinases are usually involved and can be of host or viral origin. Host proteinases 
are frequently involved in the maturation of viral proteins that are eventually
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associated with the viral envelope whereas viral proteinases usually function in the 
cytoplasm of the host cell early in the replication cycle, 4
Virus-encoded proteinases appear to fulfil one of two functions during the replication 
cycle. First, most are involved in the processing of a high-m olecular weight 
polyprotein into functional gene products. The second general process involves the 
maturation of structural proteins during the virion assembly process.
In viral proteolytic processing, two types of cleavage events are observed: a cis or 
monomolecular reaction and a trans or bimolecular reaction. In cases of cis cleavage, 
the reaction is intramolecular, dilution independent and follows zero-order kinetics. 
The cis reactions, which are often quite rapid and occur during translation are also 
referred to as ‘autocatalytic’. The trans reaction is exemplified by a protein with 
proteolytic activity cleaving a second molecule which contains the substrate cleavage 
site. This is an intermolecular reaction which proceeds with second-order kinetics 
and is sensitive to dilution.
In FMDV, there are three identified virus-encoded proteinases. These are described 
below and discussed in relation to their counterparts in other picornavimses.
1. The L proteinase
Amongst the picornaviruses, only the cardioviruses and FMDV have an L or 
‘leader’ protein, situated at the poly protein N terminus and only in FMDV is the L 
protein a proteinase.38 The precise nature of L is not known but recently, a thiol 
proteinase inhibitor has been shown to inhibit its function in FMDV, suggesting 
that L is a cysteine-type proteinase,21 The main function of L in aphthoviruses is 
thought to be the suppression of host protein synthesis in infected cells.20 This is 
achieved by inactivation of the cap-binding protein complex which is required for 
the formation of ribosome initiation complexes with capped mRNAs. The L 
proteinase proteolytically cleaves p220, a component of the cap-binding protein 
complex resulting in the shutoff of host cell translation during infection by
FMDV. 22
2. The 3C proteinase
All picornaviruses use the activity of viral polypeptide 3C as their major source of 
proteolytic cleavage activity.4 As all 3C processing reactions aie sensitive to thiol 
inhibitors, the proteinase was originally categorized as a cysteine-type agent.31 
Subsequently, sequence comparisons have shown that picornavirus 3Cs are
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probably more closely related to serine proteinases and bear a strong resemblance 
to trypsin and c b y m o t r y p s i n . 2 , 2 6  Thus, it seems that the 3C proteinases, although 
containing a nucleophilic thiol residue, are structurally similar to certain cellular 
serine proteinases. X-ray crystallographic studies are needed to show the true 
structure of the active site. All picornavirus 3C proteinases have a high substrate 
specificity and almost exclusively catalyse the proteolysis of viral precursor 
p o l y p r o t e i n s . 2 0 ' 3 9  addition to strict substrate requirements for proteolytic 
cleavage, the 3C proteinases have interesting properties as enzymes, participating 
in both uni- and bimolecular reactions.40 EMCV 3C has been shown to cleave 
itself from precursors in an autocatalytic manner and also to participate in the 
cleavage of substrates in dilution-dependent bimolecular reactions.37
3. The 2A proteinase
Cleavage by the 2A proteinase in aphtho- and cardioviruses is fundamentally 
different from that of the rhino- and enteroviruses. The FMDV 2A proteinase 
cleaves at its C terminus to generate a P I -2A intermediate. In contrast, the 2A 
proteinase of the rhino and enteroviruses performs a cis cleavage at its own N 
terminus to separate the PI precursor from the growing 2A-P2-P3 polyprotein. 
Interestingly, the 2A proteinase of rhino- and enterovimses also has an important 
trans cleavage activity, indirectly inducing cleavage of the p220 component of the 
cap-binding protein complex through activation of latent cellular proteinases.4i 
This results in selective inhibition of host cell protein synthesis. Thus, the rhino- 
and enterovirus 2A proteinases are perform ing the function for w hich 
aphtho viruses have evolved a separate proteinase, L (see above). It should be 
noted that for cardioviruses, neither the L protein nor the 2A proteinase have 
shown any activity which would lead to cleavage of p220.
On the basis of sequence alignment and site-directed mutagenesis studies, rhino- 
and enterovirus 2A proteinases have been shown to resemble trypsin-like serine 
proteinases but with an active-site cysteine nucleophile instead of s e r i n e . 4 2 , 4 3  The 
activity of the cardio- and aphthovirus 2A proteinases has not yet been resolved. 
Although cardiovirus 2A proteins contain 143 residues, the FMDV 2A region is 
only 16 amino acids in length and it is unprecedented for such a short peptide 
sequence to have the ability to mediate autocatalytic cleavage. It has not been 
conclusively proven whether the 2A/2B junction is very efficiently recognized by 
host proteinases in a wide variety of host cells or whether the 16 amino acids 
represent a veiy small self-cleaving proteinase.
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1.1.11 FMDV 2A: active element or passive substrate?
There are three explanations which may account for a cotranslational cleavage event
occurring with such a short amino acid sequence.
1. FMDV 2A functions as a substrate for a cellular proteinase which, to account 
for the observed cleavage kinetics, would need to be closely coupled to 
translation.
2. The FMDV 2A sequence in some manner disturbs the normal peptide bond 
formation during translation.
3. The FMDV 2A sequence possesses an entirely novel type of proteolytic 
activity.
Various investigations have provided evidence which is consistent with the third 
possibility.
□  FMDV 2A shows high sequence similarity to the C terminal region of the much 
longer 2A protein of cardioviruses. Molecular biology studies have shown that 
when the amino-terminal two-thirds of EMCV 2A (Table 1.1) are deleted, this 
does not block its proteolytic activity.43
□  Cleavage at the FMDV 2A/2B junction shows characteristics of a unimolecular 
event e.g. insensitivity to dilution and resistance to a range of proteinase
inhibitors. 32,36
□  The cleavage occurs in a range of heterologous expression systems: rabbit 
reticulocytes, human HTK-143 cells, wheatgerm extracts and insect cells. 36,44
□  Recent studies have shown that introduction of a 16-19 amino acid segment, 
including the FMDV 2A sequence, into a totally foreign protein induces 
cleavage of the novel protein at the 2A/2B junction. 44,45
Although the mechanism of FMDV 2A mediated cleavage is not yet understood, its 
utility is apparent. The strategy of self-processing polyproteins may be adapted in 
many applications to enable the coordinated and stoichiometric expression of multiple 
proteins from a single open reading frame.
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1.2 Peptide structure
1.2.1 Protein and peptide conformation
One striking characteristic of proteins is that they have w ell-defined three- 
dimensional structures. A denatured protein, which consists of a randomly arranged 
polypeptide chain is devoid of biological activity. The biological function o f a 
protein is, therefore, dependent on its conformation, which is the three-dimensional 
arrangement of its atoms.
Small peptide fragments of proteins have also been shown to adopt relatively stable, 
well-defined structures in both organic solvents and aqueous s o l u t i o n . 4 6 - 6 3  general, 
short linear peptides are more likely to exhibit structure in organic solvents than in 
aqueous s o l u t i o n . ^ b 6 4  Common structural features adopted by linear peptides are 
p-turns and helices w hich are m ost often detected in solvents such as 
dimethylsulfoxide (DMSO), trifluoroethanol (TFE) and methanol. The ability of 
membranes to influence the conformation of short peptides has also been illustrated in
several instances. ^ 2
Since the FMDV 2A polypeptide has been shown to be active in foreign proteins, it 
can be assumed that its active conformation is not structurally dependent on other 
parts of the FMDV p o l y p r o t e i n . ^ 3 , 6 6  The 2A region is probably not large enough to 
contain tertiary structural elements so one must consider its three-dimensional 
conformation in terms of secondary structural units such as turns, helices and 
p-sheets.
1.2.2 Conformation and mechanism of 2A
The self-cleavage hypothesis involves cleavage as an intrinsic property o f the 2A 
region, which may form a structure that is unstable under physiological conditions. 
Computer modelling studies and experimental results (see chapter 2) have indicated 
that a favourable conformation for the 2A peptide would contain an a-helical region 
and also a reverse turn in the carboxyl terminal section. Calculating the most 
energetically favourable conformation of the 2A  peptide will provide strong clues as 
to its mechanism of action.
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If the 2A peptide is indeed a small, self-cleaving proteinase, then it must have a 
suitable nucleophile positioned close to the Gly-Pro scissile bond.
Many groups in active sites of enzymes serve as acid or base catalysts acting upon 
different groups in a substrate and thereby contributing to rate acceleration. 
Concerted general acid or base catalysis is particularly effective. Several amino acid 
side chains can act as general acid or base catalysts in enzymes, including those of 
glutamic acid, aspartic acid, lysine, tyrosine, histidine, serine and cysteine. In their 
protonated forms they are acid catalysts, and in their unprotonated forms they are base 
catalysts.
The FMDV 2A region does not contain any cysteine, tyrosine or histidine residues. It 
contains one serine residue but from mutation experiments, it is not thought to be 
involved directly in c a t a l y s i s . Site-directed mutagenesis studies have also shown 
that the Glu, Asp, Lys and Asn residues in 2A are essential for c l e a v a g e . ^ 7  since only 
one of these is likely to act as a nucleophile in the cleavage mechanism, the others 
must all be important from a structural point of view. Molecular modelling studies 
have shown that in one energetically favourable conformation, the aspartate residue 
could be situated close to the scissile bond, with a strong hydrogen bond existing 
between the Glu and Asn residues (Fig. 1.5). Therefore, a possible mechanism for the 
mode of action of FMDV 2A is one where an acidic residue, such as Asp, participates 
in a general base catalyzed hydrolysis of the Gly-Pro bond (Scheme 1.3).
Gly
Asp ProO
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Scheme 1.3: Possible mechanism o f cleavage o f the FM DV 2A peptide
The aspartate residue can only be situated sufficiently close to the cleavage site if  the 
Gly-Pro amide bond is in the cis conformation. This causes a sharp p-bend in the 
peptide backbone. An optimised structure of the 2A region in a potentially cleavable 
conformation (calculated in a low dielectric medium) with a cis Gly-Pro bond is 
shown overleaf (Fig. 1.5).
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Figure 1.5: Optimised structure o f the 2A region in a low dielectric medium
M olecular biology experim ents have been carried out in w hich a series of 
recom binant polyproteins were constructed by deleting either the upstream  or 
downstream context of the 2A r e g io n .A n a ly s i s  of the processing properties of 
these recombinant polyproteins showed than the sequence of the region downstream 
of the N-terminal Pro of 2B did not affect cleavage activity and the upstream context, 
although influential in, was not crucial for activity. Other deletion experiments 
showed that truncated versions of the 2A region in which the first few N-terminal 
residues were removed could also mediate cleavage.
In the FMDV polyprotein 2A region, the sequence at the cleavage site is Pro-Gly-Pro 
with scission occurring between the glycine and the second proline. The presence of 
a proline residue in a peptide or protein is expected to result in unique conformational 
preferences that may, or may not, be biologically significant.^^ In globular proteins, 
most proline residues occur at protein-aqueous interfaces, where they are involved in 
p-tums. Only 12% of prolines were found to be buried in protein interiors, compared 
with 38% for an average amino acid.^^
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11.2.3 Structural influence of proline
The influence of proline on secondary structure can be summarised into three main 
classes.
^  Proline is a classical breaker of a-helical structure in proteins. It is hardly ever 
found at the carboxyl terminus of a helix and is rarely in the centre o f this 
structure.
^  A  high proportion of proline residues are found in reverse turns. Over 48% of 
prolines which are followed by glycine are involved in a tum.'^o 
^  W ith proline, the possibility of cis/trans isomerism of the X-Pro peptide bond 
arises. The observed abundancy of cis X-Pro bonds in small peptides is 
between 10 and 30%, as compared to less than 0.1% for other amino acids.
W hile individual proline residues are tolerated in P-strands and the first turn of 
helices, proline pairs, whether adjacent of separated by several residues, strongly 
inhibit the formation of classic secondaiy structural units. Thus, proline-rich regions 
of proteins are unlikely to adopt conventional stmctures.
Proline residues occur in many proteins as random single units, in pairs or included in 
multiple tandem repeats. Perhaps the most striking of these is the one observed in 
the circum sporozoite protein of Plasm odium  fa lciparum  (one of the malarial 
parasites) where Asn-Ala-Asn-Pro is repeated 37 t i m e s . ' ^ 2 , 7 3  o th e r proline-rich 
proteins have been isolated and chaiacterized from diverse sources, including bovine K
colostrum, rat prostate, serum chylomicrons and the respiratory tract, in addition to ^
the saliva of rats, humans and rabbits.
There are very few crystal structures of proline-rich regions in proteins so most of the 
structural information on such sections has come from NMR and CD spectroscopy as 
well as predictions from molecular modelling studies.^ ^  It is thought that the role of 
proline in such regions is to stabilize extended structures, such as the polyproline II 
helix, an extended structure with three residues per turn. This is the preferred 
conformation in solution for a sequence of four or more consecutive prolines and is 
also commonly adopted by repeat sequences in which every third residue is a proline.
Many viral proteins are now known to contain segments rich in proline repeats, for 
example, polyoma V Pl protein, simian virus 40 V Pl, influenza virus haemaglutinin 
and hepatitis B core antigen. A nuclear protein in Epstein-Barr virus has no fewer 
than 29 proline residues in succession.
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1.2.4 Occurrence of cis proline residues
In two recent protein database searches^^’”^  ^ the frequency of cis proline residues in 
globular proteins whose structures have been determined by X-ray crystallography 
was calculated. The percentage of proline residues that form cis peptide bonds was 
around 6%, as compared with an average of 0.05% for other amino acids. It is a 
matter of debate as to whether the amino acid sequence in the immediate environment 
o f a proline residue influences the isomeric state of the X-Pro bond.
Residue 111 of the capsid protein V Pl of FMDV is a cis proline (see section 1.3) and 
this residue in not conserved as a proline in any of the other picornaviruses. Residue 
84 of VP2 on the other hand, is also a cis proline and is conserved across the entire 
family of picornaviruses. ^ 3
Using inform ation from  a protein crystallography database, the frequency of 
preceding residues in protein cis X-Pro bonds has been recorded (Fig. 1.6).'^^ Since 
only 59 proteins were included in the search, the number of occurrences for every 
residue is less than ten which is a small sample size. However, the high occurrence of 
tyrosine may be noted, and glycine also appears to be a rather favourable preceding 
residue for formation of a cis X-Pro bond.
In the FMDV polyprotein 2A region, the sequence at the cleavage site is Pro-Gly-Pro 
with scission occurring between the glycine and the second proline. Of the 87 
Pro-X-Pro entries on the database, the statistical spread of possible conformations is 
shown in the table below.
Table 1.2: Conformations adopted by X-P-X motifs in proteins
trans P - X - trans P 80
trans P - X - cw P 3
cis P - X - trans P 3
cis F - X -  cis F 1
Thus, the proposed assignment of the terminal section of the FMDV-2A peptide as 
trans P ~ G - c is  F as illustrated in Fig. 1.5 would be unusual but certainly not 
unprecedented, cis Proline residues are found primarily in bends and turns (73%), 
suggesting a specific structural role for this type of bonding.75
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1.2.5 Reverse turns
Globular proteins have rather spherical structures, in spite of being composed of 
straight segments of polypeptide chain. This is because the polypeptide chain 
generally makes rather sharp bends at the surface, thereby reversing the direction of 
the chain. It is these reverse turns that give proteins their globular shape, and a 
substantial fraction of residues of every protein are involved in them. They are also 
known as hairpin bends, (3-bends, and (3-turns, because they often connect antiparallel 
(3-strands.
A p-turn is a segment composed of four amino acids (/ to /+3) that occurs when a 
peptide strand changes direction. If, on the other hand, the segment is composed of 
three amino acids, one speaks of a y-turn. The standard criterion for a p-turn is that 
the distance between the a  carbons of the first and fourth residues is less than 7Â.
Although four consecutive residues in the polypeptide chain are generally considered 
to comprise a reverse turn, it is only the torsion angles of the second and third 
residues (i+l and i+2) that are critical. The first and fourth residues are usually 
included because a hydrogen bond exists between them in most cases.^^ All observed 
chain reversals involving four residues can be subdivided into ten types: I, T, II, IT, 
III, IIT, IV, V, VI and V I I . T h e s e  types are characterized by the values of the 
observed dihedral angles, ({)(/+1), \|/(/-f-l), (j)(/+2) and \j/(/+2). An example of an 
‘ideal’ type I bend where the four angles are -60°, -30°, -90° and 0° respectively is 
shown below (Fig. 1.7).
m
c,a
Figure 1.7: An ideal type I  p-turn
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Many examples of turns are observed in proteins, but the conformational angles are 
not usually ideal, and a hydrogen bond is not always formed between residues / and 
i+3. A type VI bend owes its existence to a cis peptide group between residue /+1 
and a proline at position i+2 in the bend.^^/^^ A new type of structural motif, the 
pseudo p i turn which also contains a cis X-Pro peptide bond has recently been 
identified in cyclic hexapeptides.
A type VI turn has been observed in the X-ray crystal structure of the protein Bovine 
R ibonuclease S (Fig. 1.8).?6 The turn occurs at residues 91-94 which are 
Lys-Tyr-Pro-Asn respectively. The cis peptide group is geometrically suited for 
reversing the direction of the polypeptide chain and no hydrogen bond is needed to 
stabilize the turn.
Lys
Asn
Tyr
Pro
Figure 1.8: A type VI fi-turn
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1.3 Prolîne cis/trans isomerism
1.3.1 introduction
In most peptide bonds, the side chain groups of the amino acids are held as far apart 
as possible in a trans configuration for the peptide bond. This is much preferable to 
the more crowded cis arrangement. For bonds involving proline, however, both trans 
and cis arrangements are possible (Scheme 1.4). The trans configuration is still 
slightly preferable to the cis form, the former being more energetically stable by 
approximately 10.5 kJ mol-k^i
trans CIS
Scheme 1.4: X-Pro peptide bond isomerism
Proline differs from the other amino acids in that it contains a secondary rather than a 
primary amine group. Also, the side chain is bonded to both the amine nitogen and 
the a-carbon, resulting in a cyclic structure as shown above. This has several 
structural implications for peptides and proteins containing proline residues. Since 
there is no amide hydrogen, hydrogen bonding to other residues is impossible and the 
five-membered pyrrolidine ring also imposes rigid constraints on the N-C®' rotation. 
Uniquely, proline residues have a relatively high intrinsic probability (0.1 to 0.3) of 
having the cis rather than the trans conformation of the preceding peptide bond as 
compai'ed with less than 0.001 for other amino acids.^2 The activation energy barrier 
for cis-trans isomerization is also less for proline: 55 kJ moF^ compared with 
85 kJ mol‘1 at other peptide bonds.83 This is partly due to the greater length of the 
X-Pro bond (1.36Â instead of 1 .3 3 Â),^^ which results from the redistribution of 
charge and lack of resonance stabilization caused by the loss of the amide hydrogen. 
The amino acid residue preceding proline must also be given special consideration 
because the bulky pyrrolidine ring restricts the available conformational space.
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Proline residues are, therefore, recognized as being of special significance in their 
effect on chain conformation and the process of protein folding.85
It is clear that the presence of proline in a polypeptide chain imposes restrictions on 
its susceptibility to most p e p t i d a s e s . 8 6 . 8 7  These restrictions are related both to the 
presence of an X-Pro bond and the geometry of this bond. The unique effect of 
proline in a polypeptide chain suggests that this residue functions in a regulatory 
capacity to protect the peptide and perhaps to initiate the processing of biologically 
active peptides.88
NMR studies have shown that two distinct folded conformations of staphylococcal 
nuclease coexist in solution and that these two states can interconvert directly without 
passing through an unfolded s t a t e . 8 9  it has been proposed that cis/trans isomerism at 
a single peptide bond between a proline and its preceding residue might be the origin 
of the conformational multiplicity. Proline 117 was identified as a likely candidate 
for the site concerned. In the crystal structure of the nuclease-inhibitor complex, 
proline 117 is cis and is located in a p-reverse t u r n . ^ O  A mutant protein, in which 
proline 117 was replaced by glycine, was constructed in order to test this proposal and 
lent powerful support to the theory due to the fact that alternative conformations are 
not observed in the spectrum of this mutant. Similarly, two-dimensional NMR 
spectroscopy has shown that the calcium-binding protein, calbindin has two 
native conformations in solution.^^ This is also believed to be the result of the 
cis/trans isomerism of proline 43, one of its four proline residues.
1.3.2 Mechanism of amide bond rotation
The amide bond is one of the most important molecular structures and a proper 
representation of its chemical characteristics is essential to explain the chemical and 
biochemical properties of peptides and proteins. The nature and reactivity of the 
amide bond has been mainly explained by the concept of chemical resonance which 
suggests a partial % character for the C-N bond, due to a transfer of electrons from the 
nitrogen to the carbonyl group.9^.93 This hypothesis explains a large number of 
molecular properties of amides, such as their planarity, IR C = 0 frequencies, and the 
short length of the N-C bond.
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Scheme 1.5: Mechanism fo r  proline cis/trans interconversion
From a chemical point of view, the cis/trans interconversion involves the disruption 
of the amide resonance and a high rotational barrier would be expected due to the loss 
of the 71 conjugated bond (Scheme 1.5). Recently however, the classical model for 
amides has been questioned due to molecular mechanics studies which have pointed 
out some inconsistencies.
1. In dialkyl substituted amides, the nitrogen atom deviates significantly from the 
plane of the three carbon atoms to which it is a t t a c h e d . ^ ^
2. The electronic population at the carbonyl oxygen does not noticeably change 
when the amide bond r o t a t e s . "phe force constants for the C-O bond do not 
change either and only small changes in the C-O distance occur on rotation.
These findings would suggest that the role of the oxygen is not as important as is 
suggested by the classical mechanism and that although the rotation of amides is a 
highly unfavourable process, the energy barrier is perhaps not as great as is generally 
assumed.
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1.3.3 Factors affecting the cis/trans ratio
It has been shown from the calculation of activation energy parameters that the barrier 
to isomerization is almost entirely enthalpic in all solvents studied. There are 
several major factors which affect the kinetics of cis/trans interconversion in small 
peptides and also disturb the equilibrium by preferential stabilization o f one o f the 
two conformers.
1. Solvent effects
Although it has been reported that the cis/trans rotational barrier is very similar 
for small peptides in a range of s o lv e n ts ,m o re  recent studies have shown that 
the rate constants for both cis to trans and trans to cis interconversions are 
significantly larger in non-polar, aprotic s o l v e n t s . T h i s  observation is 
consistent with a mechanism involving a less polar transition state as shown in 
Scheme 1.5. The fact that protic solvents restrict isomerization suggests that the 
barrier for interconversion is proportional to the strength of hydrogen bonds 
foimed to the amide oxygen.^^ This may be of biological relevance, since it has 
been suggested that the enzymic acceleration of peptidyl prolyl isomerization 
(section 1.4) stems largely from the hydrophobic environment of the active 
site. 102 It has been noted for two nonapeptides that the rate o f cis  to trans 
isomerization is accelerated to a greater extent on going from water to methanol 
than the rate of trans to c i s / ^  It seems that changes in conformation take place 
which destabilize the cis isomers in the less polar solvent. Other studies on di- 
and tripeptides also observed an increase in the relative amount of the cis  
isomer present going from less polar to more polar solvents.^'7,99,ioi phese 
studies have suggested that polar, protic solvents tend to stabilize the cis  
conformation probably due to hydrogen bonding. Although the trans isomer 
has a generally more extended conformation, there is lower solvent accessibility 
to the amide carbonyl in this isomer relative to the cis form.
2. pH effects
In addition, the cis/trans ratio in small peptides has been shown to be extremely 
sensitive to pH.^7,99,ioi phe ionized forms of various small peptides have 
shown strong preferences for one particular rotational isomer. In basic solution, 
it has been observed that peptides which have proline as the carboxyl terminal 
residue exhibit a large increase in the proportion of the cis isomer. This is most 
readily explained on the basis of electrostatic repulsions between the 
deprotonated proline carboxylate oxygen and the preceding amide carbonyl
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oxygen. The two carbonyls are closer in the trans conformation leading to 
greater destabilization. The proportion of the peptides in the trans form 
increases at low pH which would seem to be the result of favourable hydrogen 
bonding between the protonated acid group and the neighbouring amide 
carbonyl.
Stereoelectronic effects
The nonapeptide, bradykinin (RPPGFSPFR) contains the sequence Ser-Pro-Phe 
and the Ser-Pro bond is known to exist in both the cis and trans isomeric forms 
where the cis conformation is populated by about 10% of the total ensemble. 
Substitution of a glycine residue for serine-6 was shown by NMR studies to 
lead to a dramatic increase in the population of the cis  isomer to 3 5 %. 1^ 3 
Studies with model tripeptides have demonstrated that the phenylalanine residue 
adjacent to the proline is also important in determining the cis/trans ratio. A 
stereoelectronic argument has been suggested to explain the unusually high 
cis/trans ratio exhibited by peptides containing the Gly-Pro-Phe sequence. It 
has been proposed that the trans conformation is destabilized due to a repulsive 
interaction between the glycine carbonyl oxygen and the % electrons in the 
phenylalanine aromatic ring (Fig. 1.9a).^^^ This destabilizing interaction could 
not exist in the case of the cis isomer (Fig. 1.9b). It should be noted that 
Gly-Pro-Phe is the sequence of the FMDV polyprotein at the 2A/2B junction.
.COR'
repulsionNHR
H
COR'
NHR
(a) trans isomer (b) cis isomer
Figure 1.9: Electrostatic interactions in Gly-Pro-Phe
33
4. A rtificial receptors
The cis/trans ratio can be perturbed by the addition of artificial receptors which 
preferentially bind to one of the two rotamers. The terephthaloyl receptor 
shown below binds tightly to the appropriately spaced carboxylic acid groups of 
succinyl proline which shifts the equilibrium towards the less favourable cis 
isomer (Fig. 1 .10).^06
Figure 1.10: Prolyl peptide coordinated to artificial receptor
1.3.4 Examples of non-prolyl cis peptide bonds
In those instances where the cis isomer is present, a proline residue is almost 
invariably a participant in the peptide linkage. There are however, several 
structural and environmental conditions which can cause the occurrence of a cis 
peptide linkage between amino acids other than proline.
1 . N-methyl amino acids which occur naturally in various plant metabolites 
display a strong preference for the P VI folded conformation containing a cis 
amide b o n d . 0^ 8  As w ell as providing increased resistance against 
biodégradation and increased hydrophobicity, the N-methylation of peptides 
induces various structural perturbations. One of these is the stabilization of the 
cis conformation due to the presence of a tertiary amide b o n d .  0^9
2. cis Amide bonds have been observed within strained cyclic tetrapeptides which 
do not contain proline or any other N-substituted amino acid r e s i d u e s .  
these cases, the conformation is largely governed by the restriction of ring 
closure. In a study o f a w eakly constrained cyclic hexapeptide 
(cyc/o-AFVKWF), the presence of a small amount (6 %) of a second isomer was
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detected. Ill This was shown to be a conformer containing a cis peptide bond 
between lysine and tryptophan, thought to arise due to steric interactions with 
the bulky side chain of an adjacent valine residue.
3. An example of a molecular constraint that generates a cis peptide bond is the 
presence of two adjacent cysteine residues which are connected via both amide 
and disulfide linkages, The eight-m em hered ring resulting from  the 
formation of the disulfide bond compels the peptide linkage to adopt the cis 
arrangement since the trans conformation is highly strained as shown below 
(Scheme 1.6).
H2C^
Leu-Arg-Arg-HC
^CH2\CH-Leu-GIy
o
HzCILeu-Arg-Arg-HC
H
O
\ . N . 'CH-Leu-Gly
■CHp
CIS trans
Schem e 1.6: Isomerism o f Cys-Cys peptide bond
4. Peptide-membrane interactions can be energetically more important than the 
steric constraints usually associated with the cis arrangement. When in the 
presence of membrane-mimicking SDS micelles, a cis  peptide bond was 
observed between isoleucine and lysine in Bombolitin I, a linear 17-residue 
peptide (IKITTMLAKLGKVLAHV), isolated from bumble bee venom .^3 
This is the first and only report of a cis amide bond in a completely linear 
peptide without proline or N-substituted amino acids and is thought to arise 
from the association of the peptide with the hydrophobic surface of the micelles. 
In aqueous solution, the peptide adopts a random conformation but when SDS is 
added above the critical micelle concentration, the peptide adopts a well-defined 
a-helix. This study clearly indicates that the membrane can have a dramatic 
effect on the conformation of a peptide and underlines the importance of 
examining peptides within an environment similar to the conditions wherein 
they exhibit activity.
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1A  Prolyl cis/trans isomerases
1.4.1 introduction
The cis-trans isomerization of X-Pro peptide bonds is thought to be involved in the 
refolding reactions of many p r o t e i n s .  These processes are slow and they frequently 
determine the overall rate of folding, particulaiiy for small, monomeric proteins.
In a study by Schmid, it was observed that various unfolded proteins consist of a 
mixture of conformational species that differ vastly in their rates of folding. 
Brandts et al. first put forward a hypothesis which provided a plausible molecular 
explanation for this p h e n o m e n o n .  ^ 2 They suggested that the fast-folding (Up) and 
slow-folding (Us) species differed in the geometry of one or more X-Pro peptide 
bonds. Normally, in the native protein, N, each prolyl peptide bond has a unique 
conformation, either c is  or trans. However, during unfolding, (N—>Up), the 
conformational restraints of the native state vanish and these bonds become free to 
isomerize slowly in the Up—>Us reactions.
folding transition prolyl isomérisationN > Up " Us
The relative concentrations of Up and Us at equilibrium are determined by the 
number of prolyl peptide bonds, their isomeric state in the folded protein and by the 
cis/trans equilibria in the denatured protein.
1.4.2 Immunophliins
The search for an enzymic activity that would catalyse prolyl peptide bond 
isomerization began soon after the proposal that prolyl isomerism was responsible for 
different folding rates in proteins. Success came in 1984 when Fisher et al. isolated 
an enzyme from porcine kidney that catalyzed the cis-trans isomerization of prolyl 
bonds in o l i g o p e p t i d e s .  The enzyme promoted a 180“ rotation about the X-Pro 
amide bond without cleavage or formation of a covalent bond and was termed 
peptidyl-prolyl cis-trans isomerase (PPIase), rotamase or conformase. In addition to
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this activity towards small substrates, PPIase was also found to accelerate slow steps 
in the folding of several proteins ^417
A surprising result emerged from the sequencing of PPIased^^ n  was found to be 
identical with cyclophilin, the major high-affinity binding protein in the cell for the 
immunosuppressive dmg cyclosporin A.
After the initial discovery of cyclophilin by virtue of its isolation from porcine 
kidney, * additional members of the cyclophilin family were detected in many cells 
and tissuesri^9“i2i All members of the cyclophilin group possess prolyl isomerase 
activity and are able to accelerate the slow steps in the folding ^ 2^ ^nd unfolding^23 of 
various proteins. The PPIases act as true catalysts and, unlike molecular chaperones, 
they do not depend on the presence of stoichiometric amounts of the helper protein or 
low molecular weight additives. 2^4 ppiases were also the first enzymes known to be 
specialized for the catalysis of conformational changes.
A second class of prolyl cis-trans isomerases, the FK506-binding proteins (FKBPs), 
was discovered  in 1 9 8 9 . ^ 2 5 - 1 2 7  T hese pro teins are inh ib ited  by the 
immunosuppressants FK506 and rapamycin, but they do not bind cyclosporin A. 2^8 
Schreiber et a l  introduced the term “immunophilins” for the family of PPIases in 
order to point out their role as receptor proteins in the mammalian immune system. 2^9
Immunophilins occur in all organisms, both prokaryotic and eukaryotic and in various 
subcellular departments, including the endoplasmic reticulum and the periplasm of 
E. coZf. ^ 30 Although the exact cellular concentrations of the immunophilins are not 
known, they are abundant proteins and cyclophilins are estimated to constitute up to 
around 0.4% of the total cellular protein. ^ 25
1.4.3 Immunosuppressants
In surgical transplant procedures, immunosuppressive agents are used to control 
rejection of the new tissue. Advances in the area of organ transplants and bone 
marrow therapy have been greatly aided by the use of such immunosuppressants as 
cyclosporin A and the more recently discovered FK506 and rapamycin (Fig. 1.11). 
FK506 and rapamycin have been the subjects of considerable s y n t h e t i c  ^ 3 i - 1 3 4  and
d e g r a d a t i v e  ^ 3 5 ,1 3 6  studies.
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Figure 1.11: Immunosuppressant drugs
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These life saving drugs appear to interact with receptor proteins that are located in the 
cytoplasm, such as cyclophilin and FK506-binding protein. As both FKBP and 
cyclophilin have PPIase activity, the medical relevance of the immunophilins has 
been a driving force for new insights into proline cis-trans isomerism.
Cyclosporin A, a cyclic undecapeptide, has found widespread clinical use in the 
prevention of graft rejection following bone marrow and organ t r a n s p l a n t a t i o n .  ^ ^ 7  
FK506 is a structurally novel macrolide of bacterial origin and, in addition to its 
immunosuppressive activity, it also has significant in vivo neuro- and nephrotoxicity. 
It has been demonstrated to have potent immunosuppressive activity at concentrations 
several hundredfold lower than cyclosporin A.^^6 Rapam ycin inhibits T-cell 
activation at concentrations comparable to those of the structurally related FK506, yet 
with mechanisms that are strikingly different from those mediated by FK506, and 
thus cyclosporin A.^^^ The mechanisms of immunosuppression mediated by FK506 
and cyclosporin A appear to be remarkably similar, suggesting that these unrelated 
structures act on a common receptor or on similar molecular targets.
The immunosuppressive activity of these drugs involves repression of a discrete set of 
lymphokine genes. This acts on the immune system by inhibiting initial steps 
involved in the activation of T-cells, thymus-dependent lymphocytes that act directly 
to incapacitate  or destroy tissues bearing foreign antigens or invading 
microorganisms.
Both FKBPs and cyclophilins catalyze the interconversion of the cis  and tra n s  
isomers of prolyl residues in peptides, and the appropriate immunosuppressants 
inhibit this activity. FK506 and rapamycin are inhibitors of FKBP but not of 
cyclophilin, likewise, cyclosporin A does not inhibit FKBP, yet is a potent inhibitor 
of cyclophilin. The FKBPs and cyclophilins are members of an emerging class of 
proteins which regulate T-cell activation and other metabolic processes, perhaps by 
the recognition and isomerization of proline-containing epitopes in target proteins.
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1.4.4 Biological function of prolyl cis/trans isomerases
Defining the biological role of the immunophilins and their substrates may illuminate 
the process of protein trafficking in cells and the mechanisms of signal transmission 
through the cytoplasm.
The immunosuppressive drugs, cyclosporin A, FK506 and rapamycin are highly 
effective inhibitors for PPIases. Surprisingly, these compounds effect the signal 
cascade o f T-cells but not through enzyme inhibition; the inhibitor-enzym e 
complexes themselves are the active agents. In the case of cyclosporin A and 
FK506, the complex of drug and immunophilin binds to calcineurin, a calcium- 
activated phosphatase that is essential for T-cell s i g n a l l i n g .  ^ 3 9 , 1 4 0  Rapamycin is 
thought to behave differently, hampering T-cell activation at a later stage in the 
immunoresponse.
Intensive efforts are being made to understand the role of prolyl cis/trans isomerases 
and of their complexes with immunosuppressants. Three-dimensional structures of 
the cyclophilin-cyclosporin A and FKBP-FK506 complexes have been determined by 
X-ray ciystallography 142,143 and NMR s p e c t r o m e t r y .  4^4,145
At present, it is too early to speculate whether the primary cellular function of prolyl 
cis/trans isomerases is correlated with processes that involve protein folding or with 
signal transduction pathways. Possibly, they are involved in all these processes and 
the isomerase activity is important for their regulation. Whether such a multitude of 
tasks is accomplished by the same enzymes or rather by specialized prolyl isomerases 
is not known.
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1.4.5 Mechanism of prolyl cis/trans isomerases
The reaction catalyzed by prolyl cis/trans isomerases differs from most other enzymic 
reactions. It is not associated with the formation or breakage of covalent bonds, 
intermediates do not accumulate and no cofactors are known to participate in catalysis 
(Scheme 1.7). Therefore, none of the usual experimental methods are available to 
help probe the mechanism. On the other hand, prolyl isomerization provides the 
enzym ologist with a rare opportunity since both the catalyzed and uncatalyzed 
reactions occur at measurable rates.
o
PPIase
o
H
Scheme 1.7: Peptide bond rotation catalyzed by prolyl isomerases
The main barrier to prolyl cis/trans isomerization is the resonance stabilization energy 
possessed by the C-N imide bond. The task of a prolyl isomerase is, therefore, to 
develop an enzymic strategy that will result in the lowering of this barrier. There are 
two general mechanisms which have been suggested: nucleophilic catalysis and 
catalysis by distortion. The first of these two mechanisms is covalent catalysis in 
which a nucleophile attacks the carbonyl carbon to form a tetrahedral intermediate 
(Fig. 1.12a). In this intermediate, resonance stabilization of the C-N bond has been 
removed and collapse of the intermediate can produce either the cis or trans X-Pro 
bond. The alternative non-covalent catalysis mechanism is one in which the enzyme 
utilizes its binding energy to stabilize selectively the transition state with a 90° 
rotation of the amide bond out of planarity (Fig. 1.12b). This mechanism is 
dependent on the binding energy between enzyme and substrate, since the substrate is 
considerably distorted and strained.
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Figure 1.12: Transition state structures fo r  (a) covalent catalysis mechanism and (b)
mechanism o f catalysis by distortion
Initial studies on cyclophilin led to the suggestion that an enzymic thiol group was 
im portant for catalysis and a nucleophilic mechanism was proposed involving a 
covalent intermediate, possibly a hemiortho-thioamide. Site-directed mutagenesis 
of human cyclophilin allowed the systematic replacement of all four cysteine residues 
with alanine. Since all four mutant enzymes were fully active in rotamase and 
binding assays, cysteine was ruled out as a participating residue in catalysis. 4^8
A dditional mechanistic studies with both c y c l o p h i l i n ^ 2 7  and FKBP 1^ 9 strongly 
support a mechanism involving catalysis by distortion in which the PPIase binds and 
stabilizes a transition state that is characterized by partial rotation about the C-N 
amide bond. This mechanism is supported by crystal structures of FK506 and 
cyclosporin A that reveal substmctures which mimic the twisted amide bond of the 
suggested substrate-enzyme complex. 129,149
42
The energy that is required to distort this bond out of planarity with the C = 0  bond, 
thereby destroying the resonance stabilization of the amide linkage, is supplied by 
favourable transition state binding interactions between enzyme and substrate. The 
structural basis for the ability of the prolyl isomerases to stabilize this transition state 
must await further analyses. The bond distortion need not be completely the result of 
mechanical deformation but could also be due to desolvation or electrostatic 
destabilization,
The energetic cost for bond distortion is reflected in the large entropy of activation 
(-TAS* = 56 kJ mol'i at 300K) that is required to distort and constrain the substrate to 
a conformation that allows optimal interaction with the enzyme. Once the entropie 
bill has been paid, the reaction occurs with little enthalpic cost (AH* = 16.6 kJ 
moT^ ).
This mechanism is unique in enzymology. PPIases appear to use none of the usual 
catalytic "devices" that enzymes typically employ {e.g. general-acid, general-base or 
nucleophilic catalysis) but, rather, utilize the intrinsic binding energy that is available 
from substrate-enzyme interactions in stabilizing the transition state for catalysis.
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1.5 Peptidomimetîcs
1.5.1 introduction
Peptides influence a multitude of physiological processes and their role in the 
appearance or maintenance of various diseases has been unequivocally proven. 
Agents that can imitate or block the biological function of bioactive peptides can be 
considered as aids for the investigation of the system and also as therapeutic agents. 
It has been shown that due to their pharmacological properties, such as degradation 
by peptidases or poor bioavailability, peptides could be employed as drugs in only a 
few cases. To solve this problem, compounds that act as substitutes for peptides in 
their interaction with receptors, peptidomimetics, have been synthesized.
In the many studies aiming to obtain specific and superactive peptide analogues, 
attempts have been made to design molecules which are able to favour a particular 
conformation by introducing geometrical constraints. As well as cyclization and the 
insertion of nonproteinogenic amino acid residues, the alteration of the peptide bond 
can also influence conformational properties and biological activity. These modified 
molecules are known as peptidomimetics or pseudopeptide a n a l o g u e s .  ^^ 2-154
Previous investigators have sought to design and incorporate constraints into 
bioactive molecules which mimic features of peptidyl secondary structure while 
retaining or enhancing biological potency and if possible, introducing desirable 
properties such as enhanced oral absorption or increasing in vivo  half life. A 
secondary structure mimetic is a building block that forces a defined secondary 
stmcture after its incorporation into a peptide.
1.5.2 p-turn mimics
The P-turn is a structural m otif common in many biologically active cyclic 
p e p t i d e s 2 8 . 8 0  and it has been postulated that the activity of many linear peptides 
depends on the existence of a p - t u r n .  56 por this reason, there has been great 
interest in the synthesis of p-turn mimetics but the majority of these have been found 
to be inactive after incorporation into model peptides. The y-spirolactam segment (2) 
has been used to replace Pro-Tyr units as a type II P-tum mimic. ^ 2^
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(2); Spirolactam p-turn mimetic
Although computational studies show that distances and torsion angles for peptides 
containing the spirocyclic unit are in good agreement with those expected for type II 
p-turns, the results of biological tests have proved disappointing and often the peptide 
analogues fail to bind to recognition sites. ^ 8^
The type VI p-turn contains a cis X-Pro peptide bond and various cis amide bond 
surrogates have been designed to mimic this feature. The cis Gly-Pro mimetic (3) has 
been synthesized and incorporated into model peptides using solid-phase methods. 
The bicyclic system allows retention of the peptide backbone and amino acid side 
chains in positions closely similar to those likely to occur in native cis X-Pro type VI 
turn conformations. When tested, however, analogue peptides containing the unit 
proved less active than the natural peptides.
N
O
NZ/,, H
HN R >
(3): cis Gly-Pro mimetic unit
A very similar type VI P-turn mimic, (4), has recently been synthesized by Cun*an 
and McEnaney.^^o In this case, the two adjacent a  carbons are tethered by a 
lactam methylene (CO-NH-CH2) linker which provides additional constraint to the 
bicyclic framework compared with the alkyl (CH2CH2 ) linker used in the previous
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example. This bicyclic unit has not yet been incorporated into larger peptides, so its 
biological activity as a p-turn mimetic is unknown.
V-
o
-COaCHaPh
(4): cis X-Pro dipeptide
Paul et al. have shown using molecular dynamics calculations that the pyroglutamic 
acid residue (Glp), (5), is a natural motif for a cis peptide bond.^^i effective type 
VI p-turn mimetic can be made by starting from a Glp residue and extending it 
appropriately from its C7 atom. The Glp residue contains a cis amide bond in the ring 
- the CYC^G^NHC® chain can be visualized as a peptide unit C®^CONHC“ with the 
side chains at both atoms being fused at CP.
y p
(5): Pyroglutamic acid residue
M odelling studies on tripeptides containing the Glp residue show that one of the 
minimum energy structures obtained is a type VI P-turn. Experimental work on these 
systems has yet to be carried out.
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1.5.3 Cis and trans X-Pro mimics
Various conformationally constrained proline analogues have been prepared which 
favour the cis c o n f o r m a t i o n . ^ ^ 2 - 1 6 5  Compounds such as a«r/-5-methylproline ( 6 ), 
5,5-dimethylproline (7) and 2,2-dimethylthiazolidine carboxylic acid ( 8 ) have been 
shown to exhibit a relatively high percentage of the cis isomer in model compounds. 
Such modified proline surrogates should prove useful in assessing the role of cis 
X-Pro peptide bonds in biologically active peptides.
(6) (7)
(8)
Figure 1.13: Proline analogues which stabilize the cis X-Pro conformation
Unlike its trans-olefinic counterpart which can be considered as an ideal mimic for 
the trans peptide bond, the synthesis of cis olefins as cis amide bond mimics is not 
synthetically attractive because of facile isomerization into the stable trans form.
1,2-disubstituted pyrroles and 1,5-disubstituted tetrazole u n i t s have been used as 
cis amide bond surrogates. Compound (9) was prepared as a cis Trp-Nleu mimetic 
but showed less activity than the parent peptide, suggesting that other structural 
characteristics are important for biological activity. ^68
pH
(9): cis Trp-NLeu mimetic
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A novel disulfide constrained cyclic segment, (10), is formed by the closure of two 
neighbouring cysteinyl residues and was incorporated into a cyclic hexapeptide 
(cyc/o-PFWKTF) to replace a Phe-Pro unit. ^^ 9 nM R  studies have established that in 
solution the amide bond of this unit was essentially all cis. The amide bond in the 
mimetic compound is fixed in the cis geometry by the eight-membered ring, with 
apparently little disturbance of stereoelectronic parameters. Biological assays o f the 
artificial peptide showed retention of high potency which would seem to be 
confirmation of the unit as a good mimetic for cis amide bonds.
NH
(10): cis Phe-Pro mimetic
trans Prolyl peptidomimetics have also been prepared. These possess a trans  
substituted alkene in place of the proline peptide bond. The Leu-Pro-Tyr analogue 
(11), was synthesized by Andres et al. and proved to be a potent inhibitor o f the 
prolyl isomerase activity of FKBP 12.^70 xhis shows that the simple carbocyclic 
system possesses considerable potential in mimicking the prolylamide substructure of 
polypeptide species. It is recognised by the enzyme and binds tightly to it but since 
the amide bond is removed, so is the possibility of peptidyl isomerization.
MeO
'*OH
NH
HO
Me
(11): trans X-Pro peptide bond mimetic: Leu-Pro-Tyr analogue
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C H A PTER  2: RESULTS AND DISCUSSION
2.1 Synthesis and structural studies of 2A-containing 
oligopeptides.
2.1.1 Methods of structural analysis
Information on the three dimensional sti*ucture of peptides containing the FMDV 2A 
sequence may provide important insights into the relationship between structure and 
activity of this protein region. The solution phase conformations of small peptides 
(5-30 residues) are usually investigated by use of NMR s p e c t r o s c o p y 5 4 . 5 6 , 5 8  and 
CD (circular dichroism) spectropolarimetry i , 17 1,17 2
CD is the differential absorption of circularly polarized radiation by a non racemic 
s a m p l e . peptides, it is the interaction between adjacent amide groups during 
light absorption which accounts for most of the CD bands. The key structural 
elements that are responsible for the wavelengths and intensities of the bands are the 
relative orientation of the neighbouring amide groups and the distances between 
them. When the peptide molecules organize themselves into a helical shape and start 
to form intramolecular hydrogen bonds, absorption of radiation by the numerous 
properly oriented chromophores is enhanced. This leads to the appearance of more 
intense CD bands at characteristic wavelengths. CD spectroscopy allows the presence 
of a-helices to be inferred with greater certainty than that of any other structural 
feature.^9
Two-dimensional NMR spectroscopy provides an important tool for identifying 
preferred conformers in otherwise unstructured p e p t i d e s . This stems from its 
usefulness in detecting highly localized conformations that are not easily observable 
by other methods, and from its ability to identify the particular residues involved in a 
given structural motif. NMR can be used to discern conformations that resemble 
regular secondary structures of proteins, such as helices'^’^ -^ ’^^ '^  and tight tums.^^’^ ^dvi 
The NMR approach to studies of peptides is largely oriented around the ability of 
nuclear Overhauser enhancement (nOe) experiments to provide data on intemuclear 
d i s t a n c e s . 2D NOESY spectra are used to identify protons physically close in space 
within large molecules which tumble slowly enough to lie in the negative nOe 
region. In characterizing conformations, however, it must be appreciated that a 
peptide is frequently in dynamic equilibrium between a large number of conformers. 
Therefore, at any one time the peptide population in solution contains multiple 
conformers, only some of which are revealed by NMR.
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2.1.2 Influence of different solvents on peptide structure
Small, biologically active, linear peptides often have significant secondary structure, 
usually as turns or helices, in organic solvents while they are largely unstructured in 
aqueous solution.^^’^ ^’^ ^’^ ’^^  ^ The influence of organic solvents on the experimentally 
determined secondary structure of a peptide is thought to be consistent with a role for 
the membrane-lipid interface in stabilizing an active c o n f o r m a t i o n . ^2 Although it is 
not clear why such peptides acquire a specific conformation at the lipid interface, 
reduction in the dielectric constant and the activity of water molecules is obviously 
part of the driving force.
2,2,2-Trifluoroethanol (TFE) has been widely used as a structure-inducing cosolvent. 
As well as enhancing the solution structure of small protein fragments, TFE can 
induce the formation of stable conformations in peptides w hich are otherwise 
randomly arranged in aqueous s o l u t i o n . 4 6 , 5 0 , 5 1  Several properties have been 
suggested to be responsible for the observed secondary structure stabilization.
□  The dielectric constant of TFE is about one third that of water and more closely 
resembles conditions in the interior of a protein.^^ Thus, one would expect 
strengthened interactions between charged groups in this medium.
□  Differences in solvent acidity and basicity between TFE and water are thought 
to change the relative stability of hydrogen b o n d s . T h e  hydrogen bonding of 
amide protons to the solvent is decreased in TFE, w hich strengthens 
intramolecular hydrogen bonds and therefore stabilizes secondary stmcture.
□  TFE is a less polar or more hydrophobic solvent than water. It interrupts 
hydrophobic interactions and can act as a dénaturant of tertiary and quaternary 
structures."^^
TFE is not a helix-inducing solvent in the sense that it will induce helix formation 
independently of the sequence. It is rather a helix-enhancing cosolvent, which 
stabilizes helices in regions with some helical propensity. This can be fairly 
accurately determined by secondary stmcture p r e d i c t i o n s . ^ ^
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2.1.3 Peptide synthesis and structural analysis
In order to investigate the mechanism of the self-cleavage of the 2A region of the 
FMDV polyprotein, we decided to synthesize model peptide fragments. Molecular 
biological studies carried out by Ryan et al. were used to decide the lengths of 
peptides to be prepared.^^ In these studies, recombinant DNA experiments were 
carried out in which specific portions of the FMDV polyprotein were deleted in order 
to investigate the region involved in the 2A/2B cleavage. Initial results indicated that 
a truncated version of the 2A region in which the first 6  residues were deleted, 
exhibited self cleavage.^^
lD-> 2A ^  2B
-LLNFDLLKLAGDVESNPGPFF-
The first oligopeptide prepared, ALAGDVESNPGPF (12), was thirteen amino acids 
in length and included the ten C-terminal residues of the 2A region. The peptide was 
prepared by solid-phase s y n t h e s i s ( g e e  Appendix 1) using Fmoc protection.
The peptide (12) was analyzed by HPLC using a reversed phase Cig column and was 
found to elute as a single peak (>90%) using an H2O/ acetonitrile gradient and 
214 nm detection. The FAB mass spectrum of (12) gave the expected molecular ion 
([M +  H]+ = 1273) using a glycerol matrix. The NMR spectrum of (12) was 
recorded in 2H 2O and the carbonyl region was found to contain the expected 16 peaks 
(Fig. 2.1).
CONH2
H2 N-ALAGDVESNPGPF-CO 2 H
HO2C QO2H
Figure 2.1: Carbonyl region o f  the NMR spectrum o f  (12)
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The synthetic peptide (12) was found to be insoluble in DMSO and TFE. A range of 
2D NMR experiments were therefore performed in water in order to see if the peptide 
contained any secondary structural elements in this medium.
From  the NM R results, it seemed that (12) was predominantly in an unfolded 
conformation in H^O/ 2H 2O (9:1) (see Appendix 2).
□  The proton chemical shifts in the NMR spectrum corresponded very closely 
to the known random coil shifts for amino acid residues in w a t e r .  1^ 4
□  The ROESY spectrum contained a series of sequential a(0 -N H (/+ l) crosspeaks 
from Ala^ to Val^, but there were no NH(/)-NH(/+l) or a(/)-a(i+3) interactions
which are characteristic of a helical c o n f o r m a t i o n . ^ ^ 4 7 5
□  Strong nOe crosspeaks were observed between the a-protons of Asn^ and Gly^^ 
and the 6 -methylene protons of Pro^^ and P r o ^2 respectively. This is conclusive 
evidence that both X-Pro amide bonds are predom inantly in the trans 
conformation.
Using the same synthetic methodology (see Appendix 1), a 23 residue peptide, 
NFDLLKLAGDVESNPGPFFFSDF (13), was prepared. This peptide contained the 
entire 2A sequence as well as seven residues from the adjacent 2B region. The reason 
for the inclusion of the 2B portion was twofold. First, it was thought that an extended 
C-terminal might be important for cleavage activity and second, it was hoped that the 
additional hydrophobic groups might make the peptide more soluble in organic 
solvents. It is known that short linear peptides are more likely to exhibit stmcture in 
organic solvents than in aqueous s o l u t i o n . ^ 3 ,6 4
The peptide (13) was analyzed by HPLC using a reversed phase Cig column and was 
found to elute as a single peak (>90%) using an H2O/ acetonitrile gradient (Fig. 2.2). 
The FAB mass spectram of (13) gave the expected molecular ion ([M + H]+ = 2577) 
using a NOBA matrix.
Peptide (13) was found to be water soluble and, unlike (12), when the pH was 
adjusted to 7.8, it also became sparingly soluble in both DMSO and TFE. We 
therefore decided to investigate the structure of (13) in different solvents, using both 
CD and NMR techniques (see Appendix 2).
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The CD spectra of (13) in H2O (Fig. 2.3a) and H2O/ TFE (1:1) (Fig. 2.3b) were 
recorded at pH 7.8 and 35 °C. On changing the solvent from H2O to the H2O/ TFE 
mixture, a large maximum band appears at 190 nm, the minimum absorption peak 
(nn* transition) shifts from 200 to 205 nm and the intensity of the negative ellipticity 
at 2 2 2  nm (nTC* transition) increases.
d : . . _ 7
^ -7 - 7
■ i-’--
I  1.7:
I 0.5
I M e
f.s.cL 2.0
——
‘  j _ _ _ _ _ _ _ ,_ _ _ _ _ _ ^
--------
30 r.L (mins)
Figure 2.2; RPHPLC trace o f (13)
(A2 1 4  - Absorbance at 214 nm, fs .d . - fu ll scale deflection, r.t. - retention time)
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10000.
(a)
-10000 200.01 9 0 .0 Wavelength (nm)
RHO 0 .5 m g /m l 0 .0 2 cm  1 / 9 / 9 4  COHROPT
RHO + 50% TFt 0.5mg/ml 0.02cm 1 /9 /94  COHROPT
Figure 2.3: CD spectra o f (13) in (a) H2 O and (b) H 2 O / TFE (1:1)
The shape of the red curve (Fig. 2.3b) is characteristic of a peptide containing 
a-helical secondary s t r u c t u r e . 73 The large intensity of the minimum at 205 nm 
relative to the minimum at 2 2 2  nm implies that the conformation is a mixture of 
a-helical and random coil structures.
The amount of helical structure at 37 °C was estimated by two methods. First, the 
procedure of Provencher and Glockner was used.^^ This is a computational method 
which is based on describing the spectrum as a combination of the spectra of various 
proteins of known secondary structure. This method gave a value of 10% for the 
amount of a-helix present. An alternative approach is to use the value of the molar 
ellipticity at 208 nm, [0 ]2O8 (measured in units of degrees cm^ dm opi) to calculate the 
amount of a-helical structure present in the peptide. Using a simple formula,"^^ a 
value of 1 1 .2 % for the estimated a-helical content was obtained.
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Although CD spectra can reveal overall characteristics of the secondary structure, no 
local information is available on the conformation of peptides. Therefore, analysis of 
2D NMR spectra is essential to identify the secondary stmcture of each residue and to 
obtain a clearer picture of the conformation of the peptides.
High resolution NMR methods made it possible to investigate specific residues in 
(13) and a range of 2D NMR experiments were mn in H2O/ -H 2O (9:1), ^/g-DMSO 
and û?2"TFE.
The first step in stmcture determination was to assign each proton in the molecule to a 
specific resonance in the NMR spectmm. 2D TOCS Y experiments were employed to 
connect via scalar coupling all resonances belonging to different protons in the same 
amino acid residue. ^ ”^4 Although the TOCS Y spectrum enables assignment of each 
resonance to a type of amino acid based on the observed coupling patterns, it does not 
give the sequential location of the amino acid. The sequential asssignments were 
obtained from observation of inter-residue interactions between protons in the 
NOESY spectmm, e.g. NH(/)-NH(/+l) or a(0-NH(?+l).55
A 2D NOESY spectmm yields a map of protons that are spatially close irrespective of 
bonding networks. Different elements of regular secondary stmcture have different 
anticipated patterns of short distances. For instance, in a regular a-helix, the distance 
between sequential amide protons is quite short (d^N 2 .8  A), whereas this distance is 
considerably longer in a p-sheet (d^N 4.3 A) or extended stmcture (d^N 4.2 A).^74 
The a-helix is also characterized by close approach between residues i and (/+3), and 
between residues z and (z+4) which result in medium range nOe interactions. These 
characteristic interactions, NH(z)-NH(z‘+ l)  and a(z)-NH(z+3) can be used to determine 
regions which have helical as opposed to extended conformations.
The NMR spectra of (13) in H2O/ 2H2O (9:1) showed the peptide to be unstructured 
in that medium. The proton chemical shifts closely corresponded to known random 
coil values^'^^ and no NH(z)-NH(z+l) crosspeaks were observed in the NOESY 
spectmm.
In the NOESY spectra of (13) in both DMSO and TFE, however, seven sequential 
NH(z‘)-NH(z+l) interactions were observed from Leu*^  to VaF^, suggesting an area of 
secondary stmcture such as an a-helix (Fig. 2.4). No a(z>NH(z+3) interactions were 
detected which may indicate that the helix is not very stable. The number of NOE 
interactions, especially a(z)-NH(z+3), is indicative of the size of the helical population 
and the stability of the helix. The amide region of the TOCSY spectrum of (13) is
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shown for comparison (Fig. 2.5). This contains crosspeaks arising from interactions 
between the side chain amide protons of the asparagine residues and the e-amine 
group of the lysine residue.
(pptnl
8 . 0 % 6/7
9/10
4 VO 8/9
4/5
7 . 0 6 . 8 6 . 67 . 27 . 8 7 . 6 7 . 48 . 08 . 5 8 . 28 88 4
F2 (ppm)
Figure 2.4; Amide region o f NOESY spectrum o f (13) in TFE
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8 . 0 -
, 2 -
H . e  6 . 6  8 . 4  8 . 2  8 . 0  7 . 8  7 . 6  7 . 4  7 . 2  7 . 0  6 . 8  5 . 6
F2 (ppm)
Figure 2.5: Amide region o f TOCSY spectrum o f (13) in TFE
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2.1.4 Conclusions
The results reported here present experimental evidence that the conformation of 
peptide (13), which contains the complete 2A sequence is solvent dependent, 
changing from a random coil in H 2O to a partial a-helix  in TFE or DMSO. The 
helical area is believed to be located in the N-terminal region of the peptide. These 
results are in agreement with molecular modelling studies which indicated that the 2 A 
sequence might form an a-helix of seven to eleven residues followed by a reverse 
turn in close proximity to the scissile bond (see Fig. 1.5, p. 23).^ '^^"^
The adoption of some form of structure upon exposure to a more hydrophobic 
environment (such as DMSO or TFE) is typical behaviour for peptides which are 
active at membrane surf aces. In the case of the FMDV polyprotein, the 2A region
appears to display proteolytic activity when still closely associated with host cell 
ribosomes (see section 1.1.8, p. 15). Ribosomes are large globular protein complexes 
and may provide an apolar or interfacial environment, similar to those of membrane 
surfaces.
Molecular modelling studies indicated that the presence of a cis X-Pro bond would 
cause a sharp turn in the 2A peptide backbone which would enable the scissile 
Gly-Pro bond to be positioned close to potentially nucleophilic residues (see 
section 1.2.2, p. 21).^'^ The occurence of cis/trans isomerism about an X-Pro bond in 
a peptide or protein is often manifested as a set of minor peaks present in the 2D 
NMR s p e c t r a . ^ 3 , 9 1 , 1 8 0 , 1 8 1  Diagnostic evidence for the presence of a cis peptide bond 
is the observance of an a (;)-a (f+ l)  NOESY c r o s s p e a k .  174 Nq such evidence of 
conformational multiplicity was apparent in the NMR spectra of (12) or (13), and it 
can be assumed that the two X-Pro bonds, present in both synthetic peptides exist in 
the more usual trans configuration.
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2.2 Synthesis and studies on short 2A peptide fragments
2.2.1 NPGP - Introduction
Since 1990, there have been various reports in the literature that the synthetic 
tetrapeptide NPGP (Asn-Pro-GIy-Pro) spontaneously cleaves when incubated in 
alkaline b u f f e r . 2 d 4 . i 6 , 4 3  y^e NPGP sequence corresponds to the 2A/2B cleavage site 
of the FMDV polyprotein and these accounts suggest that the inherent instability of 
the NPGP fragment may be a driving force in the scission of the viral protein.
These literature reports consist only of brief comments in papers and reviews on the 
general topic of viral proteases and no experimental details have yet been published. 
We decided to synthesize several protected and deprotected forms of the tetrapeptide 
fragment in order to investigate its alleged autocatalytic properties and to examine the 
accuracy of these literature reports. Several points about the pm-ported cleavage have 
been noted in these short accounts.
□  The autocatalytic reaction is reported to be carried out most efficiently in 
slightly basic reaction mixtures {i.e. pH 8,5), as might be expected for an 
authentic physiological event.
□  Thus far, the spontaneous degradation has reportedly been observed only for
peptides with unmasked a m i n o - t e r m i n i . ^ ^
□  The cleavage of the tetrapeptide is thought to produce two dipeptide fragments; 
NP and GP .^4 jj^ contrast, the cleavage in the viral polyprotein occurs at the 
NPG/P junction, suggesting a different mode of cleavage.
□  Palm enberg et al. have reported that a synthetic peptide of the sequence 
NPGP-NH2 (Asn-Pro-Gly-Pro-am ide) spontaneously hydrolysed to yield 
predominantly NP and GP-NH2 f r a g m e n t s . ^ 3
In contradiction to the last point,^^ the present study has shown conclusively that the 
dipeptide amide GP-NH2 is unstable, particularly in a basic environment and rapidly 
reacts to form a diketopiperazine (see Section 2.4, p. 80).
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2.2.2 Solution phase synthesis of the NPGP tetrapeptide
The tetrapeptide (NPGP) was prepared using classical solution phase peptide 
chemistry. A convergent approach was employed, involving the coupling of two 
dipeptide fragments: NP and GP (Scheme 2.2).
There are numerous excellent methods for synthesizing peptides in the solution phase, 
including the use o f acid chlorides or carbodiimides for peptide c o u p l i n g s .  ^ ^ 2  We 
synthesized peptide fragments using the mixed anhydride method of peptide coupling. 
This method was chosen for its advantages in speed, yield and relative purity of the 
products. The mixed anhydride method has been studied in detail to increase yield 
and m inim ize the possibility o f racem ization. 183,184 xhe reaction uses alkyl 
chloroformâtes as peptide forming reagents. A suitably protected amino acid reacts 
with the alkyl chloroformate in the presence of a base, to form an anhydride. A 
second suitably protected amino acid is then added which reacts with the anhydride to 
form the peptide linkage.
An im portant consideration is that of racemization, which can be minim ized 
depending on the steric bulk of the base and the choice of solvent. It has been found 
that methylamine reacts the fastest, but causes maximum r a c e m i z a t i o n . ^^ 2  Base, 
solvent, temperature and alkyl chloroformate variations have been examined, and it 
was found that the best results are obtained using a combination of NMM, wo-butyl 
chloroformate and dry THF.^^^ This combination of reagents was used for the 
synthesis of the NPGP tetrapeptide where possible.
Reactions involving proline and asparagine are known to be problematic due to the 
hindered nature of the proline amine group and the poor solubility of asparagine 
compounds. The Asn-Pro dipeptide proved to be difficult to synthesize in good yield 
largely due to these factors and various reaction conditions and solvents were tried 
out in order to improve the yield.
(26")-Proline methyl ester hydrochloride (21) was found to be insoluble in THF and 
could not be successfully coupled to tBOC-(25)-asparagine (14) for this reason. In 
contrast, (25)-proline allyl ester p-toluene sulfonate (15) was found to be soluble in 
THF and was reacted successfully with ^BOC-(25)-asparagine (14) using the mixed 
anhydride methodology to give ^BOC-Asn-Pro-allyl ester (16) in 63% yield after 
recrystallization.
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OHHN +O Oo
Me
(14)
/so'butyl chloroformate 
NMM, THF, -1 5 ° C ,6 3 %
H2N
HN
(16)
Scheme 2.1: Synthesis of^BOC-Asn-Pro-allyl ester (16)
D eprotection of the allyl ester using conventional W ilkinson’s catalyst^^s or 
Pd(PPh3)4 ,^s6 proved unsuccessful, as was the use of lithium d i m e t h y l c u p r a t e . ^ ^ ?  
Rhodium(I) complexes such as W ilkinson’s catalyst are known to catalyze the 
isomerization of the allyl moiety as shown below which leads to the liberation of the 
carboxy function when reacted with water.
Rh(l) R
Y “ .
o
I t  is generally accepted that migration of hydrogen occurs with involvement of a 
7i-allyl complex as shown below.
OilR" 'OA,
H1M
It seems likely that the allyl group of the protected dipeptide (16), was not sufficiently 
accessible to the bulky metal reagents for coordination to occur. This may be due to 
intramolecular hydrogen bonding involving the asparagine side chain as has been 
shown for several small peptides containing the Asn-Pro p a i r .  8^8,189 ^his restriction 
of conformational flexibility would greatly affect the reactivity of the allyl ester group 
(Fig. 2.6).
6 1
Figure 2.6: Proposed conformation of^BOC-Asn-Pro-allyl ester (16)
As an alternative, (25)-proline benzyl ester p-toluene sulfonate (17) was reacted with 
^BOC-(2»S)-asparagine (14) in an analogous manner to that above to give ^BOC-Asn- 
Pro-benzyl ester (18) in 79% yield after recrystallization, m.p. 111-13 °C (lit.,^^® 
115-16 °C) (Scheme 2.2). The benzyl ester was then rem oved by catalytic 
hydrogenation to give the deprotected dipeptide (19) in 87% yield, m.p. 110-15 °C 
(lit.,1^^ 108-16 °C). Both and NMR spectra of (19) showed the complete 
disappearance of aromatic signals.
The second dipeptide, ^BOC-Gly-Pro-OMe (22) was also prepared by the mixed 
anhydride coupling of (25)-proline m ethyl ester hydrochloride (2 1 ) w ith 
^BOC-glycine (20)  in 89% yield. Removal of the ^BOC group was easily 
accomplished using trifluoroacetic acid to give the methyl ester (24) as a clear oil in 
quantitative yield.
62
NHg
.OHHN (i)+ HN
O
•Me .0
O
(14) (19)
hn- Y "  
°  +
(20)
•OMe
Cl
(21 )
Y (V),NH B
I—  (22) X = OMe (24) X = OMe 
(’V) (25) X = NHg
(23) X = NH2
R eagents and  conditions: (i) NMM, wo-butyl chloroformate, THF, -15 °C, 79%;
(ii) H2(g), Pd/C, MeOH, rt., 96%; (iii) NMM, wo-butyl chloroformate, THF/ DMF, 
-15 °C, 89%; (iv) NHsCg), MeOH, 72 h, 98%; (v) TFA, CH2CI2 , rt., 100%.
Scheme 2.2: Synthesis o f  the dipeptide fragments (19), (24) and (25)
As the mixed anhydride method was found to be unsuccessful for the final coupling 
step to produce the tetrapeptide, the coupling reagent PyBOP (benzotriazolyloxy- 
tris[pyrrolid ino]-phosphonium  hexafluorophosphate) was em ployed for the 
condensation o f the two dipeptides, (19 ) and ( 2 4 ) . The  te trapeptide 
(^BOC-Asn-Pro-Gly-Pro-OMe (26) was isolated as a white solid in 75% yield, 
m.p. 168-70 °C. The peptide was analyzed by HPLC using a reversed phase C^g 
column and was found to elute as a single peak (>98%) using an H 2O/ acetonitrile 
gradient and 214 nm detection.
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.OH
HaN-
HN,
O
A
(19)
+ N H 3
B
(24) X = OMe
(25) X = NH2
(i)
NH
Hgl
HN
,0
(26) X = OM e
(27) X = NHg
Reagents and  conditions: (i) PyBOP, NMM, THF/ DMF, rt., 50 min. 
Scheme 2.3: Synthesis o f NPGP tetrapeptides (26) and (27)
It is not clear which factors impeded the mixed anhydride coupling reaction between 
(19) and (24). If the proline carboxyl group of the NP dipeptide (19) is involved in an 
intramolecular hydrogen bond, this would render it rather hindered and unreactive. 
Phosphonium coupling reagents such as PyBGPi^^ and the related PyBroP^^^ have 
been shown to be extremely effective for the coupling of hindered peptides and, 
indeed, proved successful in this case.^^3
In order to ascertain the role (if any) of the terminal amino group in cleavage activity, 
we decided to prepare the peptide H2N-Asn-Pro-Gly-Pro-OMe (28). After treatment 
of the tetrapeptide ester (26) with TFA, NMR showed from the disappearance of 
the large signal at 1.42 ppm that the ^BOC protecting group had been completely 
removed. Since TFA is a strong acid, the initial product of the deprotection reaction 
was a TFA salt of the terminal amine but, the free amino peptide (28) was produced 
in basic solution.
In order to synthesize the corresponding tetrapeptide (27), the dipeptide ^BOC-Gly- 
Pro-OM e (22) was reacted with a solution of methanol saturated with NH 3 gas 
(Scheme 2.2). The resulting dipeptide (23), m.p. 152-4 °C, was then deprotected and 
coupled with com pound (19), as described above, to give the tetrapeptide 
^BOC-Asn-Pro-Gly-Pro-NH2 (27). The amino terminus of this compound was also
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dep tro tec ted  using TFA  to give, in basic so lu tion , the te trapep tide  
H 2N-Asn-Pro-Gly-Pro-NH2 (29). This was the exact form of NPGP prepared by 
Palmenberg et
NH
HgN
HN
(26) X = OMe
(27) X = NH2
NH
HgN
NH;
(28) X = OM e
(29) X = NHg
Scheme 2.4: The NPGP tetrapeptides (26-29) examined fo r  cleavage activity
2.2.3 Investigation of structure and reactivity
The four tetrapeptides: (26), (27), (28) and (29) were incubated at pH 8.5 and 37 °C 
for 12 h, and no cleavage activity was observed, as determined using TLC and NMR 
spectroscopy. Even in the cases of (28) and (29) where the amino termini were 
deprotected, no spontaneous degradation was observed, in contrast to the report by 
Palmenberg et alA^ Although the peptides showed no propensity to cleave, it was 
decided to examine the solution structure of the NPGP segment, given that it forms 
part of the sequence of the FMDV 2A region.
In order to find out if the NPGP fragment contained any interesting secondary 
stmctural features, the solution state conformation of the tetrapeptide (26) was studied 
in various solvents, using both NMR and CD. Some small proline-containing 
peptides have been shown to possess secondary structural features such as p bends. 
An example of this is Tuftsin, an immunoactive tetrapeptide (Thr-Lys-Pro-Arg) 
which has been shown by CD analysis to adopt a p-bend conformation in s o l u t i o n .
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The protected tripeptide Ac-Asn-Pro-Tyr-NHMe has also been shown to contain a 
P-bend which is thought to be stabilized by an intramolecular hydrogen bond between 
the asparagine side chain carbonyl and the terminal amide NH proton. The tripeptide 
^BOC-Asn-Pro-Ser-NHMe has also been shown to adopt an Asx (p III) type turn in 
both solution and solid phases which is not stabilized by an intramolecular hydrogen 
bond.^^^ The tetrapeptide (26), however, was shown by CD spectra in both water and 
TFE to be in an extended conformation. There was no evidence of any secondary 
structure (Fig. 2.7).
The ^H and NM R spectra o f the tetrapeptide (26) revealed that a minor 
conformational isomer was present in 15% abundance. In the NOESY spectrum, the 
minor component gave rise to a cross peak between the glycine methylene protons 
and the a-proton of one of the proline residues (Fig. 2.8). This is diagnostic evidence 
for the presence of a cis  amide bond.^'^^ The two proline residues were 
unambiguously assigned from the COSY spectrum and it was shown that the cis 
amide bond was between the glycine and the terminal proline residue.
The results from these studies did not provide any substantial evidence for the 
mechanism of cleavage of the 2A peptide. However, it was shown that the NPGP 
sequence has a reasonably high propensity for the cis conformation at the Gly-Pro, 
rather than the Asn-Pro, amide bond. This has important implications for the 
conformation of the larger 2A peptide which is cleaved at the Gly-Pro junction. A cis 
Gly-Pro bond would cause a reversal in the peptide chain direction and would enable 
the scissile bond to be situated close to potentially nucleophilic residues within the 2A 
segment (see Fig. 1.5, p. 23).
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Figure 2.7: CD spectra o f (26) in (a) H2 O and (b) H 2 O / TFE ( 1:1)
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Figure 2.8: ROESY spectrum o f (26)
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2.2.4 GPF - Introduction
There have been numerous discussions in the literature on the factors which 
determine the cis/trans ratio of X-Pro peptide bonds. Previous studies have noted a 
correlation between the steric bulk in the side chain of the residues preceding or 
following proline and the cis/trans ratio.^3 From other results, however, it appears 
that the nature of the side chain in the amino acid preceding proline has a negligible 
effect on the cis/trans r a t i o .  ^ ^ 4  since simple steric arguments fail to explain the 
observed experimental results, there is a need for a more detailed understanding of 
this phenomenon.
London et al. have noted the unusually high cis/trans  ratio exhibited by peptides 
containing the sequence Gly-Pro-Phe. They have proposed that the trans 
conformation is destabilized due to a repulsive interaction between the glycine 
carbonyl oxygen and the k  electrons in the phenylalanine aromatic ring (see Fig. 1.9a, 
p. 3 3 ).^05 Since GPF is the sequence of the FMDV 2A  polyprotein at the site of 
cleavage, it was decided to synthesize tripeptides containing this sequence to see if 
they did indeed possess large fractional concentrations of the cis isomer.
2.2.5 Synthesis of the GPF tripeptide
To avoid hydrogen bonding interactions involving terminal amine or acid groups, we 
opted to synthesize the peptides with protecting groups on both ends. Phenylalanine 
methylam ide (31), was coupled to ^BOC-proline (30), using the mixed anhydride 
method to give ^BOC-prolyl phenylalanine methylamide. The ^BOC protection was 
rem oved using HCl gas to give Pro-Phe-N H M e.H C l (32) in 94% after 
recrystallization, m.p. 212-14 °C. Subsequent coupling of the dipeptide (32) with 
CBZ-glycine (33), again using the mixed anhydride method, gave the tripeptide 
CBZ-Gly-Pro-Phe-NHMe (34) in 83% yield as a white solid, m.p. 62-6 °C.
In order to investigate the effect of different protecting groups on the cis/trans ratio, 
the dipeptide (32) was coupled to ^BOC-glycine (20) as described above, to give 
tBOC-Gly-Pro-Phe-NHMe (35) in 82% yield, m.p. 75-7 °C.
Unfortunately, X-ray quality crystals of (34) and (35) could not be obtained so it was 
impossible to investigate the solid state conformations of these peptides.
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From the NMR spectra o f (34) and (35), it could be seen that the cis/trans ratios 
were not particularly high. In the case of (34), the cis isomer was present in 
approximately 7% abundance and this figure was slightly lower for (35) (5%). The 
cis/trans ratios for the GPF tripeptides were considerably lower than those of the 
NPGP tetrapeptide, (26) which was shown to contain around 15% of the cis isomer 
due to isomerization of the Gly-Pro bond.
Thus, it can be concluded that the presence of the phenylalanine residue does not have 
a significant effect on the cis/trans ratio of the GPF tripeptides, (34) and (35). From 
the studies on NPGP peptides, it seems that the residues directly preceding the 
Gly-Pro bond are more influential in stabilizing the cis conformation.
NHCHH;
O
(34) X = CBZ
(35) X = *BOC
(31)
(!), (Ii)
(32)
H
NHCHs +
. H
NHCHg
O
NHX
OH
HN'
X o
(33) X = CBZ 
(20) X = ^BOC
R eagen ts  an d  cond itions: (i) NMM, ijo-butyl chloroformate, THF, -15 °C; 
(ii) HCl(g), Etc Ac, 0 °C, 20 min; (iii) NMM, Ao-butyl chloroformate, THF, -15 °C.
Scheme 2.5: Synthesis o f  GPF tripeptides (34) and (35)
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2.3 Synthesis of cis prolyl peptides
2.3.1 Introduction
In order to verify the existence of a cis Gly-Pro bond in the 2A region of FMDV, we 
decided to prepare a variety of synthetic peptides which contained this structural 
element.
The obvious approach for holding an X-Pro amide bond in the cis configuration is to 
tether the a-carbons of the two amino acids with a linker Y (36).
COgH
(36)
Various bicyclic compounds with different linkers have been prepared and have been 
proposed as cis  proline mimetics (see section 1.5, p. 4 4 ), 159,160,195 Although 
com putational studies have shown that distances and torsion angles in these 
compounds are similar to those of naturally occurring cis X-Pro units, they have 
displayed little activity in biological tests. 1^ 9
The main objective of this study was to synthesize a bicyclic compound where the 
linker Y could be broken under mild conditions to give the natural c is  X-Pro 
dipeptide. This synthetic unit could then be incorporated into larger peptides and the 
linkage cleaved as the final step to release the free cis oligopeptide.
The thermodynamic parameters for amide bond rotation in a number of proline- 
containing peptides have been measured by a variety of methods,9 6 , 10 9 , 15 0 , 19 6 - 2 0 0  "phe 
results all give values for the free energy of rotation about the X-Pro amide bond of 
80-90 kJ moTL Using the Eyring equation, it can be calculated that the isomerization 
is slow at room temperature with a half life of several seconds.^^ It is also known that 
the rate of cis-trans isomerization decreases with increasing length of the peptides on 
either side of the b o n d .  ^ 2 7  was envisaged that the cis X-Pro unit could eventually 
be inserted into the larger 2A peptide and that the cis species could be retained long 
enough for self-cleavage to occur, presuming that is the criterion required.
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2.3.2 Synthesis of a cis Gly-Pro mimetic
A bicyclic system with a five-membered pyrrolidine ring fused to a seven-membered 
triazepine ring in a [2,1-d] fashion was chosen as our initial target. Reductive 
cleavage of the larger ring across the nitrogen-nitrogen single bond would give an 
open chain cis peptide (Scheme 2.6).
N R
N R '
reduction N H RO
N H R '
H
Scheme 2.6: Synthesis o f  a cis X-Pro peptide from  a bicyclic pi^ecursor
It was planned to synthesize these systems from bifunctional proline dipeptides and 
suitably substituted hydrazines. This strategy would only be successful if the 
formation of seven, rather than six-membered rings was favoured. Previous studies 
by Cignarella et a /.,201,202 on the reactivity of simple hydrazines indicated a strong 
tendency for double alkylation at one nitrogen (Scheme 2.7).
C0 2 Me
NHgNHg
CO2MGOÙ:"•o
Scheme 2.7: Reaction o f hydrazine with a bifunctional molecule
Initially, the synthesis of a simple model compound was attempted in order to 
ascertain the feasibility of this approach. Bromoacetic acid, (37) was condensed with 
proline methyl ester hydrochloride (21), using mixed anhydride methodology to give 
com pound (38) as a colourless oil. The reaction of (38) with excess hydrazine 
hydrate in refluxing ethanol was followed by TLC which showed the complete 
disappearance of starting material after 90 min. Upon cooling, a white precipitate 
formed, m.p. 265-6 °C. All spectroscopic and analytical data were consistent with 
the assignment of the product as the 5,7-bicyclic compound (39) (Scheme 2.8).
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Hg O
OCH3
OCH3
Br
(37) (21) (38)
(ii) W NH
NH
(39)
Reagents and conditions: (i) NMM, wo-butyl chloroformate, THF/ DMF, -15 °C, 
83%; (ii) NH2NH2 .H2 O, EtOH, 78 °C, 1.5 h, 100%.
Scheme 2.8: Synthesis o f a bicyclic cis Gly-Pro mimetic
It was not immediately obvious whether the structure of the product was the seven- 
membered triazepine (39) or the isomeric six-membered diketopiperazine, (40). Both 
compounds would give the same molecular ion in mass spectroscopy and their NMR 
spectra would be expected to be similar. The compound was eventually assigned as 
the seven-membered ring structure from its chemical reactivity and rather unusual 
NMR properties.
□  The compound showed no reactivity with benzaldehyde. If a primary amino 
group was available, the isomer would give the benzylhydrazone derivative, 
(41), as shown below . 202
PhCHO
□  The NMR spectrum in D2 O showed only one set of signals but when the 
same sample was run in ^/g-DMSO, two sets of signals of similar intensity were 
observed. There is a good deal of information available on the solution 
conformations of proline-containing diketopiperazines in various solvents and 
they are not known to display conformational isomerism in any solvent.203-5
□  Two sets of signals of approximately equal intensity were also observed in the
NMR spectra of (39) in both 2H2 O and c/g-DMSO. Conformational 
isomerism has never been observed in the spectra of proline-containing
d i k e t o p i p e r a z i n e s .  204
7 2
The two sets of signals observed in the NMR spectra of (39) may be due to two 
interconverting conformational isomers which could arise from the geometry of the 
seven-membered ring. The two forms of (39) must be of similar stability with a 
reasonably high energy barrier of conversion between them. It has been calculated 
that the most stable conformations of cycloheptane rings are the twist chair and the 
twist boat which can only be interconverted through major deformations of bond 
angles.206 Although the seven-membered ring system under discussion differs greatly 
from a cycloheptane molecule, molecular modelling studies indicate two energetically 
favourable conformations (Fig. 2.9). The isomer where the seven-membered ring is 
in a pseudo boat conformation (39a) was calculated to be slightly more stable 
(2.4 kJ m ol'O  than the pseudo chair conformation (39b). The NMR spectra 
appear to illustrate the different rates of interconversion in different solvents with 
only one set of signals observed in 2H 2O and two distinct sets apparent in Jg-DMSO. 
The ring-flipping may be too fast in water to be discerned by NMR but is slowed 
down in DMSO to the extent that the different conformers are clearly discernable.
H .N
(39a)
H
'—N
(39b)
Figure 2.9: Two possible conformational isomers o f (39)
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2.3.3 Synthesis of c/s Ala-Pro mimetics
In order to extend the synthesis to the preparation of other cis X-Pro mimetics and to 
shed some light on the mechanism of formation of the seven-membered triazepine 
(39), we decided to synthesize the bicyclic cis Ala-Pro mimetics, (49) and (50) 
(Scheme 2. 9 ).
(2S)-Bromopropionic acid (44) was prepared by the method of Freudenberg from 
(25)-alanine (42).^07 Reaction of the a -h a lo  acid w ith proline m ethyl ester 
hydrochloride (21) using mixed anhydride activation gave the ester (47) in 83% yield, 
m.p. 116-8 °C. The a-brom o centre of (47) was found to be extremely reactive and 
the coupling reaction was carried out at a lower temperature than usual (-40 °C) and 
left stirring for only 30 min. Higher temperatures and longer reaction times resulted 
in epimerization at this chiral centre, detected from the appearance of a second set of 
signals in the and NMR spectra.
The reaction of a-brom o ester (47) with excess hydrazine hydrate gave the fused 
bicyclic compound (49) in 98% yield as an oil. The corresponding diastereomeric 
com pound (50) was synthesized from (2R)-bromopropionic acid (45), using the 
procedure described above (Scheme 2. 9 ). The {R,S) a-brom o ester (48) was a 
crystalline compound and and its stereochemistry was unambiguously assigned from 
the results of a single crystal X-ray structure analysis (Fig. 2.10).
C!6)C(5I
C(7I
C(8) 0(3)C(3) C(910(21C(2)
0(11
0 (1)Br
Figure 2,10: X-ray structure o f (48)
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HgN
(i)
CO2H
( 4 2 )  X =  H, Y  =  C H 3
( 4 3 )  X  =  CHg, Y  =  H
O c"N X O 2H  H
(46 )
(ii)
Br^^CO sH
( 4 4 )  X  =  H, Y  =  C H 3
( 4 5 ) X  =  C H 3 , Y  =  H
OCH3
(iii)
.O C H 3
Br
( 4 7 )  X  =  H, Y  =  CHg
( 4 8 ) X  =  CHg, Y = H
(iv)
( 5 3 )  X  =  H, Y  =  CHg
( 5 4 ) X  =  CHg, Y  =  H
O
Y
( 5 1 ) X  =  H, Y  =  CHg
( 5 2 ) X  =  C H 3 , Y  =  H
(V)
NH
NH
(49)  X  =  H, Y  =  C H g
(50)  X =  CHg, Y  =  H
Reagents and  conditions: (i) HBr, KBr, NaNÛ2 , H2O, 0 °C, 2 h; (ii) SOCI2 , MeOH, 
65 °C, 30 min; (iii) NMM, /5c?-butyi chloroformate, THF/ DMF, -40 °C, 30 min; (iv) 
NH2NH2 .H2O, EtOH, 78 °C, 16 hr; (v) NH3(1), Na, -78 °C.
Scheme 2.9: Synthesis and reactivity o f bicyclic cis Ala-Pro mimetics (49) and (50)
NMR studies showed that the cyclizations of (47) and (48) took 16 h to reach 
completion. The large difference in rate between the reaction of hydrazine hydrate 
with compounds (47) and (48), compared with the unsubstituted compound (38) 
obviously arises from the presence of a methyl group on the halogenated sp^ carbon. 
This gives a strong indication of the mechanism of formation of the bicyclic 
compounds (Scheme 2.10). It can be assumed that the initial attack of the hydrazine 
occurs at the ester, giving an intermediate hydrazide. The rate determining step is 
probably the intramolecular 8 ^ 2  attack of the NH2 group on the halogenated carbon 
to produce the cyclized product with inversion of configuration at the centre of attack.
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Br
CHs NH2 - N H
CH3
Scheme 2.10: Proposed mechanism o f formation o f the bicyclic hydrazides
2 .3 .4  Reduction of the bicyclic hydrazides
The reductive cleavage of the N-N bond of the bicyclic hydrazides (49) and (50) 
proved more difficult than expected. The most usual literature method for achieving 
N-N cleavage is catalytic hydrogenolysis. However, the use of several catalysts, 
including Adams’ catalyst, PdCl2 , palladium on charcoal and rhodium on alumina all 
failed to give the desired product. A i e x a k i s ^ o s  reported an ultrasound-assisted 
cleavage of hydrazine N-N bonds by Raney nickepo^ but this method also proved 
unsuccessful.
The dissolving metal reduction system has been used for the cleavage of N-N bonds 
where one or both nitrogens are attached to a carbonyl g r o u p .210-12 This method was 
employed, using the procedure of Kemp et a/.^io to successfully reduce the bicyclic 
compound (50), giving one product in reasonable yield (Scheme 2.9).
It was clear, however, from spectroscopic data and from the chemical reactivity of the 
reduced compound that it was not the expected product (52):-
□  The (El) mass spectmm of the reduced product showed a molecular ion peak at 
m/z 168. This corresponded to loss of NH3 from the expected product.
□  The NMR spectra of the open chain compound (52) would be expected to show 
a mixture of cis and trans isomers. The NMR spectrum of the reduced 
compound showed the presence of one set of peaks only.
□  The reduced product showed no reactivity when heated with acetic anhydride. 
The primary amino group of the open chain compound (52) would be expected 
to undergo acétylation under these conditions.
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2.3.5 Alternative synthesis of the reduction products
In order to identify the products from the reduction of (49) and (50), we decided to 
prepare the trans isomers of the desired products (51) and (52) via a different route.
Both enantiomers of A^-benzyloxycarbonyl alanine, (55) and (56), were coupled with 
proline methyl ester hydrochloride (2 1 ) using standard mixed anhydride methodology 
(Scheme 2.11). The amino-protected esters, (58) and (59) were obtained in 84% and 
72% yield respectively. Removal of the CBZ protecting group by catalytic 
hydrogenation gave the known cyclic compounds, (53) and (54) in excellent yield 
{for compound (53), m.p. 128-30 °C (lit.,203 127-9 °C)}. The intramolecular reaction 
of an amine with an ester to form a six-membered ring is facile, and is the standard 
method for the preparation of diketopiperazines.
Ammonolysis of the dipeptide esters, (58) and (59) gave the dipeptide amides, (61) 
and (62) as crystalline solids (for compound (61), m.p. 167-9 °C). Removal of the 
CBZ protecting group again led to the formation of the individual diastereomeric 
diketopiperazines, presumably via an intramolecular transamidation reaction (see 
section 2.4). It was surprising that the formation of the diketopiperazines was equally 
facile to the analogous reaction with the methyl esters (58) and (59) when the leaving 
group was that of an amide.
The CBZ groups were removed in an acidic solution, in an attempt to trap out (51) 
and (52) as their hydrochloride salts before cyclization occurred. Although this was 
successful and hindered the cyclization process, NMR spectra showed that after 
8 h, >80% of the deprotected dipeptide had formed the diketopiperazine.
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COgH
(3 3 )  X =  H, Y  =  H
( 5 5 ) X  =  H, Y z z C H g
(5 6 )  X =  C H 3 , Y  =  H
OCH3
(21)
OCH3
NH
C B Z "
( 5 7 ) X  =  H, Y  =  H
( 5 8 )  X =  H, Y  =  C H 3
( 5 9 )  X =  CHg, Y  =  H
X Y
(64)  X  =  H, Y  =  H 
(54)  X =  H. Y  =  C H 3  
(53)  X =  CH g, Y  =  H
NHg
NH
CBZ
(60 )  X =  H, Y = H
(6 1 )  X =  H, Y  =  C H g
( 6 2 ) X  =  CHg, Y  =  H
NHgO
X
(6 3 )  X =  H, Y  =  H
( 5 1 ) X  =  H, Y  =  C H g
(52)  X  =  CHg, Y  =  H
R eagents and  conditions: (i) NMM, /5 0 -butyl chloroformate, THF/ DMF, -15 °C, 
2 h; (ii) NHgCg), MeOH, rt., 48 h; (iii) H 2 (g), Pd/C(cat), MeOH, rt., 8 h.
Scheme 2.11: Alternative diketopiperazine syntheses
An alternative method of trapping out the dipeptide amides directly would be to 
choose an acid labile protecting group for the amine, such as ^BOC. The ^BOC 
protected dipeptides, (23) and (67) were therefore prepared as outlined in Scheme 
2.12. Removal of the ^BOC groups using hydrogen chloride gas gave the dipeptide 
amide hydrochlorides (68) and (69) as hygroscopic solids. The ^H and NMR 
spectra for each compound contained two sets of peaks, the minor set due to the cis 
isomer (15%), providing strong evidence in support of open chain structures.
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‘B o c .
N X O 2 H 
H
(20) X = H, Y = H 
(65)X = H, Y = CH3
c+N
Cl" O
(21)
OCH3
(
(i) Y
X
O C H 3
O
*BOC' ,NH
(22) X = H, Y = H 
(6 6 ) X = H, Y = CH3
NH;
NH
(23) X = H, Y = H 
(67) X = H, Y = CH3
(iii)
NH2
(68) X = H, Y = H
(69) X = H. Y = CH3
R eagents an d  conditions: (i) NMM, wo-butyl chloroformate, THF/ DMF, -15 °C, 
2 h; (ii) NHsCg), MeOH, rt., 48 h; (iii) HCl(g), EtOAc, 0 °C, 15 min.
Scheme 2.12: Synthesis o f  open chain dipeptide amides
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2.4 Intramolecular transamidation reactions
2.4.1 introduction
There aie very few cases reported in the literature of intramolecular transamidation 
reactions, and even fewer examples where such reactions occur, spontaneously.-^^ 
The few existing examples have been classified into two types (Scheme 2.13).2i4.2i5 
Type 1 is an amine elimination which occurs with formation of a cyclic lactam and 
the second type is a rearrangement, combined with N-->N' acyl migration.
o
—  N■NHR \
RN
O HN'
Type 1 : C-Aminoalkyl 
transamidation
» /V V V V V / \A /V /V \ / '
o
RHN
/ NH
Type 2: N-Aminoalkyl 
transamidation
Scheme 2.13: Types o f intramolecular transamidation
An example of Type 2 is the “zip” reaction, an interesting ring expansion which 
proceeds via intramolecular transamidation (Scheme 2.14).216,217 starting  from 
A^-substituted lactams, successive incorporation of aminopropyl units produces 
macrocyclic polyazalactams. The zip reaction can be used to form macrocycles with 
up to 53 ring atoms. These reactions are not spontaneous and strong bases such as 
^BuOK or potassium-3-aminopropyl amide (KAPA) are required to deprotonate the 
exo-cyclic amine group.
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HzN
NH
(i)
NH
Reagents: (i) KAPA, H3O+; (ii) Na salt of the amide, CH2=CH-CN; Ha/Pt.
Scheme 2.14: The “zip" reaction
The reaction is only successful with aminopropyl groups, as this chain length results 
in a favourable six-membered transition state. In such cases, there is no obvious 
release of ring strain and the driving force of the reaction can be regarded as the 
conversion of the initially generated amino anion into the comparatively stable amide 
anion.
Examples of spontaneous intramolecular transamidation tend to be of type 1, where 
there is an additional entropie driving force due to the elimination of an amine 
molecule. It was noted by Barrass and Eltmore in 1 957 ,^ 18  that the side chains of 
derivatives of basic amino acids such as lysine, underwent spontaneous reactions of 
type 1 to produce cyclic lactams (Scheme 2.15).
HN-CBZ
H: NH2
H2 -Pd
p-TOS NH + NH3
Scheme 2.15: Formation o f cyclic lactams from  basic amino acid amides
8 1
2.4.2 Formation of diketopiperazines
A problem often encountered in both solution and solid phase peptide synthesis is that 
of base catalyzed ring closure. Such side reactions often occur during the process of 
adding a third residue to a dipeptide derivative. In particular, alkyl esters of 
d ipep tides are know n to undergo spontaneous cycliza tion  to produce 
2,5-diketopiperazines (DKPs) (Scheme 2.16).
o.^ ®
N H
H N C a r"  L  ^o
R'R '
Scheme 2.16: Formation o f DKPs from  dipeptide esters
Both amide bonds in DKPs are in the cis configuration. Accordingly, the cyclization 
process requires the energetically unfavourable conversion of the trans open chain 
dipeptide to the less stable cis form. The energy liberated in the formation of the veiy 
stable DKP structure provides the necessary driving force for the reaction. There are 
certain cases in which spontaneous DKP formation is especially favoured.
□  Ring formation is particularly pronounced in glycine-containing peptides, since 
the absence of a bulky side chain makes the cyclization process easier.
□  DKP formation is highly favoured for proline-containing peptides as the cyclic 
side chain lies in the plane of the DKP molecule and is out of the way during 
ring closure. In addition, the cis  conform ation (which is required for 
cyclization) is more stable relative to the trans than for other amino acids (see 
Section 1.2.3, p. 24).8i-84
□  DKPs are more readily formed when one of the residues has {S) chiral 
configuration and the other, (R). In such cases, the side chains are on opposite 
sides of the general plane of the DKP.^03 jf  both amino acids have the same 
configuration, then both side chains are on the same side and their bulk 
interferes with ring closure.
DKP formation is known to occur readily in methyl, ethyl and benzyl esters of 
dipeptides, but not in tertiary butyl esters. The formation of diketopiperazines from
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dipeptide amides was first reported by Huang and Niemann in 1950,-^^ who observed 
this phenomenon with non-prolyl dipeptides and suggested the reaction was restricted 
to primary amides.
2.4.3 Diketopiperazine formation from X-Pro amides
The facile transformation of the dipeptide amides, (51), (52) and (63) into the DKPs, 
(53), (54) and (64) was an undesirable reaction for the puipose of obtaining cis X-Pro 
peptides (Schem e 2.11, p. 78). We therefore decided to investigate this 
intramolecular transamidation further to find out how it could be prevented.
Substitution of the amine nitrogen was first tried to see if this would slow the rate of 
cyclization (Scheme 2.17). Due to the high cost of //-m ethyl alanine, sarcosine 
(//-m ethyl glycine) (70), was employed. //-Benzyloxycarbonyl sarcosine (71) was 
coupled to proline m ethyl ester hydrochloride (2 1 ) using mixed anhydride 
methodology to produce the protected dipeptide ester (72) (Scheme 2.17). Compound 
(72) was isolated as an oil and was purified using column chromatography. 
Ammonolysis of (72) in methanol produced the dipeptide amide (73) in almost 
quantitative yield. The NMR spectra of (72) and (73) were extremely complex, 
showing the presence of four conformational isomers. This is due to the sarcosyl 
tertiary amide bond which exists as both cis and trans conformations (see section 
1.3.4) in a roughly 4:6 {cis'.trans) ratio. Since both conformations of the prolyl amide 
bond were also present in an approximately 1:4 {cis:trans) ratio, the result was a 
mixture of four conformers in an 8:12:32:48 ratio.
After removal of the CBZ group by hydrogenolysis, both the and NM R 
spectra of the product were greatly simplified, showing only one set of peaks. This 
suggested that the A-methyl DKP (74) had been formed. Although this compound 
has been reported in the literature as an oil, no accompanying spectroscopic data were 
p u b l i s h e d .  220 Further spectroscopic and analytical analysis confirmed the structure of 
the DKP to be that of (74). Thus, it was clear that substitution of the amine nitrogen 
did not significantly slow down the transamidative cyclization reaction.
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(
(70)
OH
O
(i) CBZ n r "“NICH3
(71) (21 )
OCH3 (ii)
OCH;
(iii)
NH.
CBZ
(Iv)
(72) (73) (74)
R eagents and  conditions: (i) NaOH (1 mol dm-3), PhCH2 0 C0 Cl, 0 °C, 4 h, 96%; 
(ii) NMM, ffo-butyl chloroformate, THF/ DMF, -15 °C, 2 h, 77%; (iii) NHs(g), 
MeOH, rt., 48 h, 80%; (iv) H2(g), Pd/C, MeOH, rt., 12 h, 90%.
Scheme 2.17: Synthesis o f  an ^-m ethylated DKP compound
Secondly, the amide functionality was changed to see if this would have any effect on 
the rate of cyclization. The dipeptide esters, (58), (59) and (72), derived from 
(5')-alanine, (Æ)-alanine and sarcosine respectively, were dissolved in methanol 
saturated with methylamine gas and the reaction was followed by TLC and by NMR 
spectroscopy (Scheme 2.18). The rate of the reaction of methylamine with alkyl 
esters was found to be faster than that of ammonia and the NMR spectra showed 
the disappearance of the methyl ester (6  3.4 ppm) after 6  h. This greater reactivity 
was expected, due to the increased nucleophilicity of methylamine and also due to its 
greater solubility and therefore higher concentration, in methanol.
The resulting dipeptide methylamides, (75), (76) and (79) were then hydrogenated 
and the NMR spectra showed the complete disappearance of aromatic signals 
( 6  5.0 & 7.5 ppm) after 12 h. The structures of the resulting compounds, (77), (78) 
and (80) were assigned on the basis of spectroscopic evidence.
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□  Two sets of signals were observed in the NMR spectra of the products. 
This characteristic was suggestive of cis/trans  isomerism and therefore 
indicative of open chain structures.
□  The products reacted easily with acetic anhydride and NMR studies showed the 
appearance of new signals at 2.1 ppm, due to N-acetyl functionalities. These 
observations provide good evidence for the presence of a free amine group.
□  After three days, NMR spectra recorded for the {R,S) diastereomer (78) showed 
a new set of minor peaks. These corresponded exactly to the signals observed 
for the diketopiperazine, (53). No set of minor peaks were observed in NMR 
spectra of the {S,S) diastereomer, (77) after the same time period had elapsed. 
These observation are consistent with the greater propensity of {R,S) dipeptides 
to undergo DKP formation (see p. 82).
y'.H OCH3
CBZ
.NH
(i)
NHCHq
NH
CBZ'
(ii) NHCHs
( 5 8 ) X = H ,  Y  =  C H 3
( 5 9 ) X  =  C H 3 , Y  = H
( 7 5 ) X  =  H, Y  =  C H 3
(7 6 )  X =  C H 3 , Y  =  H
( 7 7 )  X =  H, Y =  C H 3
( 7 8 )  X =  CHg, Y =  H
.H
CBZ" "cHa
(72)
(i)
.H
NHCHa
,N
CBZ ^CH3
(79)
(ii)
V'.H NHCH3
NH
HsC'
(80)
Reagents and  conditions: (i) H2NCH3(g), MeOH, rt., 8  h; (ii) H2 (g), Pd/C, MeOH, 
rt., 1 2  h.
Scheme 2.18: Effect o f amide substitution on transamidation
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From these observations, it was clear that substitution of the primary amide for a 
methylamide group led to a dramatic reduction in the rate of DKP formation. In order 
to synthesize cis prolyl peptides via reductive N-N bond cleavage, a secondary amide 
had to be produced in order to prevent consequent deamination of the product. These 
results also showed that, in contradiction to the observations of Huang and 
N i e m a n n ,219 DKP formation can occur for secondary amides, albeit at a much slower 
rate.
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2.5 Synthesis of A/-substituted cis prolyl peptides
2.5.1 Introduction
The next step towards the synthesis o f cis  X-Pro peptides was therefore to use 
substituted hydrazines in the formation of 5,7-bicyclic compounds. It was hoped that 
the N-N bond in these compounds would be cleaved under the same conditions as 
(49) and (50) but that the resulting open chain peptides would not undergo such rapid 
diketopiperazine formation.
In order to establish the regioselectivity of the ring formation with substituted 
hydrazines, the a-brom o-dipeptide esters, (38), (47) and (48) were reacted with 
m ethylhydrazine (84), the simplest monosubstituted hydrazine (Scheme 2.19). 
Excess methylhydrazine was added to the a-brom o dipeptide esters in re fluxing 
ethanol and TLC indicated the complete disappearance of the starting material after 
ai'ound 15 min.
OCH.
(i) No reaction
(38) X=H, Y=H
(47) X=H, Y=GH3(48) X=CH3, Y=H
(81)X=H, Y=H
(82) X=H, Y=CH3
(83) X=CH3, Y=H
R eagents and  conditions: (i) NHCH3NH2 , BtOH, 78 °C, 30 min; (ii) Na, NH 3 (1), 
THE, -60 °C, 1 h.
Schem e 2.19; Synthesis and reactivity ofN-m ethylated bicyclic cis X-Pro mimetics
The NMR spectra of the products were indicative of bicyclic compounds since no 
cis/trans conformational isomerism was observed. The reactions were apparently 
highly regio and stereoselective in all cases and NMR spectroscopy indicated that one 
product had formed in greater than 95% yield. Although all analytical and spectral
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data were consistent with the structures, (81), (82) and (83), the orientation of the 
methylhydrazine moiety in the products was not immediately clear. Since it had been 
understood that the ester functionality in (38), (47) and (48) was primarily attacked by 
unsubstitu ted  hydrazine (Schem e 2.10), it was assum ed that attack by 
methylhydrazine would initially occur at the same site. It is known, however, that 
methylhydrazine generally reacts with simple esters to give a mixture of 1-acyl-l- 
methyl and l-acyl-2 -methyl i s o m e r s .221
2.5.2 Structural studies
Various NMR experiments were employed to try and establish whether the methyl 
group was situated on the amide or the amine nitrogen However, these proved 
inconclusive and a single crystal X-ray diffraction study of compound (81) was 
carried out in order to determine the correct structure.
0 ( 2 )
Figure 2.11; X-ray structure o f (81)
The X-ray structure (Fig. 2.11) showed that the methyl group was situated on the 
amine nitrogen. In the solid state, the seven-membered triazepine ring was found to 
be in a pseudo boat conformation with the N-methyl group in an equatorial position 
(Fig. 2.12). The pyrrolidine ring has an envelope structure with approximate Cg 
symmetry, the mirror plane passing through the C(4) or CY atom. The N (l), C(2), 
C(3) and C(5) groups are almost planar and the C(4) and C (l) atoms are on opposite 
sides of the plane. Thus, the conformation of the ring is C^-0(-exo as defined by 
A shido and Kakudo222  and corresponds to conform ation A according to 
Balasubramian et
C(7I N(2)
Nil)
N(3)C(6)
0 ( 2 ) 0 (1)
0 ( 1)
Figure 2.12: X-ray structure o f (81)
The rapid formation of compounds (81), (82) and (83) supports the previously 
proposed mechanism (Scheme 2.10). The increased nucleophilicity of the methylated 
nitrogen would facilitate the intramolecular cyclization step. If this step proceeded by 
an Sn2  mechanism, then inversion of stereochemistry would have taken place at the 
a  carbon.
In order to establish the correct stereochemistry of the products, a single crystal X-ray 
diffraction study was carried out on the product of the reaction between the (S,S) 
a-brom o ester (47) and methylhydrazine. The product bicyclic compound (82) was 
found to posess (R,S) stereochemistry (Fig. 2.13). This showed that inversion of 
configuration had taken place and provides evidence for an SN2 -type mechanism.
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C(4)
C(3)C(5)
C(2)N(1)
0 ( 1)
C(1)
0(21 0 (6 )
N(3)
0(7)
N(2)
0 (8 )
0(9)
Figure 2.13: X-ray structure o f (82)
C(2)
C(7)C(6) N(2)
N(l)
N(3)
C(])0(21
0(1)
F igure 2.14: X-ray structure o f (82)
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The seven-membered ring of (82) adopts a pseudo boat configuration (Fig. 2.14), as 
observed for the related compound (81). In this case, however, the conformation of 
the pyrrolidine ring is C^-Ct-endo  as defined by Ashido and Kakudo222 and 
corresponds to conformation B according to Balasubramian et
The A-methylated bicyclic compounds, (81), (82) and (83), were all found to be 
stable to dissolving metal reduction (Scheme 2.19). Addition of excess amounts of 
sodium and long reaction times failed to cause reaction of the stalling materials. The 
reasons for this are not immediately clear. The presence of the alkyl group on the 
amine nitrogen obviously deactivates the compounds relative to the unsubstituted 
analogues, (41), (50) and (51). This could be due to steric constraints, as the methyl 
group may make it harder for a solvated electron to attack the amide carbonyl.
2.5.3 Synthetic strategy
From the results obtained from the preceding studies, it was clear that cis X-Pro 
peptides could only be prepared from compounds which possessed the following 
characteristics. Firstly, a bicyclic precursor was required which did not contain an 
alkyl group on the amine nitrogen of the hydrazide bond. This appeared to prevent 
successful reductive cleavage of the N-N bond using the sodium/ liquid ammonia 
methodology (Scheme 2.19). Secondly, the presence of an alkyl group on the amide 
nitrogen of the hydrazide bond was essential for the prevention of diketopiperazine 
formation (see section 2.4.3).
Previous studies had shown that the unsubstituted nitrogen of m onoalkylated 
hydrazines reacted in preference with the ester groups of a-brom o dipeptide esters 
such as (37), (47) and (48) (Scheme 2.19). It was therefore clear that a hydrazine 
derivative was required where the unsubstituted nitrogen was deactivated relative to 
the alkylated nitrogen. Protection o f the unsubstituted nitrogen was not 
straightforward due to the unusual reactivity of hydrazines.
2.5.4 Reactivity of hydrazines
In contrast to the situation in amines, substitution of hydrogens by alkyl groups in 
hydrazines lowers the basicity. The hydrazine, however, is protonated on the more 
highly alkylated nitrogen. Similarly, alkylation of hydrazines usually takes place on
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the more substituted n i t r o g e n . 2 2 4  Acylation of unsymmetrical hydrazines, however, is 
less predictable than alkylation and more dependent on the conditions used .^21
The methyl-bearing nitrogen of methylhydrazine (84) has been shown to attack 
selectively reactive functional groups such as carboxylic acid anhydrides and 
c h l o r i d e s . 2 2 5 , 2 2 6  Conditions have been devised by Peet et a i  for acetylating 
methylhydrazine using acetyl chloride to give 1-methyl-1-acetylhydrazine in excellent 
y i e l d . 2 2 7  in contrast, the reaction of an ester and methylhydrazine yields a mixture of 
the 1-acy 1-2 -methyl and I-acyl-1-methyl i s o m e r s .221 it is thus extremely difficult to 
acylate selectively the primary amine of methylhydrazine in one step.
We decided that the most successful strategy towards the synthesis of a cis Gly-Pro 
mimetic would therefore require reaction of the a-brom o ester (38) with a suitably 
N-protected-N '-m ethylhydrazine, follow ed by subsequent deprotection and 
cyclization (Scheme 2.21).
An N-protected-N'-methylhydrazine could easily be obtained, starting with selective 
protection of the methyl-bearing nitrogen. Protection of the primaiy amine then with 
a different protecting group which was stable to conditions for the deprotection of the 
methylated nitrogen would give the desired compound. We decided to use the 
benzyloxycarbonyl group to protect the latter, since this group is easily removed by 
catalytic hydrogenation which would not affect a fgrf-butoxycarbonyl group on the 
adjacent nitrogen.
Pederson reported the synthesis of A-benzyloxycarbonyl-A^-methylhydrazine (85) in 
60% yield from the reaction of m ethylhydrazine w ith d i b e n z y l c a r b o n a t e . ^ 2 8  
However, as the procedure involved separating the required compound from the 
l-acyl-2-methyl isomer, we opted for an alternative synthesis. By using benzyl 
chloroformate as the acylating agent, and employing the conditions of Peet et a/. ,227
(85) was obtained in high yield (89%) with excellent regioselectivity. The NMR 
showed that less than 3% of the undesired isomer had been formed.
The m onoacylated derivative of m ethylhydrazine was then reacted with 
ditertiarybutylcarbonate to give the dihydrazide (8 6 ). Removal of the CBZ group by 
hydrogenolysis using palladium on activated charcoal gave the desired product, 
A/^-rer^-butoxycarbonyi-A-methylhydrazine (87), m.p. 46-9 °C.
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HsCHN— NHg 
(84 )
(i)
CHg
(85) ^
CHg O
o
(86)
H gC "  N O '
(87)
R eagents an d  conditions: (i) PhCH 2 0 C0 Cl, CH2C I2, 0 °C, 30 min, 89%; 
(ii) (tBu0 2 C)2 0 , iPrOH/ CH2CI2 , r t ,  3 h, 80%; (iii) H2(g), Pd/C, MeOH, r t ,  12 h, 
85%.
Scheme 2.20: Synthesis o f ]>l~tQvt-butoxycarbonyl-N'-methylhydrazine
2.5.5 Synthesis of AZ-methyl cis X-Pro mimetics
The methylhydrazine derivative (87) and the dipeptide ester (38) failed to react 
together in boiling ethanol, even after 48 h. This was probably due to steric hindrance 
since the synthesis of secondary and tertiary amides from carboxylic esters is known 
to be difficult for this r e a s o n .2 2 9
CHg
NH
Br
HN 7 8  °C, 4 8  h No reaction
( 3 8 )  (8 7 )
Scheme 2.21: Attempted reaction o f (87) with dipeptide ester (38)
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Although the reaction of (87) with esters was not favourable, such hindered amines 
are known to react with carboxylic acid groups using various peptide coupling 
t e c h n i q u e s 4 9 3  A^-Chloroacetyl-(25')-proline (8 8 ) was prepared from chloroacetyl 
chloride and proline (46) by the method of Ronwin^^o (Scheme 2 .2 2 ) and reacted with 
the methylhydrazine derivative (87). W hen the mixed anhydride method was used, 
compound (89) was obtained in 79% yield, m.p. 64-7 °C. Although the coupling 
reagent PyBroP,!^^ which is supposed to be a specialized reagent for the coupling of 
A-methyl amino acids, gave a slightly improved yield (8 6 %), its considerable expense 
did not justify its use.
Removal of the ^BOC protecting group using HCl gave the hydrochloride salt (90) as 
a hygroscopic white solid. NMR showed the complete loss of the r^rf-butyl signal 
at 1.48 ppm. Excess NMM was then added to a solution of (90) in methanol and after 
removal of the solvent, the reaction mixture was partitioned between water and ethyl 
acetate. The organic layer was found to contain the bicyclic product (91), 
m.p. 75-9 °C.
The intramolecular Sn2 cyclization step appeared to be extremely facile, even though 
the leaving group in this case was chloride rather than bromide, as in the formation of 
(81) (Scheme 2.19). Although the mass spectrum of (91) gave a molecular ion at the 
same m/z as compound (81), all other spectroscopic data were different, confirming it 
as a chemically distinct isomer. Unlike that of the isomeric compound (81), the 
NMR spectrum of (91) contained two sets of peaks. This is presumably due to 
conform ational isomerism, as displayed by the related cis Gly-Pro bicyclic 
compound, (39).
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(!)
( 4 6 )
ÇHs
(ii)
-
(87 )
Cl ( 8 9 )
(!!!)
H
( 9 1 )
(iv)
CHg
Cl
( 9 0 )
R eagents and  conditions: (i) CICH2COCI, NaHCOs, CH2CI2, 0 °C, 30 min, 6 8 %; 
(ii) NMM, wo-butyl chloroformate, THF, -15 °C, 12 h, 73%; (iii) HCl(g), EtOAc, 
0 °C, 15 min, 100%; (iv) NMM, MeOH, 5 min, 79%.
Scheme 2.22; Synthesis o f an N-fnethylated cis Gly-Pro mimetic
The synthesis of analogous cis (R) and (5) Ala-Pro mimetics was more difficult due to 
unwanted reactions at the second chiral centre. The carboxylic acid precursors, (96) 
and (97) were obtained from hydrolysis of esters (94) and (95) respectively, using 1 
mol dm-3 sodium hydroxide (Scheme 2.23). It was this hydrolysis step which 
rendered use of the bromo dipeptide esters, (47) and (48) unsuitable. The brominated 
carbon centre in these compounds was found to be extremely reactive (see section 
2.4.3). Although the ester groups of (47) and (48) were readily hydrolysed, ^H and 
NMR spectra showed the presence of two sets of signals. We therefore reasoned 
that the brominated centre had undergone base-catalyzed enolization which led to 
scrambling of the stereochemistry.
95
VHgN^^COgH
(4 2 )  X  =  H, Y  =  C H g
( 4 3 ) X  =  C H 3 , Y = H
(i)
O c"
(4 6 )
CO2H
(ii)
C 1""^C 02H
( 9 2 ) X  =  H, Y z z C H g
( 9 3 ) X  =  C H 3 , Y  =  H
OCH3
(iii)
OCH;
Cl
( 9 4 ) X  =  H , Y  =  C H 3
(95)  X =  CH g, Y  =  H
(iv)
(9 8 )  X =  H, Y  =  C H 3
(9 9 )  X =  CHg, Y  =  H
(vi)
(V)
CHg
.NHHN 
0 ^ 0
( 8 7 ) (96 )  X =  H, Y  =  C H g(9 7 )  X =  CH g, Y  =  H
u  CHg
( 1 0 0 ) X  =  H, Y  =  CHg
( 1 0 1 ) X  =  CHg, Y  =  H
(vil)
( 1 0 2 ) X  =  H, Y  =  CHg
( 1 0 3 ) X  =  CHg, Y  =  H
Reagents and conditions: (i) HCl, KCl, NaNO], H2 O, 0 °C, 2 h, 91%; (ii) SOCI2 , 
M eOH, 65 °C, 30 min; (iii) NMM, wo-butyl chloroformate, THF/ DMF, -15 °C,
1.5 h; (iv) 1 mol dm-^ NaOH, M eOH/ H 2 O, rt., 2 h; (v) NMM, /.yo-butyl 
chloroformate, THF/ DMF, -15 °C, 12 h; (vi) HCl(g), EtOAc, 0 °C, 15 min; (vii) 
NMM, MeOH, 5 min.
Scheme 2.23: Synthesis o f ^ -methyl cis Ala-Pro mimetics
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The a-chloro analogues, (94) and (95) were found to be less reactive and underwent 
base-catalyzed hydrolysis w ithout any epim erization. The (25) and {2R) 
chloropropionic acids, (92) and (93) were synthesized according to the method of 
Greenstein et a/.23i and coupled with proline methyl ester (21) using mixed anhydride 
m ethodology. The esters (94) and (95) were obtained in 71% and 83% yield 
respectively (for compound (95), m.p. 118-20 °C). Base catalyzed hydrolysis of (94) 
and (95) then gave the corresponding acids, (96) and (97) (for compound (96), 
m.p. 164-5 °C). The and NMR spectra showed only one set of peaks for each 
compound, suggesting that no side reactions had taken place.
The acids, (96) and (97) were then coupled to the methylhydrazine derivative (87) 
using mixed anhydride methodology to produce the prolyl hydrazides, (98) and (99) 
in reasonable yield (62% and 6 6 % respectively), (Scheme 2.23). These compounds 
were easily purified by column chrom atography and showed the expected 
spectroscopic and analytical data (for compound (98), m.p. 81-3 °C and for (99), 
m.p. 132-5 °C). Removal of the ^BOC groups, followed by the subsequent cyclization 
of the resulting hygroscopic salts, (100) and (101), using 2 equivalents of NMM gave 
(102) and (103) (for compound (102), m.p. 108-10 °C and for (103), m.p. 112-15 °C). 
The bicyclic compounds, (102) and (103) were found to have different spectroscopic 
characteristics to the isomeric compounds (82) and (83) (Scheme 2.19).
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2,5.6 Reductive cleavage of bicyclic compounds
Compounds (82) and (83) were found to be completely stable to reduction by sodium 
in liquid ammonia (Scheme 2.19). In contrast, compounds (102) and (103) were 
easily reduced under these conditions. Although the sodium in liquid ammonia 
reducing system is a general method for the cleavage of N-N bonds,2 ^o-i2 the 
mechanism of cleavage has never been investigated.
An unexpected product was obtained from the reaction of (102) and (103) with 
sodium in liquid ammonia at -60 °C (Scheme 2.24). The first surprising observation 
was that both diastereomers gave the same reduction product. This indicated loss of 
one of the chiral centres. Secondly, the NMR spectra contained a triplet at 
1.1 ppm and a quartet at 2.3 ppm which is characteristic of the presence of an ethyl 
group.
(102)X = H,Y = CH3
(103)X = CH3, Y = H
Na, NH3(1)/THF 
-60 °C,
( 1 0 4 )
Scheme 2.24: Reduction o f bicyclic hydrazides (102) and (103)
It seemed that as well as N-N bond cleavage and loss of ammonia, a C-N bond had 
been cleaved to give the reduction product (104), m.p. 49-52 °C. Compound (104) 
was prepared by an alternative route (Scheme 2.25) and all spectral and analytical 
data matched those of the reduction product of (102) and (103).
In order to make sure that (104) was not the result of over-reduction of the desired 
dipeptide products, the reaction was repeated with (102), using 0.5 equivalents of 
sodium. NMR spectra clearly showed the presence of (104) as well as some 
unreacted starting material. This demonstrated that a rapid C-N hydrogenolytic 
fission had taken place in preference to the N-N reductive cleavage. This event was 
very rapid and could not be prevented by altering the reaction conditions.
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(i). (il), (iii)
(46) (104)
Reagents and conditions: (i) CH3 CH2COCI, NaHCOs, CH2CI2 , 0 °C, 30 min, 82%; 
(ii) SOCI2 , MeOH, 65 °C, 30 min, 100%; (ii) H2NCH3(g), MeOH, rt., 8  h, 99%.
Scheme 2.25: Alternative synthesis o f reduction product (104)
Hesse et al. reported a similar reaction for (105), an intermediate in the synthesis of 
the spermidine alkaloid A^-Acetyl-A/^-deoxymayfoline.232 On treatment with sodium 
in liquid ammonia, a hydrogenolytic C(5)-N(6) fission occurred in preference to the 
desired N (l)-N (6 ) cleavage. It was concluded that, under these conditions, C-N bond 
cleavage will be more favourable than N-N cleavage if the latter is ally lie to a double 
bond. The N-N bond in (102) and (103) can be thought of as heteroallylic as it is a  to 
a carbonyl group.
( 1 0 5 )
Catalytic hydrogenation of (102) and (103), using palladium on charcoal, also 
resulted in C-N bond cleavage and the formation of (104). The reactivity of these 
compounds with sodium in liquid ammonia can be rationalized by the mechanism 
shown in Scheme 2.26. If the prolyl amide carbonyl acts as an acceptor for a solvated 
electron produced by the dissolved sodium, a radical anion, (106), would be formed 
where the radical is adjacent to the C-N bond. Homolytic cleavage of the C-N bond 
would then follow to give the intermediate, (107) which would undergo subsequent 
N-N bond cleavage and loss of ammonia to give (104).
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0  o'
C H g (106)
(102)
(104)
C H g
CH g (107)
0  ^
^  H—  NH g0 o H^NHa
Scheme 2.26; Proposed reduction mechanism
In the case of the reduction of the bicyclic hydrazides, (49) and (50), the secondary 
amide carbonyl was probably the electron accepting site (see p. 76). This would have 
generated a radical next to the N-N bond and resulted in the observed cleavage of the 
bond. According to this mechanism, if a radical could be produced which was 
adjacent to the N-N bond in (102) or (103), then the bond could be cleaved in a 
similar manner.
The thoiurea derivative (108) was prepared from the reaction of (102) with phenyl 
wo-thiocyanate in 76% yield, m.p. 100-3 °C (Scheme 2.27). The thioamide double 
bond was expected to be a better electron acceptor than either of the amide carbonyls 
and it was hoped to produce a radical at this site. This radical would be a  to both the 
C-N and N-N bonds and it was thought that selective cleavage of the N-N bond would 
occur. On treatment of (108) with sodium in liquid ammonia, however, the reduction 
product was again (104), emphasizing the ease of cleavage of the C-N bond. Clearly, 
in order to avoid cleavage of this bond, a radical was required which was exclusively 
a  to the N-N bond.
1 0 0
o
CH
(i)
( 102)
N - C H 3
C H 3
( 1 0 4 )
Reagents and  conditions: (i) PhNCS, CH2CI2, 40 °C, 2 h; (ii) NHsCl), THF, Na, 
-60 °C, 30 min.
Scheme 2.27: Synthesis and reactivity o f thiourea derivative (108)
The surprising ease of cleavage of the C-N bonds of (102) and (103) in dissolving 
metal reductions may be partly due to the orientation of the acceptor carbonyl relative 
to the C-N bond. Computer modelling studies on the bicyclic compound (102) show 
that the C-N bond is almost orthogonal to the adjacent carbonyl group (Fig. 2.15). 
This means that the orbital containing the radical would be lined up with the C-N 
bond in a manner which would facilitate subsequent homolytic cleavage of the bond.
Figure 2.15: Geometry o f C-N bond o f (102)
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2.5.7 Synthesis and reactivity of an A/-methyl cis |3Ala-Pro mimetic
The 5,8 bicyclic compound, (109), is a cis pAla-Pro mimetic. Since the hydrazine 
C-N bond in this case is p to the nearest carbonyl, it should not be possible for it to 
cleave via the mechanism outlined in Scheme 2.26. In the absence of this competing 
reaction, it was hoped that the dissolving metal reduction of (109) would result in the 
selective cleavage of the N-N bond.
o
N - C H 3
NH
(109)
To synthesize (109), iV-3-chloropropanoyl-(25)-proline (110) was coupled to the 
methylhydrazine derivative (87) using mixed anhydride methodology to produce the 
prolyl hydrazide (111) in 8 8 % yield, m.p. 108-11 °C (Scheme 2.28). Removal of the 
•^BOC group, followed by the subsequent cyclization of the resulting hygroscopic salt 
using 1 mol dm-^ NaOH gave the novel 5,8 -bicyclic pyrrolo-triazocine compound 
(109), m.p. 129-32 °C. Although the formation of the eight-membered rings is 
generally considered to be less favoured than the formation of seven-membered rings, 
the cyclization to produce (109) was very rapid, as judged by TLC.
OH
Cl
(110)
ÇH3  
• NH (i)HN
m  Q . .
^ N-CH3
(109)
GH3 o
(111)
Cl
R eagents and  conditions: (i) NMM, iso-butyl chloroformate, THF, -15 °C, 1.5 h, 
8 8 %; (ii) HCl(g), EtOAc, 0 °C, 15 min; (iii) 1 mol dm-3 NaOH, MeOH, 5 min, 60%.
Scheme 2.28: Synthesis o f  an ISl-methyl cis pAla~Pro mimetic
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It was hoped that the N-N bond of (109) could be selectively cleaved to give an open 
chain dipeptide, but reduction of (109) with sodium in liquid ammonia gave 
A/^-propionyl-(25)-proline methylamide (104) in almost quantitative yield. It seems 
likely that in the presence of a strong base (such as sodamide), compound (109) 
underwent a re^ro-Michael reaction (Scheme 2.29) to give the acryloyl proline 
intermediate (112). The double bond of (112) would be rapidly reduced under the 
conditions used, and the terminal hydrazide cleaved, to give the final product, (104).
I\j—CH3
(109) (112)
4e®
C H g
‘CHr
(104)
Scheme 2.29: Proposed mechanism o f reduction o f (109)
Although the reduction of the 5,8-bicyclic compound (109) did not give the desired 
product, it has been shown that cis X-Pro mimetics where X is a p-amino acid, can be 
easily prepared using the synthetic protocols outlined in section 2.5.5 (p. 93) for 
a-am ino acids.
2.5.8 Extension of cis X-Pro mimetics
It was important that the new bicyclic cis X-Pro mimetics could be extended at both 
the amino and carboxy termini to provide longer peptide mimetics. In particular, it 
was hoped to incoiporate this unit into the FMDV 2A sequence in order to study the 
structural effects.
In order to assess the possibility that the triazepine compounds might be extended at 
the N-terminal to provide more elaborate peptide mimetics, compound (102) was 
reacted w ith A^-benzyloxycarbonyl-(25)-phenylalanine (113) using the m ixed 
anhydride coupling method (Scheme 2.30). The product (114), a protected cis  
Phe-Gly-Pro mimetic was obtained in excellent yield (82%), m.p. 82-5 °C. This 
demonstrated that N-terminal extensions with acyl group activated peptides should be 
straightforward.
103
N-CH;
NH
CHs
( 102)
OHHN
O
(i)
O
( 1 1 4 )
Reagents and conditions: (i) NMM, wa-butyl chloroformate, THF, -15 °C, 1.5 h, 
82%.
Scheme 2,30; N-tetminal extension o f a cis Ala-Pro mimetic
Extension at the proline carboxamide terminal is more difficult, requiring the 
synthesis of unsymmetrical alkylhydrazines protected on the primary amino group, 
such as the methylhydrazine derivative (87). Nevertheless, the successful synthesis of 
the cis Gly-Pro-Phe methyl ester mimetic (116) has been carried out by co-workers-33 
using A^-chloroacetyl-(25)-proline (8 8 ) and a protected form of hydrazino-(25)- 
phenylalanine (115).
.OH
HN
01 NHCBZ
(1 1 5 )
NH
O
( 1 1 6 )
Reagents and conditions; (i) SOCI2 , DMAP, it., 12 h; (ii) HBr, AcOH, 3h; NMM. 
Scheme 2.31: Synthesis o f a cis Gly-Pro-Phe mimetic
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2.6 Synthesis and reactivity of glyoxyl-proline
2.6.1 Introduction
The successful preparation of the cis Gly-Pro bicyclic compound, (91) was achieved 
by reacting the a-chloro acid (8 8 ) with a protected form of methylhydrazine. It was 
important that the compound had the correct regiochemistry. This would be the case 
if the primary group of methylhydrazine had attacked at the halogenated carbon. 
Substitution of the a-chloro group with an aldehyde should facilitate preferential 
attack of a primary amine at this site.
(91)
As part of an earlier study, we had wished to synthesize the N -g lyoxy l-p ro ly l 
compound (119), which should react with methylhydrazine to give an alternative 
synthesis of the cis Gly-Pro bicyclic compound, (91).
2.6.2 Attempted syntheses of /V-glyoxyl proline
The aldehyde function is particularly unstable when situated a  to an amide group and 
would almost certainly exist in its hydrated form, as in (119). The best strategy 
towards the synthesis of this compound would be to prepare the glyoxyl proline in a 
protected form, followed by subsequent deprotection. The dimethyl acetal of 
glyoxylic acid, (117), was coupled to proline methyl ester (21) using the mixed 
anhydride method to give dimethoxyacetyl-(25')-proline methyl ester, (118) in 91% 
yield as an oil (Scheme 2.32).
The conversion of acetals into aldehydes is normally accomplished by acid-catalyzed 
h y d r o l y s i s , 234 but the protected glyoxyl proline (118) proved to be completely 
unreactive under these conditions. NMR showed only the presence of unreacted 
starting material after treatment with HCl (2 mol dm-3) for 12 h. Various other 
deprotection methods, including use of the electrophilic reagent, trimethylsilyl 
i o d i d e , 2 3 5  also proved unsuccessful.
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HsCO^  ^ ^
H3 C O  OH  
( 1 1 7 )
O C H '
(21 )
(i)
O C H  3
//
< * ^ 0 CH3
( 1 1 8 ) ( 1 1 9 )
R eagents and  conditions: (i) NMM, wo-butyl chloroformate, THF/ DMF, -15 °C,
1.5 h, 91%; (ii) HCl (2 mol dm-3), MeOH/ HiO (1:1), 20 °C, 12 h; (iii) CF3CO 2H/ 
CH2CI2 (1:1), 20 °C, 2 h; (iv) p-T SA , acetone, reflux, 12 h; (v) MesSil, CH 2CI2, 
20 °C, 15 min.
Scheme 2.32; Attempted synthesis o f lA-glyoxyl-proline methyl ester
Another masked form of the aldehyde is the A-a,a-dichloroacetyl proline derivative, 
(122). Smissman et a i  reported the synthesis of A^-phenylglyoxylhydroxamic acid 
m onohydrate, (1 2 1 ) from the base-catalyzed hydrolysis of A -p h e n y l-a ,a -  
dichloroaceto-hydroxamic acid, (120) (Scheme 2.33).236 Dichloroacetyl-(2S)-proline 
(122) was easily prepared from proline (46) in 63% yield, m.p. 133-5 °C. This 
compound, however, proved to be completely stable to hydrolysis, even in strongly 
basic solution and at elavated temperatures.
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N
O H  Cl
( 120)
(46)
Cl
(i)
O H  O H
OH
Cl
Cl
OH
H O
OH
( 122) (123)
R eagents and  conditions: (i) NaOH (2 mol dm-3), 2 h; (ii) ChCHCOCl, E t]0 , 
NaHCOs, 0 °C, 30 min.
Scheme 2.33: Hydrolysis o f a,a-dichloroacetyl compounds
It seemed clear that the N-CO-CHO fragment was very unstable and that its protected 
forms were extremely difficult to unblock. As formation of compound (123) proved 
difficult, we decided to synthesize (127) through the ozonolysis of A-crotonyl-proline 
methyl ester (126) (Scheme 2.34).
2.6.3 Synthesis and reactivity of A/-glyoxyl proline
A-Crotonyl-proline (125), was prepared by coupling trans crotonyl chloride (124) to 
proline (46) in 64% yield, m.p. 161-3 °C. The and NMR spectra of (125) 
showed that it contained an unusually high percentage of the cis isomer in solution 
(37%). A single crystal X-ray diffraction study of (125) was carried out in order to 
establish its conformation in the solid state. In the crystal lattice, the prolyl amide 
bond was found to be in the trans conformation (Fig. 2.16).
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C(5) C(2)
0 (2 )0 (1)
0 (6)
0 ( 1)
0(7) 0(3)
0 (8 )
0(9)
Figure 2.16: X-ray structure o f (125)
A^-Crotonyl-proline (125), was then esterified under non-acidic conditions, using the 
methanol adduct of BF3 , to give iV-crotonyl-proline methyl ester (126) (Scheme 
2.34).237 Ozonolysis of (126) in CH2CI2 was complete after approximately one hour, 
as judged by TLC and dimethylsulfide was used to brealc down the intermediate 
ozonide. Due to its inherent instability, the aldehyde (127) was directly treated with 
methylhydrazine in situ.
The NMR spectra of the resultant product were extremely complex. It appeared that 
two major species and two minor species were present, which was suggestive of 
conformational isomerism. Mass spectral data confirmed that the structure of the 
product was that of the hydrazone (128) ([M + H]+= 214). M olecular modelling 
studies suggested that (128) could exist in four relatively stable conformations, due to
1 0 8
cis/trans  isomerism of both the imine bond and the amide bond (Fig. 2.17). This 
would explain the presence of four species in the NMR spectra.
.OH
(46)  
H a C .^n r Cl
(1 2 4 )
OH
(i)
HaC ( 1 2 5 )
Cl" ^OCHa
ICHo
( 1 2 8 )
OCHa
( 1 2 6 )
îL .001^
( 1 2 7 )
(Hi)
Reagents and conditions: (i) NaOH, 0 °C, 1 h; HCl, 64%; (ii) BFg.MeOH, reflux, 
2  h; NaHCO], 73%; (iii) O3 , CH2CI2 , -78 °C, 1 h; Me2S, NHCH3NH2 , rt., 8  h, 94%.
Scheme 2.34: Synthesis and reactivity o f N-glyoxyl-proline methyl ester
^  .0 CH3 ^  .0 CH3
trans-trans trans-cis
0 CH3
CHç
OCH,
cis-trans CIS-CIS
Figure 2,17: Possible conformers o f (128)
109
The hydrazone, (128) was structurally rather rigid and hence unable to undergo 
intramolecular cyclization. It was hoped that (128) could be reduced to give the more 
flexible hydrazine compound, (129). The terminal amine group of (129) would then 
be able to attain the correct conformation for cyclization to occur (Scheme 2.35). 
Hydrazones are normally reduced to amines with the use of reducing agents such as 
NaBH4 , LiAlH^ or sodium in ethanol. Compound (128), however, could not be 
reduced by any of these methods, as judged by NMR. It can be concluded that the 
hydrazone is rather unreactive due to the presence of the adjacent amide group.
O C H ;
N
N ICHg
(1 2 8 )
reduction
N H
"N  
ICHg
(1 2 9 ) (91)
Scheme 2.35: Proposed synthesis o f (91)
Although this line of investigation did not provide a viable synthetic route to the 
bicyclic compound (91), we were able to synthesize successfully an A-glyoxyl- 
proline compound via ozonolysis (Scheme 2.34). It should be noted that due to its 
inherent instability, the aldehyde should be generated in situ for immediate reaction 
with an appropriate nucleophile.
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2.7 Conclusions and future work
A successful route has been developed for the synthesis of cis constrained, prolyl 
dipeptides. These bicyclic compounds could be incorporated into larger peptides and 
used as P VI turn mimetics (see section 1.5, p. 44). The reactivity of these 
compounds has been investigated with a view to their conversion into natural cis 
X-Pro peptides via low temperature, reductive cleavage. Although dissolving metal 
reduction has not resulted in the formation of the desired open chain dipeptides, 
information has been gained on the reactivity of the bicyclic compounds.
In the future, it is hoped to prepare bicyclic cis X-Pro mimetics that are substituted on 
the amide nitrogen with a radical-producing group. If a radical could be generated in 
a position exclusively a  to the N-N bond, it is hoped that this might result in selective 
cleavage of the bond. Oligopeptides containing the FMDV 2A sequence could be 
synthesized containing a cis Gly-Pro mimetic unit and it is hoped that this unit could 
be converted to the natural peptide under mild conditions. This peptide might then be 
able to attain the correct conformation to exhibit self-cleavage properties, as observed 
in the replication process of the virus itself.
Studies on oligopeptides containing the FMDV 2A sequence have indicated the 
presence of a-helical structure in the N-terminal region of these peptides in non-polar 
media. In the future it is planned to synthesize the oligopeptides with helix-capping 
groups at the amino t e r m i n a l . ^ 3 8  jg hoped that the presence of these groups will 
result in the formation of a more stable a-helix  in the peptides, which might be a 
structural prerequisite for auto-hydrolysis to occur.
The influence of prolyl cis/trans isomerism on the structure of polypeptides is poorly 
understood. The mechanisms of the isomerization process in free solution and at the 
active site of peptidyl-prolyl cis-trans isomerases {e.g. cyclophilin) are also not 
known. A synthetic approach to the preparation of cis X-Pro peptides, such as the 
one reported here would facilitate a com prehensive kinetic and m echanistic 
examination of the isomerization process.
I l l
C H A PT E R S: EX PERIM ENTAL
Experimental Procedure:
Elem ental m icroanalyses were perform ed in the departmental microanalytical 
laboratory.
NMR spectra were recorded on a Brtiker AM-300 (300 MHz; f.t. ^H-NMR, and 
74.76 MHz; ^^C-NMR), Varian gemini 200 (200 MHz; f.t. ^H-NMR and 50.31 MHz; 
^^C-NMR) or by the SERC service at Warwick using a Brtiker AM-400 (400 MHz; 
f.t. ^H-NMR, and 100 MHz; ^^C-NMR) spectrometers. ^H-NMR and ^^C-NMR 
spectra are described in parts per million downfield from TMS and are reported 
consecutively as position (Ôh or Ôc), relative integral, multiplicity (s -singlet, 
d -doublet, t -triplet, q- quartet, dd -doublet of doublets, sep -septet, m -multiplet and 
br -broad), coupling constant (Hz) and assignment (numbering according to the 
lUPAC nomenclature for the compound). ^H-NMR were referenced internally on 
2HOH (4.68 ppm), CHCI3 (7.27 ppm) or DMSO (2.47 ppm). i^c-N M R were 
referenced on CH3OH (49.3 ppm), C^HCl3 (77.5 ppm), or DMSO (39.7 ppm).
Pyrrolidine ring carbons and hydrogens are assigned in NMR spectra as a , p, y and Ô, 
going anticlockwise from the ring nitrogen, according to normal convention. Where 
more than one confoimational isomer can be seen in the NMR spectrum due to the 
presence of a tertiary amide bond, these are assigned as c (cis) or t (trans), according 
to the isomeric state of the amide bond. When two such tertiary amide bonds are 
contained in one compound and four conformational isomers are present, these are 
assigned as tt (trans, trans), tc (trans, cis), ct (cis, trans) and cc (cis, cis). The first 
assignment refers to the amide bond on the left hand side of the molecule as it is 
pictured diagramatically in the preceding chapter. Where two sets of peaks arise in 
NMR spectra due to different conformations of a constrained seven-membered ring, 
these are assigned as A  and B, with A  being the major isomer.
IR spectra were recorded on a Perkin-Elmer 1710 f.t. IR spectrometer. The samples 
were prepared as Nujol mulls, solutions in chloroform or thin films between sodium 
chloride discs. The frequencies (u) as absorption maxima are given in wavenumbers 
(cm- ^  ) relative to a polystyrene standard. Mass spectra and accurate mass 
measurements were recorded on a VG 70-250 SE, a Kratos MS-50 or by the SERC 
service at Swansea using a VG AZB-E. Fast atom bombardment spectra were 
recorded using glycerol as a matrix. Major fragments were given as percentages of 
the base peak intensity (100%). UV spectra were recorded on Pye-Unicam SP8-500 
or SP8-100 spectro-photometers.
1 1 2
Flash chromatography was performed according to the method of Still et using 
Sorbsil C 60 (40-60 jim mesh) silica gel. Analytical thin layer chromatography was 
carried out on 0.25 mm precoated silica gel plates (Macherey-Nagel SIL g/UV254) 
and compounds were visualised using UV fluorescence, iodine vapour, ethanolic 
phosphomolybdic acid or ninhydrin.
M elting points were taken on an Electrothermal melting point apparatus and are 
uncorrected. Optical rotations were measured at 22 °C on an Optical Activity 
AA-1000 polarimeter using 10 or 20 cm path length cells.
The solvents used were either distilled or of analar quality and light petroleum ether 
refers to that portion boiling between 40 and 60 °C. Solvents were dried according to 
literature procedures. Ethanol and methanol were dried using magnesium turnings. 
DMF, wopropanol, /.sopentanol, toluene, CH2CI2 , acetonitrile, diwopropylam ine, 
triethylamine and pyridine were distilled over CaH2 . THE and diethylether were 
dried over sodium/ benzophenone and distilled under nitrogen. Thionyl chloride was 
d istilled  over sulphur and the in itia l fractions w ere always discarded. 
V-Methylmorpholine was distilled over ninhydrin.
General procedure for dissolving metal reductions
To liquid ammonia (40 cm^) at -60 °C under an atmosphere of dry nitrogen was 
added a solution of the starting material (10 mmol) in dry THF (10 cm^). If the 
starting material was found to be insoluble in THF, it was added directly to the liquid 
ammonia. The resultant solution was stirred vigorously and sodium (approx 0.8 g, 
30 mmol) was added in small pieces until a homogenous dark blue colour was 
obtained. This blue colour was maintained for 15 min, after which time the solution 
cleared and ammonium chloride ( 1.60 g, 30 mmol) was added. The reaction mixture 
was allowed to warm to room temperature, methanol ( 2 0  cm^) was added, and the 
mixture was left stirring for 1 h. The solvents were removed under reduced pressure 
and the resultant white solids* were dissolved in water (25 cm^) and extracted with 
ethyl acetate (3 x 25 cm^). The combined organic fractions were dried (MgSO^) and 
the solvent removed under reduced pressure to give the reduced product. In the case 
of polar products, the white solids* were extracted into hot ethanol (2 x 25 cm^), the 
solvent rem oved under reduced pressure and the resultant reduced product 
recrystallized from methanol.
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A^-^er^-Butoxycarbonyl-(2S)-asparagyl-(2S)-proline allyl ester (16)
HN
.O
To a solution of A^-rer^-butoxycarbonyl-(25)-asparagine (14) (1.16 g, 5 mmol) in dry 
THF (250 cm3) was added iV-methylmorpholine (0.56 cm^, 5 mmol) and the solution 
cooled to -15 °C. wo-Butyl chloroformate (0.68 cm^, 5 mmol) was added with 
stirring and the solution left stirring at -15 °C for 2 min. A solution of (25)-proline 
allyl ester p-toluene sulphonate (15) (1.64 g, 5 mmol) and A '-m ethylm orpholine 
(0.56 cm3, 5 mmol) in dry THF (20 cm^) was then added The reaction mixture was 
allowed to warm to room temperature and left stirring for 2 h. The hydrochloride 
salts were filtered off and the solvents removed under reduced pressure. The resultant 
yellow oil was dissolved in CH2CI2 (50 cm^) and washed with 0.5 mol dm-3 HCl 
(2 X 15 cm^) and 5% sodium bicarbonate solution (2 x 15 cm^). The organic phase 
was dried (MgSO^) and the solvent removed under reduced pressure. The resultant 
white solid was recrystallised from diethyl ether/ light petroleum to give the product 
as colourless crystals (1.17 g, 63%), m.p. 109-11 °C; (Found: C, 55.4; H, 7.65; N,
11.4. Calc, for C 17H27N 3O6 : C, 55.25 H, 7.4; N, 11.4%); m/z (Found: [M + H]+, 
370.1978. Calc, for C 17H28N 3O 6 : 370.1978); [ a g -78.0 (c 1.0 in M eOH); 
Umax (Nujol)/cm“^  3458 & 3305 (NH), 1743 (ester CO), 1694 (carbamate CO), 1674 
(tertiary amide CO), 1644 (primary amide CO) and 1521 (C=C); Ôh (300 MHz; 
C^HCls) 1.41 (9H, s, (CH3)3), 2.02 (3H, m ip C H j and^C H ;), 2.22 (IH , m, jpCHa), 
2.56 (IH , dd, Ji 14.5, J2  5 .8 ,5CH 2CONH2), 2 .6 8  (IH , dd, A  14.5, 7 2  5.6, 
jC H 2CONH2), 3.79 (2H, m, 5 CH2), 4.54 (IH , dd, Ji 5.7, J 2  9.8, aC H ), 4.58 (2H, d, 
75 .3 , CO2CH2), 4.82 (IH , m, COCHNH), 5.24 (IH , d, 7 10.4, =CJirijH), 5.31 (IH , d, 
7 17.3, = C H tra„sH ), 5.68 ( I H ,  s ,2CONH2), 5.88 (IH , m, C H = C H 2 ) , 6.02 (IH , d, 7 8.0, 
CHNH) and 6.70 (IH , s,|C O N H 2); 5c (74.76 MHz; C^HCIj) 22.39 (c, 7CH2), 25.25 
it, 7 CH 2), 28.64 i t  & c ,  C(CH 3)3 ), 29.28 it, PC H ;), 31.44 (c, PC H 2), 38.04 it, 
CH 2CONH2), 39.30 (c, C H 2CONH2 ), 46.90 (c, 5 % ) ,  47.45 it, SCH 2 ), 49.52 (c, 
ÇHNHCO), 49.85 it, ÇHNHCO), 59.47 it, aCH ), 59.94 (c, aCH ), 65.97 it, CO2CH 2 ), 
66.37 (c, CO2CH 2), 79.86 (c, £ ( ^ 3)3 ), 79.98 it, C(CH3)3), 118.80 it, CH=CH2 ),
118.91 (c,CH =CH 2), 132.10 (f,£H =C H 2), 132.20 (e, £H =CH 2), 155.15 (c, C O fB u),
155.85 it, C0 2 ‘Bu), 171.14 (c, CONH 2), 171.49 it, CONH2 ), 171.97 i t  See,
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COCHNH), 172.72 (f, Ç O 2CH2) and 173.32 (c, ÇO 2CH2 ); m/z (CI) 370 ([M + H]+ 
44%), 314 (52, [M - C(CH3)s + 2H]+), 296 (30, [M - OC(CH 3)3 ]+), 270 (40 
[M -C 02C (C H 3)3+  2H]+), 255 (100, [M - NHC02C(CH3)3 + 2H]+), 212 (100, 
[M - NHC0 2 C(CH3)3 - C3Hg]+) and 70 (45, [C4HgN]+).
A-/er/-Butoxycarbonyl-(2S)-asparagyI-(2S)-proline benzyl ester (18)
This com pound was prepared in a manner identical w ith that for N-tert~ 
butoxycarbonyl-(2S)-asparagyl-(25)-proline ally l este r ( 1 6 ) ,  using N-tert- 
butoxycarbonyl-(25)-asparagine (14) (1.16 g, 5 mmol) and (2S)-proline benzyl ester 
p-toluene sulphonate (17) (1.89 g, 5 mmol). The crude compound was recrystallised 
from CH2CI2/  light petroleum to give a white solid (1.67 g, 79%), m.p. 111-13 °C 
(lit.,190 115-16 *^ C); m /z  (Found: [M + H]+, 420.2140. C21H 30N 3O6 requires 
420.2135); [ a ]g -5 6 .4  (c 1.0 in M eOH) {lit.,i90 -53.8 (c 1.0 in M eOH)}; 
^max (Nujol)/cm-i 3393 & 3246 (NH), 1743 (ester CO), 1697 (carbamate CO), 1672 
(tertiary amide CO), 1643 (primary amide CO) and 1045 & 1026 (aromatic CH); 
ÔH (200 MHz; C2HCI3) 1.42 (9H, s, C(CH3)3), 1.98-2.09 (3H, m, 7CH 2 and &PCH2), 
2.11-2.32 (IH , m ,iPC H 2), 2.56 (2 H, m, C O C H 2) ,  3.76 (2 H , m, Ô C H 2) ,  4.57 (IH , dd, 
7i 4.0, J2 8.2, aCH ), 4.88 (IH , m, CHNH), 5.12 (2H, d, J  5.0, CH2Ph), 5.40 (IH , s, 
|CONH2), 5.91 (IH , d, J  8.2, CHNH), 6.48 (IH , s, 5CONH2) and 7.33 (5H, s, 
aromatic); ôc (50.31 MHz; C2HCI3) 25.31 (7CH2), 28.82 (C(CH3)3), 29.39 (PCH2), 
38.30 (COÇH2 ), 47.62 (ÔCH2 ), 50.00 (ÇH 2CONH2), 59.67 (aC H ), 67.31 ( C H N H ) ,  
80.28 (C(CH3)3), 128.56 (ortho aromatic), 128.82 (para aromatic), 129.06 (meta 
aromatic), 135.99 (quat. aromatic), 156.00 (C0 2 ^Bu), 171.61 (ÇONHCH), 172.28 
(C O N H 2 ) and 172.61 (C0 2 CH2Ph); m/z (FAB) 420 ([M + H]+, 36%), 364 (39, [M - 
C(CH3)3 + 2 H ]+ ) , 320 (43, [M - C 0 2 C (C H 3 ) 3  + 2H]+), 287 (40, [M - C 0 2 C H 2 P h  + 
3 H ]+ ) , 70 (22, [C 4 H g N ]+ )  and 57 (100, [C (C H 3 )3 ]+ ).
iV-/er/-Butoxycarbonyl“(2S)-asparagyl-(25)-proIine (19)
To a solution of /V-rgrr-butoxycarbonyl-(25')-asparagyl-(25)-proline benzyl ester (18) 
(2.10 g, 5 mmol) in methanol (100 cm^) was added 10% palladium on activated 
charcoal (100 mg) and the vessel flushed with hydrogen gas. The resultant 
suspension was stirred vigorously under an atmosphere of hydrogen for 12 h. The 
mixture was then filtered through a prewashed celite pad and the solvent removed 
under reduced pressure to give the product as a white solid (1.55 g, 94%),
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m.p. 110-15 °C (lit.,150 108-16 °C); m /z (Found; [M + H]+, 330.1659. C 14H 24N 3O 6 
requires 330.1665); [ a ]g  -46.8 (c 1.0 in MeOH) (lit.,>90 -50.0 (c 1.0 in M eO H)); 
)^max (Nujol)/cm-> 3405 & 3198 (NH), 1717 (acid CO), 1692 (carbamate CO), 1669 
(tertiary amide CO) and 1645 (primary amide CO); 5h (200 MHz; C^HCI;) 1.39 (9H, 
s, C(CH3)3), 1.78-2.36 (4H, m, pCH^ and 7CH 2), 2.64 (2H, m, COCH2), 3.83 (2H, m, 
8 CH2 ), 4.39 (IH , m, aC H ), 4.82 (IH , m, CHNH), 6.24 (IH, d, J  7.8, CHNH), 6.73 
(IH , s, 4CONH2), 7.22 (IH , s, ÏCONH2) and 8.12 (IH, br, COiH); 5c (50.31 MHz; 
C2HCI3) 24.51 (7 CH2), 28.00 (C(CH 3)3 ), 28.63 (PCHj), 36.98 (COCH 2), 47.02 
(5 CH2), 48.96 (CHNH), 59.27 (aCH ), 79.55 (ClCHsis). 155.24 (COj'Bu), 170.96 
(CONHCH), 173.62 (CONH2 ) and 174.12 (CO2H); m/z (Cl) 330 ([M + H]+, 23%), 
274 (51, [M - C(CH3)3 + 2H]+), 230 (33, [M - C02C(CH3)3 + 2H]+), 70 (72, 
[C+HgN]*) and 57 (100, (C(CH3)3]+).
(2S)-Proline methyl ester hydrochloride (21)
Thionyl chloride (1.6 cm^, 22 mmol) was added dropwise with stirring to dry 
methanol (30 cm^) at 0 °C. The resultant solution was slimed at 0 °C for 5 min before 
addition of (25)-proline (47) (2.30 g, 20 mmol). When dissolution was complete, the 
solution was refluxed for 1 h, and after cooling, methanol and excess thionyl chloride 
were removed under reduced pressure to give the product as a clear oil. After drying 
over P2O5 for 48 h the hydrochloride was obtained as colourless crystals (3.31 g, 
100%), m.p. 68-70 °C (lit.,239 69-71 °C); m/z (Found: [A/ + H]+, 130.1663. C6H 12NO2 
requires 130.1663); -14.8 (c 1.0 in H2O) {lit.,«9 . 1 5 ,5  (c 1 ,0  in H2 O ));
tJmax (Nujol)/cm-> 1746 (CO) and 1240 (C-O); 5» (200 MHz; *-D M SO ) 1.80-2.08 
(3H, m, 7CH 2 and îpC H 2), 2.12-2.34 (IH, m ,jpC H 2), 3.21 (2H, m, 5 CH2 ), 3.72, (3H, 
s, 0 CH 3 ), 4.34 (IH , m, aC H ), 9.30 (IH , s, NH) and 10.49 (IH , s, NH); 
5c (50.31 MHz; ds-DM SG) 23.27 (7 CH2), 27.84 (pCHz), 45.32 (5 CH2), 53.21 
(OCH3), 59.61 (aC H ) and 169.26 (CO); m/z (El) 130 ([M + H]+, 24%), 99 (62, [M - 
0 CH3]+) and 70 (100, [CaHgN]*).
116
A^-^er^-Butoxycarbonyl-gIycyl-(2S)-proline methyl ester (22)
>rYo
OChb
NH
To a stirred solution of A/^-methylmorpholine (1.12 cm^, 10 mmol) in dry THF 
(25 cm^) was added N-fgrr-butoxycarbonyl-glycine (20) (1.75 g, 10 mmol) and the 
solution cooled to -15 °C. wo-Butyl chloroformate (1.36 cm^, 10 mmol) was added 
and the resulting suspension stirred at -15 °C for 2 min. A mixture of (2S)-proline 
m ethyl ester hydrochloride (2 1 ) ( 1 .6 6  g, 1 0  mmol) and A-methylmorpholine 
(1.12 cm^, 10 mmol) in dry DMF (5 cm^) was then added. The reaction mixture was 
allowed to waim to room temperature and left to stir for 1 h. The hydrochloride salts 
were filtered and the solvents removed under reduced pressure. The resultant clear oil 
was dissolved in CH2CI2 (50 cm^), washed with 0.5 mol dm-3 HCl (2 x 25 cm^) and 
5% sodium bicarbonate solution (2 x 25 cm^), dried (M gS0 4 ) and the solvent 
removed under reduced pressure. The crude product was recrystallised from diethyl 
ether/ light petroleum to give colourless crystals (2.54 g, 89%), m.p. 6 6 - 8  °C; (Found: 
C, 54.8; H, 8.15; N, 9.8. Calc, for C 13H 22N 2O 5 : C, 54.6; H, 7.75; N, 9.8%); 
m/z (Found: [M + H ]+ , 287.1610. Calc, for C 13H 23N2 O5 : 287.1610); [ a g  -34.7 
(c 1.0 in MeOH); (Nujol)/cm'^ 3404 (NH), 1748 (ester CO), 1686 (carbamate 
CO) and 1673 (amide CO); Ôh (400 MHz; C2HCI3) 1.39 (t & c, 9H, s, (CH3)3), 
1.76-2.27 {t & c, 4H, m, PCH2 and 7CH2), 3.38-3.45 (t, IH, m ,|ôC H 2), 3.48-3.65 
(t & c, IH, m,ÎÔCH2), 3.67 (t, 3H, s, OCH3), 3.71 (c, 3H, s, OCH3), 3.86 {t, IH, dd, 
Ji 4.0, J 2  17.5,|COCH2), 3.93 (c, IH, dd, 7% 4.6, J 2  17.5, 5COCH2), 4.34 (c, IH, dd, 
Ji 2.5, J 2  7.7, aCH ), 4.46 (t, IH, dd, 7% 4.1, J2 7.0, aCH ) and 5.37 {t & c, s, IH, NH); 
ÔC (74.76 MHz; C2HCI3) 21.39 (c, 7 CH2), 23.87 {t, 7 CH2), 27.49 {t & c, C(CH3)3), 
28.17 (/, PCH2), 30.50 (c, PCH2), 42.09 {t & c, COÇH2), 45.04 (r, ÔCH2), 45.77 (c, 
ÔCH2 ), 51.28 {t, OCH3), 51.61 (c, OCH3), 57.62 (c, aC H ), 58.05 {t, aC H ), 78.34 
{t & c, C(CH 3)3), 155.00 (t & c, C0 2 tBu), 166.71 {t, COCH2), 166.98 (c, ÇOCH2), 
171.29 (c, ÇO2CH3) and 171.57 (r, ÇO2CH3); m/z (Cl) 287 ([M + H]+, 3%), 231 (18, 
[M - C(CH3)3 + 2H]+), 213 (100, [M - OC(CH3)3]+), 187 (23, [M - C02C(CH3)3 + 
2H]+) and 155 (48, [M - CH2NHC0 2 ^Bu + H]+).
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iV“/^r/-Butoxycarbonyl-glycyl-(2S)-prolinamide (23)
To a saturated solution of am monia in dry m ethanol (50 cm^) was added 
/V-ferr-butoxycarbonyl-glycyl-(25)-proline methyl ester (22) (1.43 g, 5 mmol). The 
solution was placed in a tightly stoppered vessel and left at room temperature. W hen 
the reaction was complete as judged by TLC (10 days), the stoppered vessel was 
cooled to 0 °C, opened and nitrogen gas bubbled through at room temperature for 
5 min. The solvent was then removed under reduced pressure to give the product as a 
white solid (1.34 g, 98%), m.p. 152-4 °C; (Found: C, 53.4; H, 8.05; N, 15.6. Calc, for 
C 12H 21N 3O4 : C, 53.15; H, 7.8; N, 15.5%); m/z (Found: [M + H]+, 272.1615. Calc, for 
C 12H22N 3O4 : 272.1611); [ a f  -64.0 (c 1.0 in MeOH); - u ^  (Nujol)/cm-l 3418 & 
3381 (NH), 1688 (carbamate CO), 1673 (tertiary amide CO) and 1642 (primary amide 
CO); 8 h (200 MHz; C^HClj) 1.40 (9H, s, C(CH3)3), 1.81-2.36 (4H, m, pCHz and 
7CH 2), 3.41 (IH, dd, 7i 8 .8 , J 2 17.5,|8CH2), 3.57 (IH, dd, Ji 11.0, h  17.5, &8 CH 2), 
3.91 (2H, d, J  5.2, COCH2 ), 4.52 (IH, m, aCH ), 5.57 (IH , d, J  5.2, CH2NH), 5.94 
(IH , s,îC O N H 2) and 6.96 (IH , s, iC 0 NH2); 8 c (50.31 MHz; C^HCls) 22.85 (c, 
7CH2 ), 25.15 (t, 7CH 2 ), 28.75 (t, pCH;), 29.59 (t & c, C(CH3)3), 32.59 (c, PCH2), 
43.16 (c, COCH2), 43.36 (f, COÇH2), 46.80 (f, 8CH2), 47.53 (c, 8 CH2), 59.95 (c, 
aC H ), 60.56 (f, aCH ), 79.86 (f & c, C(CH3)3 ), 156.72 (r & c, COz'Bu), 168.66 (e, 
COCH2), 169.16 (t, ÇOCH 2), 175.15 (c, CONH2) and 175.39 (f, CONH2); m/z (Cl) 
272 {[M + H]+, 32%), 216 (100, [M - C(CH3)3 + 2H]+), 198 (26, [M - 0C(CH3)3]+), 
172 (95, [M - C0 2 C(CH3)3 + 2H]+), 155 (31, [M - N H C O zC iC H ))]^) and 70 
(41, [C4HgN]+).
GlycyI-(25)-proIine m ethyl ester trifluoroacetate (24)
To a solution of trifluoroacetic acid (5.70 g, 50 mmol) in CH2CI2 (25 cm^) was added 
7V-fgrr-butoxycarbonyl-glycyl-(25')-proline methyl ester (22) (2.86 g, 10 mmol). The 
resultant solution was stirred at room temperature for 2  h and then the solvent and 
excess reagent removed under reduced pressure. The resulting oil was repeatedly 
redissolved in CH2 CI2 and the solvent removed under reduced pressure until no 
traces of TFA remained. The product was obtained as a clear oil (2.87 g, 100%), 
m/z (Found: M+, 187.1079. Calc, for C8H 15N 2 O3 : 187.1082); [ a g  -47.9 (c 0.1 in 
MeOH); max (thin film)/cm-t 1783 (trifluoroacetate CO), 1742 (ester CO), 1666 
(amide CO) and 706 (CF); 6 h (200 MHz; C2HCI3) 1.73-2.36 {t & c, 4H, m, pCHs and 
yCH2 ), 3.32-3.62 (r & c, 2H, m, 8 CH2), 3.68 (A 3H, s, OCH3 ), 3.74 (c, 3H, s, OCH3), 
3.94 {t & c, 2H, s, COCH2), 4.47 {t & c, IH, dd, 7% 3.4, J  8.2, aC H ) and 7.84 (f & c,
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and 7.84 {t & c, 3H, s, H3N+); Ôc (50.31 MHz; C^HClg) 22.41 (c, )C H 2), 24.72 (f, 
7 CH 2 ), 29.22 (t, PCH2 ), 31.10 (c, PCH2), 41.14 (t & c, OCH3), 46.58 (?, ÔCH2), 47.31 
(c, ÔCH2), 52.87 {t, COÇH2). 53.28 (c, COÇH2), 59.26 (c, aC H ), 59.71 (t, aC H ), 
116.39 (q, 7 c f  1154, COÇF3 ), 161.65 (q,7cF 147, Ç O C F 3), 165.71 (r, Ç O C H 2), 
165.99 (c, COCH2), 172.20 (c, CO2CH3 ) and 172.84 (r, CO2CH3); m/z (El) 187 (M+, 
100%), 170 (7, [M - NH3]+), 156 (19, [M - 0 CH 3]+), 130 (16, [M - CO2CH3 + 2H]+) 
and 70 (8 , [C4HgN]+).
G lycyl-(2S)-prolinam ide trifluoroacetate (25)
This compound was prepared in a manner identical with that for glycyl-(25)-proline 
m ethyl ester trifluoroacetate (2 4 ) , using A - fgrf-butoxycarbonyl-glycyl-(25')- 
prolinamide (23) (1.36 cm^, 5 mmol) to give the product as a clear oil (1.43 g, 100%), 
m/z (Found: M+, 172.2069. Calc, for C7H 14N 3O2 : 172.2065); [a |^ -4 1 .3  (c 0.5 in 
MeOH); Dmax (thin film)/cm-t 3050 (NH), 1781 (trifluoroacetate CO), 1667 (primary 
amide CO), 1656 (tertiary amide CO) and 711 (CF); Ôh (200 MHz; C2 H 3 O2H) 
1.79-2.47 (4H, m, PCH2 and 7CH 2), 3.58 (2 H, m, ÔCH2), 3.89 (2 H, s, COCH2 ) and 
4.41 (IH , dd, Ji 3.8, J  8.4, aCH ); ôc (50.31 MHz; C2H3O2H) 23.60 (c, 1C H 2), 25.66 
(t, 7 CH2), 31.08 (t, PCH2), 33.41 (c, PCH2), 41.62 (c, COCH2), 41.85 (f, COCH2),
47.85 (r, ÔCH2 ), 48.63 (c, ÔCH2), 61.34 (c, aC H ), 62.13 (f, aC H ), 117.93 (q, 
7c f  1166, COÇF3 ), 162.44 (q, JcF 143, ÇOCF3), 166.85 (t & c, CONHg), 174.12 (c, 
ÇOCH2) and 174.87 (f, COCH2); m/z (Cl) 172 (M+, 1 1 %), 155 (100, [M - N H 3]+), 
1 1 1  (5, [M - NH3 - CONH2]+), 98 (28, [M - CH2NH 3 - CONH2 + H]+) and 70 (32, 
[C4HgN]+).
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iV-tert-ButoxycarbonyI-(2S)-asparagyl-(2S)-prolyl-glycyl-(2S)-prolinemethyt
ester (NP1GP2) (26)
O HN OY
To a solution of PyBOP (0.62 g, 1.2 mmol) in dry DMF (3 cm^) was added 
N-methylmorpholine (0.13 cm^, 1.2 mmol) and a solution of A-ferf-butoxycarbonyl-
(26)-asparagyl-(25)-proline (19) (0.33 g, 1 mmol) in dry THF/ dry DMF (10 cm^, 
1:1). A mixture of glycyl-(25)-proline methyl ester trifluoroacetate (24) (0.30 g,
1 mmol) and /V-methylmorpholine (0.12 cm^, 1 mmol) in dry THF (5 cm^) was then 
added and the solution stirred vigorously at room temperature under nitrogen for 50 
min. The resultant white precipitate was filtered, washed with diethyl ether and dried 
to give the product as a white solid (0.38 g, 75%), m.p. 168-70 °C; m /z  (Found: 
[M + H]+, 498.2559. Calc, for CziHsgNgOg: 498.2563); [ a g  -131.0 (c 0.1 in MeOH); 
Dmax (Nujol)/cm-i 3355 & 3286 (NH), 1752 (ester CO), 1734 (carbamate CO), 1709 
(tertiary amide CO), 1667 (tertiary amide CO), 1654 (secondary amide CO) and 1649 
(primary amide CO); 0» (200 MHz; C^HClg) 1.42 (9H, s, C(CH3)3), 1.78-2.40 (8 H, 
m, 2 X yCH2 and 2 x pCHi), 2.62 (IH , dd, Ji 15.8, J2 3 .2 , |C H 2CONH2), 2.79 (IH , 
dd, Ji 15.8, J 2 10.0,5CH 2CONH2), 3.41-3.64 (2H, m, ÔCH2I), 3.69 (3H, s, OCH3), 
3.82 (2H, m, ÔCH2^), 4.03 (2H, d, J  6.0, CH2NH), 4.45 (IH , dd, 7i 3.6, J2 5.2, aC H i), 
4.64 (IH , d, J  5.4, aCFP), 4.83 (IH , m, CHCH2CONH2), 5.59 (IH , s,|CO N H 2 ), 5.92 
(IH , d, J  8 .8 , NHCHCH2), 6.78 (IH , s,|CONH 2) and 7.50 (IH , t, J  6 .0 , NHCH2); 
ÔC (74.76 MHz; C^UCh) 22.07 (tc, yCU2  ^ and YÇH22), 24.31 (tt, yCH2 i), 24.54 (tt, 
7 CH22 ), 28.18 (tt & tc, C(CH3)3), 28.82 (tt, PCH2  ^ and PCH2^), 31.10 (tc, PCH2  ^ and 
PCH22), 37.88 (tt & tc, ÇH 2CONH2), 41.53 (tc, CONHCH2), 41.64 (tt, CONHÇH2), 
46.04 (tt, ÔCH2O, 46.55 (tc, ÔCH2 I), 47.30 (tt, ÔCH2^), 48.69 (tc, 6 CH2^), 52.25 (tt, 
aC H i), 52.64 (tc, aC H ^), 58.56 (tc, aC H ^), 58.80 (tt, aC K ^), 60.15 (tt & tc , 
ÇHCH2CONH2), 79.63 (tt & tc, C(CH3)3), 155.16 (tt & tc, C0 2 ^Bu), 167.40 (tt, 
CONH2), 167.82 (tc, CONH2 ), 171.52 (fc, Ç O C H 2NH), 171.60 (rf, ÇO C H 2NH), 
171.78 (tt, COCHNH), 172.15 (tc, COCHNH), 172.52 (tc, ÇONHCH2), 172.54 (tt, 
ÇONHCH2) and 172.85 (tt & tc, ÇO2CH 3); m/z (Cl) 498 ([M + H]+, 41%), 398 (73,
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[M - C0 2 C(CH3)3 + 2H]+), 380 (60, [M - C0 2 C(CH3)3 - NH 2 ]+), 284 (27, [Pro-Gly- 
Pro + H]+), 212 (79, [Asn-Pro - OH]+) and 187 (100, [Gly-Pro-OMe + H]+).
iV-te/t-Butoxycarbonyl-(2S)-asparagyl-(2S)-prolyl-glycyl-(2S)-proIînamide 
(NP1GP2) (27)
This com pound was prepared in a manner identical w ith that for N-tert- 
butoxycarbonyl-(25)-asparagyl-(25)-prolyl-glycyl-(25)-proline m ethyl ester (26), 
using glycyl-(25)-prolinamide trifluoroacetate (25) (0.28 g, 1 mmol). The product 
was isolated as a white solid (0.79 g, 62%), m.p. 60-4 °C; m/z (Found: [M + H]+, 
483.2561. Calc, for C21H 35N 6 O7 : 483.2567); [ a g  -88.2 (c 1.0 in M eOH); 
'^max (Nujol)/cm ‘  ^ 3420 & 3250 (NH), 1736 (carbamate CO), 1705 (tertiary amide 
CO), 1661 (tertiary amide CO), 1649 (secondary amide CO), 1647 (primary amide 
CO) and 1638 (primary amide CO); 0» (200 MHz; d^-DMSO) 1.41 (9H, s, C(CH3)3), 
1.81-2.32 (8 H, m, 2 X 7 CH2 and 2  x g CH2), 2.53 (IH , dd, J i  16.2, J 2  3.8 
ICH 2CONH2). 2 .7 9  (IH , dd, Ji 16.2, J2  8.5, ^CHjCONHj), 3.43-3.76 (4H, m, 2  x 
SCH2), 3.97 (IH , d, J  6.4, k :H 2NH), 4.01 (IH , d, J  6.4, ^ H z N H ), 4.39 (IH , dd, 
7, 3.4, J2  6.1, a C H ') , 4.50 (IH , m, aCH^), 4.72 (IH , m, CHCH2CONH2), 6.34 (IH , 
s, ICONH2), 6.46 (IH , d, J  8.4, NHCHCH2), 6.76 (IH , s, ÎCONH2), 7.40 (IH , m, 
NHCH2 ) and 7.90 (IH , s,iCONH 2 ); 5c (74.76 MHz; C ^IjO ^H ) 23.59 (tc, 7CH 2 ' and 
•yCH22), 25.81 (tt, 7CH2>), 26.99 (tt, 7CH22), 28.94 (tt & tc, Q C H ;);) , 31.00 (tc, 
PCH2 ‘), 31.99 (tt, PCH2 2 ), 33.57 (tc, PCH2 ' and pCH2^), 38.63 ( tt & tc, 
CH2CONH2 ), 42.88 (tt, CONHCH2), 43.10 (tc, CONHÇH2), 47.87 (tt, SCH2 <), 47.97 
(fc, SCH2 *), 48.17 (tt, ÔCH2:) , 48.32 (tc, SCH22), 52.86 (tt & tc, aCH>), 61.24 (tc, 
o£H 2), 61.69 (tt, aCH2), 61.79 (tt, CHCH2CONH2 ), 61.97 (tc, CHCH^CONHg), 
80.73 (tt & tc, C(CH3>3), 155.79 (tt & tc, C0 2 ‘Bu), 169.96 (tt, CH2CONH2), 170.09 
(tc, CH2CONH2 ), 173.29 (tt, Ç O C H 2NH), 174.93 (tc , COCH2NH), 175.44 (tt, 
COCHNH), 172.15 (tc, COCHNH), 172.52 (tc, CONHCH2), 172.54 (tt, CONHCH2), 
and 177.57 (tt & tc, CHCONH;); m /z  (Cl) 483 ([M + H]+, 23%), 483 (80, [M - 
C02C(CH;)3 + 2H]+), 365 (42, [M - C02C(CH3)s - NH 2 ]+), 322 (19, [M - 
C 0 2 C(CH3)3  - NH2 - CONH2 + H]+), 197 (64, [Asn-Pro - OH]+) and 172 (100, [Gly- 
P10-NH2 + H]+).
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(2S)-Phenylalanine methylamide (31)
To a saturated solution o f methylamine in dry methanol (200 cm^) was added 
(2.S)-phenyalanine methyl ester hydrochloride (2.16 g, 10 mmol). The mixture was 
placed in a tightly stoppered vessel and left at room temperature for 12 h. The 
solution was then cooled to 0 °C, opened carefully and nitrogen bubbled through for 
10 min. The solvent was removed under reduced pressure to give a white solid. 
W ater (100 cm^) was added and the solution extracted with ethyl acetate (3 x 50 cm^). 
The combined organic fractions were dried (MgSO^) and the solvent removed under 
reduced pressure to give a white solid which was recrystallised from diethyl ether to 
give the product as colourless crystals (1.56 g, 8 8 %), m.p. 160-2 °C; (Found: C, 
67.75; H, 8.1; N, 16.0. Calc, for C 10H 14N2 O: C, 67.5 H, 7.9; N, 15.85%); m/z (Found: 
[M + H]+, 179.1180. Calc, for C 10H 15N 2O: 179.1180); [ a g  +33.9 (c 1.0 in MeOH); 
Dmax (Nujol)/cm-i 3371 (amine NH), 3241 & 3291 (amide NH), 1645 (CO) and 747 & 
701 (aromatic CH); 0» (200 MHz; C^HClg) 1.42 (2H, s, NH2 ), 2.79 (IH , dd, A  13.5, 
72  7 ,9 , |C H 2Ph), 3.03 (IH , dd, 7, 13.5, J 2  5 .1 , |C H 2Ph), 3.64 (3H, s, CH3 ), 3.68 (IH , 
dd, 7i 5.1, 72  7.9, 2-CH) and 7.09-7.31 (5H, m, aromatic); 8 c (50.31 MHz; C^HCls) 
40.20 (CH2PI1), 50.83 (CH3), 54.91 (2-CH), 125.80 (para aromatic), 127.56 (ortho 
aromatic), 128.40 {meta aromatic), 136.55 (quat. aromatic) and 174.44 (CO); m/z (Cl) 
179 ([M + H]+, 100%), 164 (3, [M - CHg + H]+), 132 (5, [M - NHCH3 - NH21+) and 
120(17, [M -C O N H C H 3M .
(25)-Prolyl-(2S)-phenylalanine methylamide hydrochloride (32)
N H C H-  + N I ,
C l H g  n  H
To a stirred solution of A-methylmorpholine (1.12 cm^, 10 mmol) in dry THF 
(25 cm^) was added A-/erf-butoxycarbonyl-(25)-proline (30) (2.15 g, 10 mmol) and 
the solution cooled to -15 °C. wo-Butyl chloroformate (1.36 cm^, 10 mmol) was 
added and the resulting suspension stirred at -15 °C for 2 min. A solution of 
(25)-phenylalanine methylamide (31) (1.78 g, 10 mmol) in dry THF (25 cm^) was 
then added. The reaction mixture was allowed to warm to room temperature and left 
to stir for 1 h. The hydrochloride salts were filtered and the solvents removed under 
reduced pressure. The resultant clear oil was dissolved in CH2CI2 (50 cm^), washed 
with 0.5 mol dm '^ HCl (2 x 25 cm^) and 5% sodium bicarbonate solution
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(2 X 25 cm^), dried (MgSO^) and the solvent removed under reduced pressure to give 
a white solid. Hydiogen chloride gas was bubbled through a solution of the solid in 
ethylacetate (30 cm^) for 20 min at 0 °C. The solvent was then removed under 
reduced pressure to give the product as a white solid which was filtered and 
recrystallized from methanol to give the product as colourless crystals (2.45 g, 78 %), 
m.p. 212-14 °C; m/z (Found: [M + H]+, 276.1712. Calc, for C 15H 22N 3O2 : 276.1712); 
[ a ] g  -17.7 (c 1.0 in MeOH); (Nujol)Zcm-^ 3342 & 3318 (NH), 1680 (secondary 
amide CO) and 1643 (methylamide CO); Ôh (200 MHz; ^H%0) 1.86-2.02 (3H, m, 
îPC H j and -jCHz), 2.39 (IH , m,&pCH2), 2.53 (3H, s, NCHj), 2.96 (IH , dd, Ji 8.0, 
72  4.2, ŸpCHzPh), 3.10 (IH , dd, 7; 8 .0 , 7 : 6.5, ^pCHzPh), 3.23 (2 H, m, ÔCHi), 4.27 
(IH , dd, 7 i 4.2, 72  6.5, aC H ), 4.43 ( IH , t, 7  8.0, CgCH iPh) and 7.21 (5H, m, 
aromatic); 5c (50.3 MHz, ^HzO) 26.49 (7 CH2), 28.43 (NCH3), 32.56 (PCH;), 39.79 
(CH2Ph), 49.28 (SCH2), 58.76 (CHCHjPh), 62.26 (aCH ), 130.06 (para aromatic),
131.92 {ortho aromatic), 131.55 {meta aromatic), 138.38 (quat. aromatic), 172.11 
(CONHCH) and 175.77 (ÇONCH3); m!z (Cl) 276 {[M + H]+, 100%), 245 (3, [M - 
NH2CH3]+), 217 (2, [M -C O N H 2CH3M , 91 (2, [PhCH2]+) and 70 (33, [C4HgN]+).
W -BenzyloxycarbonyI-giycyl-(25)-proIyI-(2S)-phenylalanine m ethylam ide (34)
To a solution of A-methylmorpholine (1.12 cm^, 10 mmol) in dry THF (25 cm^) was 
added (25)-proline-(25)-phenylalanine methylamide hydrochloride (32) (3.12 g, 
1 0  mmol) and the resultant suspension stirred vigorously for 30 min at room 
temperature, (suspension A). Meanwhile, A-benzyloxycarbonyl-glycine (33) (2.09 g, 
1 0  mmol) was added to a stirred solution of A -m ethylm orpholine ( 1 .1 2  cm^, 
10 mmol) in dry THF (25 cm^). The m ixture was cooled to -15 °C and 
zjo-butylchloroformate (1.36 cm^, 10 mmol) was added. The resultant suspension 
was stirred at -15 °C for 2 min and then suspension A was added in one portion. The 
reaction mixture was allowed to warm to room temperature and then stirred for a 
futher 1 h. The hydrochloride salts were filtered off and the solvent removed under 
reduced pressure. The resultant clear oil was dissolved in CH2CI2 (50 cm^) and 
washed with 0.5 mol dm-^ HCl (2 x 25 cm^) and 5% sodium bicarbonate solution 
(2 X 25 cm^). The organic phase was dried (MgS0 4 ) and the solvent removed under 
reduced pressure to give the product as a white solid (3.88 g, 83%), m.p. 62-6 °C;
(Found: M+, 467.2288. Calc, for C25H 31N 4O 5 : 467.2294); [o tg  -47.6 (c 0.5 in 
MeOH); Dmax (NujoI)/cm-^ 3303 (NH), 1696 (carbamate CO), 1661 (tertiary amide 
CO), 1652 (secondary amide CO) and 1648 (methylamide CO); 5h  (200 MHz; 
C2HCI3) 1.74-2.12 (4H, m, PCH2 and yCHa), 2.75 (3H, d, J  4.4, NHCH3), 2.98 (IH ,
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dd, 7i 9.5, h  14.3, jCHCHzPh), 3.37-3.55 (3H, m ,jCH CH 2Ph and 8 CH2), 3.73 (IH , 
dd, 7i 5.3, 72l6.6,5COCH2), 3.88 (IH , dd, 7 , 4.7, J j  16.6,^OCH2>, 4.44 (IH , dd, 
7i 3.3, 7 2  7.5, aC H ), 4.67 (IH , ddd, 7, 5.5, J 2  7.5, 7) 9.0, CECH 2PI1), 5.04 (IH , d, 
7 1 2 .2 , jOCH2Ph), 5.16 (IH , d, 7  12.2, lO C IbPh), 5.62 (IH , t, 7  5.0, NHCH2 ), 6.46 
(IH , q, 7  4.4, NHCH3), 6.92 (IH , d, 7  9.5, NHCHCH2), 7.21 (5H, m, aromatic, 
CHCH2PI1) and 7.36 (5H, s, aromatic, OCH2Ph); Sc (50.31 MHz; C^HCls) 24.74 
(7CH 2 ), 26.65 (NHCH3), 29.09 (PCH2 ), 37.57 (CHCH2PI1), 43.76 (COÇH2 ), 47.31 
(6 CH 2), 54.72 (CHCH2Ph), 61.42 (aC H ), 67.54 (CO2ÇH 2PI1), 127.05 (para 
aromatic), 128.45 {meta aromatic), 128.67 {para aromatic), 128.76 {ortho aromatic), 
128.98 {meta aromatic), 129.48 {ortho aromatic), 136.53 (quat. aromatic), 138.13 
(quat. aromatic), 157.64 (£ 0 2 CH2Ph), 170.01 (ÇOCH 2), 171.70 (CONHCH3) and
172.22 (ÇONHCHCH2); m/z  (Cl) 467 {[M + H]+, 2 2 %), 376 (100, [M - PhCHg + 
H]+), 359 (5, [M - PhCH2 0 ]+), 277 (4, [M - CO2CH2PI1 - CONH3 + 3H]+), 91 (3, 
[PhCH2]+) and 70 (9, [C4HgN]+).
iV-f^r^-Butoxycarbonyl-glycyl-(2S)-prolyI-(2S)-phenylananine methylamide (35)
This com pound was p repared  in  a m anner iden tica l w ith  that for 
AT-benzyloxycarbonyl-glycyl-(25)-prolyl-(25)-phenylananine methylamide (34), using 
(25)-proline-(2.S)-phenylalanine m ethylam ide hydrochloride (32) (1.12 cm^, 
10 mmol) and iV-rerr-butoxycarbonyl-glycine (20) (1.75 g, 10 mmol) to give the 
compound as a white solid (3.53 g, 82%), m.p. 75-7 °C; (Found: C, 59.9; H, 7.3; N, 
12.7. Calc, for C 22H 32N 4 O 5 : C, 61.05; H, 7.45; N, 12.9%); m/z  (Found: [M + H]+, 
433.2435. Calc, for C22H 33N4 O5 : 433.2451); [ a g  -94.4 (c 0.5 in M eOH); 
Dmax (Nujol)/cm-i 3312 (NH), 1675 (carbamate CO), 1662 (tertiary amide CO), 1658 
(secondary amide CO) and 1641 (methylamide CO); Ôh (400 MHz; C^HCls) 1.41 (c, 
9H, s, (CH3 )3), 1.43 (t, 9H, s, (CH3)3>, 1.51-1.64 (t & c. IH, m ,h C H 2 ), 1.77-1.93 
(t & c, 2H, m, ipC H 2 and 57CH2 ), 1.95-2.05 (t & c, IH, m ,|pC H 2), 2.64 (c, 3H, d, 
74 .4 , NHCH3 ), 2.73 (t, 3H, d, 7 4.4, NHCH3). 2.93 (t & c, IH, dd, 7, 9.6, J 2  14.2, 
K:H 2Ph), 3.27-3.37 (t & c, 2 H, m ,|C H 2Ph and jSCHa), 3.42 (t & c, IH, m, &5 CH2 ), 
3.67 (t & c, IH, dd, 7 | 5.6, J 2  16.8, ÎCOCH2), 3.82 (t & c, IH, dd, 7; 4.4, J 2  16.8, 
ÎCOCH2), 4.22 (c, IH, dd, 7i 2.2, J2  8 .6 , aC H ), 4.42 (t, IH , dd, 7 | 2.4, J2  8.3, aC H ), 
4.63 (t & c, IH, ddd, 7; 4.7, J2  8.5, 73  8.5, CHCH2PI1), 5.37 (f, IH, m, NHCH2), 5.45 
(c, IH , m, NHCH2 ), 6.54 (t & c, IH, q, 7 4.4, N HCH 3), 6.92 (c, IH , d, 7 8 .2 , 
NHCHCH2Ph), 6.97 ((, IH , d, 7 8.2, NHCHCHzPh) and 7.21 (t Sc c.  5H, m, 
aromatic); Sc (74.76 MHz; C^HCls) 22.52 (c, SCH2), 24.15 (t, SCH2 ), 26.17 (t Sc c, 
NHCH3 ), 28.01 (t, PCH2), 28.16 (t, C (£H 3)3). 29.14 (c, pCH j), 29.52 (c, CCCHa);),
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36.94 (f, CHaPh), 37.91 (c, CHaPh), 42.84 (r & c, COÇHa), 46.59 {t, ÔCHa), 46.84 (c, 
ÔCHa), 54.11 {t, ÇHCHaPh), 54.97 (c, ÇHCHaPh), 60.08 (c, aC H ), 60.55 (t, aC H ), 
80.04 (c, Ç(CH3)3), 80.10 {t, Ç(CH3)3), 126.58 (t & c,para  aromatic), 128.25 (t & c, 
meta aromatic), 128.86 (t & c, ortho aromatic), 136.66 (c, quat. aromatic), 137.42 (f, 
quat. aromatic), 156.06 {t, COa^Bu), 156.40 (c, COa^Bu), 168.54 (c, CONHCH3),
169.29 {t, CONHCH3), 170.67 {t & c, ÇONHCHCHa) and 171.19 {t & c, ÇOCHa); 
m/z (FAB) 433 ([M + H]+, 100%), 401 (4, [M + H - NHCH3]+), 355 (15, [M - Ph]+), 
333 (96, [M + 2H - COa^Bu]+), 302 (7, [M - CHaNHCOatBu]+), 274 (15, [M - 
COCHaNHCOa*Bu]+) and 255 (8 , {M- NHCHCHaPhCONHCH3]+).
A-Bromoacetyl-(2iS)-prolme methyl ester (38)
To a solution of A-methylmorpholine (1.12 cm^, 10 mmol) in dry THF (25 cm^) was 
added bromoacetic acid (37) (1.39 g, 10 mmol) and the solution cooled to -15 °C. 
wo-Butyl chloroformate (1.36 cm^, 10 mmol) added with stirring and the resulting 
suspension stirred at -15 °C for 2 min. A mixture of (2^-pro line methyl ester 
hydrochloride (2 1 ) ( 1 .6 6  g, 1 0  mmol) and A-methylmoipholine ( 1 .1 2  cm^, 1 0  mmol) 
in dry DMF (5 cm^) was then added in one portion to the cold suspension. The 
reaction mixture was allowed to warm to room temperature and left stirring overnight. 
The hydrochloride salts were filtered off and the solvents removed under reduced 
pressure. The resulting brown oil was dissolved in CHaCla, washed with 0.5 mol 
dm '3 HCl (2 X 20 cm^) and 5% sodium bicarbonate solution (2 x 20 cm^), dried 
(MgS0 4 ) and the solvent removed under reduced pressure to yield the product as a 
pale yellow oil. Purification by silica column chromatography using ethyl acetate/ 
light petroleum (1:1) as the eluent gave the pure product as a clear oil (2.07 g, 83%), 
m/z (Found: [M + H]+, 250.0080. Calc, for CgHi379BrN0 3 : 250.0079); [a ]g -9 6 .7  
(c 1.0 in MeOH); "Umax (thin film)/cm'^ 1741 (ester CO), 1655 (amide CO) and 1448 
(C-O); ÔH (200 MHz; C2HCI3) 1.81-2.28 ( f& c , 4H, m, PCH2 and 7 CH2), 3.48-3.73 
{t & c, 2H, m, ÔCH2 ), 3.57 (/, 3H, s, OCH3), 3.62 (c, 3H, s, O C H 3 ) , 3.73 (c, 2H, d, 
J  1.4, C O C H 2 ) , 3.96 (r, 2 H, d, J  1.4, C O C H 2 ) , 4.33 (f, IH, dd, 7i 4.0, J 2  8.2, aC H ) 
and 4.45 (c, IH, dd, 7i 3.4, J 2 7.2, aCH ); Ôc (50.31 MHz; C^HClg) 22.63 (c, -yCH2 ),
25.24 {t, 7CH2), 29.47 {t, PCH2), 31.55 (c, PCH2), 42.38 {t & c, CH2Br), 47.44 {t & c, 
Ô C H 2 ), 52.65 (r, aC H ), 53.32 (c, aC H ), 59.61 {t & c, O C H 3 ) , 165.49 (r, NCO),
165.59 (c, NCO) and 172.56 {t & c, CO2CH 3); m/z (El) 252 & 250 (M+, 3%), 170 (40, 
[M - Br]+), 156 (2, [M - Br - CH3 + H]+), 139 (14, [M - Br - OCHsl^) and 70 (100, 
[C4HgN]+).
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(9a5)-2,3,7,8,9,9a-H exahydropyrrolo-[2,l-d]-l,2,5-[6H ]-triazepine-l,5-dione (39)
e N '  'L  2NH
NH
To a solution of hydrazine hydrate (1.5 g, 30 mmol) in ethanol (50 cm^) was added 
Af-bromoacetyl-(2S)-proline methyl ester (38) (2.50 g, 10 mmol). The resultant 
solution was refluxed for 2  h and allowed to cool to room temperature whereupon 
colourless crystals o f the product were formed (1.43 g, 57%), m.p. 265-6 °C; 
m/z (Found: [M + H]+, 170.0930. Calc, for C7H 12N 3O2 : 170.0930); [a f^  -74.4 (c 1.0 
in MeOH); Umax (Nujol)/cm'* 3403 (NH), 1664 (secondary amide CO) and 1637 
(tertiary amide CO); 8h(200 MHz; % 2 0 ) 1.83-2.25 (3H, m, yCÜ2 andipCHz), 2.41 
(IH , m, ïpC H 2), 3.42-3.71 (2H, m, 5 CH2), 4.11 (IH , d, J  16.5, ^ O C H a), 4.45-4.59 
(IH , m, aC H ) and 4.59 (IH , d, J  16.5,5COCH2); 8 h (200 MHz; *-D M SO ) 1.77-2.10 
(A & B,  3H, m, 7CH 2 and 1PCH2), 2.14-2.41 (A & B, IH, m, jpCHa), 3.34-3.62 
(A & B, 2H, m, 8 CH2), 3.89 (A, IH , d, J  15.1,|C0CH 2), 4.11 (B, IH , d, J  16.0, 
ÏCOCH2), 4.40 (A, IH, d, J  15.1,;C0CH2), 4.42 (A & B, IH, m, aCH ) and 4.61 (B, 
IH , d, J  16.0,jCOCH2); 8 c  (50.31 MHz; % 2 0 ) 24.71 (A, 7 CH2), 24.85 (B, 7 CH2),
30.56 (B, pCHz), 30.72 (A, pCHz), 48.39 (A, COCH2), 48.47 (B. COÇH2), 54.51 (A, 
8 CH 2), 54.90 (B, 8 CH2), 61.44 (A, aC H ), 61.59 (B, aC H ), 166.61 (A, Ç O C H 2 ), 
166.80 (B, Ç O C H 2 ), 170.47 (B, CONH), 170.96 (A, CONH); 8 c  (50.31 MHz; 
4 -D M S O ) 25.99 (A, yCH2), 26.11 (B, 7CH2 ), 31.89 (B, PCH2), 32.12 (A, PCH2), 
48.75 (A & B, COCH2), 56.32 (B, 8 CH2), 56.53 (A, 8 CH2), 61.78 (A, aCH ), 61.88 (B, 
aC H ), 165.91 (A, COCH2), 166.17 (B, COCH2), 169.66 (B, CONH) and 170.44 (A, 
CONH); miz (Cl) 170 {[M + H]+, 100%), 155 (12, [M - NH]+), 137 (7, [M - 2NHa]+) 
and 70 (5, [CaHgN]*).
(25')-Bromopropionic acid (44)
(25)-Alanine (42) (4.0 g, 45 mmol) was added to a saturated solution of potassium 
bromide (10 cm^). Hydrogen bromide (15 cm^ of a 48% solution) as added dropwise 
and then the reaction mixture cooled to 0 °C and sodium nitrite (6.21 g, 90 mmol) 
added over 1 h. The reaction mixture was maintained below 5 for a further hour 
and then allowed to warm to room temperature. The resulting solution was extracted 
with diethyl ether (3 x 25 cm^) and the combined ethereal extracts were then dried
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(MgS0 4 ) and then concentrated under reduced pressure to give a pale yellow oil 
which was distilled to give pure (25)-bromopropionic acid (5.87 g, 85%), b.p. 100 °C/ 
10 mmHg (lit.,207 87-8 °C/ 0.5 mmHg); m/z (Found; [M + H]+, 151.9478. 
C3H579Br02 requires 151.9478); [ a f  -31.8 (c 1.0 in MeOH) {lit.,207 -3 4 .0  (c 1.0 in 
MeOH)}; Dmax (thin film)/crrrt 1724 (CO) and 1245 (C-O); Ôh (200 MHz; C2HCI3)
1.88 (3H, d, 7 6.7, CH 3), 4.41 (IH , d, J  6.7, 2-CH) and 10.75 (IH , s, CO 2H); 
ÔC (50.31 MHz; C2HCI3) 21.02 (CH3), 39.22 (2-CH) and 176.26 (CO2H); m/z (El) 
154 & 152 (M+, 5%), 73 (2 1 , [M - Br]+), 45 (32, [M - COBr]+) and 27 (100, [M - 
HBrC0 2 H]+).
(2/2)-Bromopropionic acid (45)
This compound was prepared in a manner identical with that for the (25) epimer (44), 
using (2/?)-alanine (43) to give a pale yellow oil which was distilled under reduced 
pressure to give the pure product as a clear oil (5.73 g, 83%); b.p. 100 °C/ 10 mmHg; 
[a]j^  +29.9 (c 1.0 in MeOH); All other spectral data were identical to that quoted 
above.
A^-(25)-Bromopropanoyl-(2S)-proline methyl ester (47)
,OCH;
Br
To a stirred solution of (25)-bromopropionic acid (44) (1.53 g, 10 mmol) in diy THF 
(20 cm2) at -40 °C was added A-methylmorpholine (1.12 cm^, 10 mmol). wo-Butyl 
chloroform ate (1.36 cm^, 10 mmol) was immediately added and the resultant 
suspension stirred at -40 °C for 2 min. A mixture of (25)-proline methyl ester 
hydrochloride (2 1 ) ( 1 .6 6  g, 1 0  mmol) and A-methylmorpholine (1 .1 2  cm^, 1 0  mmol) 
in dry DMF (5 cm^) was then added. The reaction mixture was allowed to warm up 
to room temperature and left to stir for a futher 1 h. The hydrochloride salts were 
filtered off and the solvents removed under reduced pressure. The resultant clear oil 
was dissolved in CH2CI2 (25 cm^) and washed with 0.5 mol d m - 2 HCl (2 x 1 5  cm2) 
and 5% sodium carbonate solution (2 x 15 cm2). The organic phase was dried 
(MgSO^) and the solvent removed under reduced pressure to yield a white solid.
127
Recrystallisation from diethyl ether/ light petroleum gave the product as colourless 
crystals (2.19 g, 83%), m.p. 116-8 °C; (Found; C, 41.85; H, 5.4; N, 5.35. Calc, for 
CgH^ErNOg: C, 42.0; H, 5.35; N, 5.3%); m/z (Found; [M + H]+, 264.0235. Calc, for 
C ,H if% rN 0 3 : 264.0235); [ a f +127.3 (c 1.0 in MeOH); (Nujol)/cm-> 1752 
(ester CO), 1648 (amide CO) and 1197 (C-O); 5» (400 MHz; C^HCla) 1.76 (r, 3H, d. 
J  6 .6 , CHCHs). 1.77 (c, 3H, d, J  6.7, CHCHs), 1.80-2.28 (t & c, 4H, m, pCHj & 
7CH 2), 3.45-3.64 (f & c, IH, m ,|5 CH2), 3.69 (r, 3H, s, OCH3), 3.73 (c, 3H, s, OCH3 ), 
3.79-3.86 it & c, IH, m ,|5 CH2 ), 4.18 (r, IH, q, J  6 .6 , CHCHj), 4.40 (c, IH, q, J  6 .6 , 
CHCH2). 4.45 it, IH, dd, 7i 4.1, J 2  8 .6 , aC H ) and 4.61 (c. IH , dd, 4.1, J 2  8 .6 , 
aC H ); Sc (100 MHz; C^HClj) 20.82 it, CHÇH3), 20.97 (c, CHÇH3), 21.53 (c, 7CH 2),
24.56 it, 7CH 2), 28.82 it, PCH2), 30.77 (c, PCH2 ), 39.25 (r, CHCHs), 39.97 (c, 
CHCH3), 46.69 (c, 8 CH2 ), 46.81 it, ÔCH2), 52.03 it, OCH3), 52.65 (c, OCH3 ), 58.99 
it, aC H ), 59.05 (c, aC H ), 167.56 (r, COCHCH3), 167.99 (c, ÇOCHCH3), 171.87 (f, 
C O 2CH 3) and 172.05 (c, CO2CH3); m/z (FAB) 264 & 266 (M+, 100%), 204 & 206 
(38, [M - HCOOCH31+), 184 (35, [M - Br]+) and 128 (62, [M - COCHCHsBr]*).
iV-(2R)-Bromopropanoyl-(2,S)-prollne methyl ester (48)
This compound was prepared in a manner identical with that for the (25, 25) methyl 
ester (47), using (2/?)-bromopropionic acid (45) (1.53 g, 10 mmol) to give the product 
as colourless crystals (2.09 g, 79%), m.p. 113-5 °C; (Found: C, 41.95; H, 5.35; N, 5.3. 
Calc, for CgHwBrNOs: C, 42.0; H, 5.35; N, 5.3%); m/z (Found; [M + H]+, 264.0232. 
Calc, for CvHis’^BrNOs: 264.0235); [ a g  +113.6 (c 1.0 in M eOH); Umax 
(Nujol)/cm '* 1752 (ester CO), 1646 (amide CO) and 1197 (C-O); Sh (400 MHz; 
C2HCI3) 1.62 (c, 3H, d, J  6.4, CHCH3), 1.64 it, 3H, d, J  6 .6 , CHCEb), 1.82-2.31 
i t & c ,  4H, m, pCHz and yCHj), 3.44-3.66 it  & c, IH, m, iSCH ;), 3.71 it, 3H, s, 
OCH3), 3.75 (c, 3H, s, OCH3), 3.82-3.94 (r & c, IH, m, fSCHj), 4.22 (c, IH, q, 7  6.5, 
CHCHy), 4.44 it, IH, q, y  6 .6 , CSCH^), 4.47 (r, IH, dd, J, 4.3, J 2  8 .6 , aC H ) and 4.69 
(c, IH , dd, / i  4.0, J 2  6.7, aC H ); Sc (100 MHz; C^HCl;) 20.21 {t, CHGH3), 20.35 (c, 
CHCH 3), 22.21 (c, 1C H 2 ), 24.67 (f, ^CH:), 28.82 it, pCHj), 30.89 (c, pCHz), 39.27 it, 
CHCHs), 40.02 (c, CHCH3), 46.70 (c, SCH2), 46.75 it, 8 CH2), 50.69 (t, OCH3), 50.81 
(c, OCH3), 58.87 (c, aC H ), 59.04 (f, aC H ), 167.44 it, ÇO CH C H 3 ), 167.79 (c, 
COCHCH3 ), 171.92 it, ÇO2CH3) and 172.24 (c, GO2CH3); m/z (FAB) 264 & 266 
(M+, 95%), 204 & 206 (62, [M -H C O O C H 3M , 184 (41, [M - Br]+) and 128 (100, 
[M - C0 CHCH3Br]+).
128
(4jR, 9a5)-4-Methyl-2,3,7,8,9,9a-hexahydropyrrolo-[2,l-d]-l,2,5-[6H]-triazepîne- 
1,5-dione (49)
2 NH
NH
To a solution of hydrazine hydrate (0.60 g, 12 mmol) in ethanol (20 cm^) was added 
N-(25)-bromopropionyl-(26^)-proline methyl ester (47) (2.64 g, 10 mmol). The 
resultant solution was refluxed for 16 h, allowed to cool slowly and the hydrazine 
hydrobromide precipitate removed by filtration. The solvents were removed from the 
filtrate under reduced pressure to give the product as a colourless oil (1.81 g, 98%); 
m/z (Found: [M + H ]+ , 184.1083. Calc, for C8H 14N 3O2 : 184.1086); [ a g  +39.0 
(c 1.0 in MeOH); Umax (thin film)/cm‘i 1665 (secondary amide CO) and 1639 (tertiary 
amide CO); Ôh (200 MHz; C^HgO^H) 1.53 (3H, d, 77.0, CHCH3), 1.86-2.15 (3H, m, 
7CH 2 and&pCHz), 2.39 (IH , m ,lpC H 2), 3.44-3.72 (2H, m, SCHj), 4.12 (IH , q, 77 .0 , 
CHCH3) and 4.38 (IH , dd, 7, 7.5, J2  7.5, aCH ); Sc (50.31 MHz; C^HgO^H) 17.01 
(CHCH3), 23.65 (-yCHî), 30.57 (pCHj), 46.97 (SCHj), 59.60 (aCH), 63.69 (CHCH3), 
167.85 (COCHCH3) and 168.49 (CONH); m/z (Cl) 184 ([M + H]+, 100%), 169 (20, 
[M - CH3 + H]+), 154 (8 , [M - NHCH3 + H]+), 138 (4, [M - NHNH - CHs]*), 126 (5, 
\M - NHNHCHCH3 + H]+) and 70 (10, [C4HgN]+).
(4 3 ,9aS)-4-MethyI-2,3,7,8,9,9a-hexahydropyrrolo-[2,l-d]-l,2,5-[6H]-triazepine- 
1,5-dione (50)
This compound was prepared in a manner identical with that for the (4/?, 9a3) 
diastereomer (49), using 77-(2jR)-bromo-propionyl-(23)-proline methyl ester (48) 
(2.64 g, 10 mmol) to give the product as a colourless oil (1.75 g, 96%); m/z (Found: 
[M + H]+, 184.1082. Calc, for C8H 14N 3O2 : 184.1086); [ a g  +28.6 (c 1.0 in MeOH); 
Umax (thin film)/cm-^ 1658 (secondary amide CO) and 1645 (tertiary amide CO); 
ÔH (200 MHz; C2H3O2H) 1.72 (3H, d, J  76.8 CHCH3), 1.93-2.29 (3H, m, 7 CH2 and 
iPCHz), 2.52 (IH , m, ipCH ), 3.54-3.86 (2H, m, 8 CH2), 4.35 (IH , q, 7 6 .8 , CHCH3) 
and 4.38 (IH , m, aC H ); Sc (50.31 MHz; C^HjO^H) 18.36 (CHCH3 ), 24.72 (7CH 2),
31.43 (PCH2), 48.55 (SCH2), 61.24 (aCH ), 64.54 (CHCH3), 167.49 (COCHCH3) and 
170.68 (CONH); m/z (Cl) 184 ([M + H]+, 100%), 169 (31, [M - CH3 + H]+), 154 (9,
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[M - NHNHCH 3 + H]+), 130 (4, [M - COCHCH3 + 3H]+), 126 (6 , [M - 
NHNHCHCH3 + H]+) and 70 (15, [C4HgN]+).
(3R, 8aS)-3-Methyl-2,3,6,7,8,8a-hexahydropyrrolo-[l,2-a]-pyrazine-l,4-dione 
(53)
g /  8 a W  Q
To a solution of 7/-benzyloxycarbonyl-(2i?)-alanyl-(23)-prolinamide (62) (0,64 g, 
2 mmol) in methanol (30 cm^) was added 10% palladium on activated charcoal 
(30 mg) and the vessel flushed with hydrogen gas. The resultant suspension was 
stirred vigorously under an atmosphere of hydrogen for 12 h. The mixture was then 
filtered through a prewashed celite pad and the solvent removed under reduced 
pressure to give a white solid which was recrystallised from methanol to give the 
product as colourless crystals (0.32 g, 93%), m.p. 128-30 °C (lit.,203 127-9 °C); 
(Found: C, 57.4; H, 7.35; N, 16.65; M+, 168.1902. C8H 12N 2O 2 requires C, 57.15 H,
7.2 N, 16.65%; M+, 168.1899); [ a ] g -175.2 (c 1.0 in EtOH) {lit.,203 -182.3 (c 1.0 in 
EtOH)}; Umax (Nujol)/cm-i 3213 & 3162 (NH), 1687 (tertiary amide CO) and 1635 
(secondary amide CO); 6 » (200 MHz; C2H3 O2H) 1.41 (3H, d, J  7.0, CH3), 1.84-2.13 
(3H, m, 7CH 2 andïPCH 2), 2.63-2.84 (IH , m ,ipC H 2), 3.42-3.70 (2H, m, 5 CH2), 3.92 
(IH , q, 7  7.1, CECH 3) and 4.28 (IH , dd, 7 i 6.5, J2  9.7, aC H ); 5c (74.76 MHz; 
C2H 3 0 2 H) 20.19 (CH3), 23.23 (7CH2), 30.21 (PCH2), 46.87 (ÔCH2), 54.71 (CHCH3), 
59.46 (aCH ), 169.34 (COCHCH3) and 171.39 (CONH); m/z (El) 168 {M*, 71%), 140 
(8 , [A7- CHCH31+), 125 (28, [M -N H C H C H 3M , 112 (8 , [M -  COCHCHs]*), 97 (41, 
[M - CONHCHCH31+) and 70 (100, [CaHgN]*).
(3 5 ,8a5)-3-M ethyl-2,3,6,7,8,8a-hexahydropyrrolo-[l,2-a]-pyrazine-l,4-dione (54)
This com pound was prepared in a m anner identical w ith that for the 
hexahydropyrrolo-[l,2-a]-pyrazine-l,4-dione (53), using N-benzyloxycarbonyl-(25)- 
alanyl-(25)-prolinamide (61) (0.638 g, 2 mmol) to give a white solid which was 
recrystallised from methanol to give the product as colourless crystals (0.31 g, 91%),
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m.p. 152-6 °C (lit.,203 1 5 3 .6  °C); (Found: C, 57.3; H, 7.25; N, 16.7; M+, 168.1900. 
Calc. forCgHi2N202: C, 57.15; H, 7.2; N, 16.65%; M+, 168.1899); [ a g  -158.4 (c 1.0 
in EtOH) {lit.,203 .160.0 (c 1.0 in EtOH)}; Umax (Nujol)/cm-i 3287 (NH), 1687 
(tertiary amide CO) and 1654 (secondary amide CO); Ôh (200 MHz; C2HCI3) 1.41 
(3H, d, J  6.6, CHg), 1.68-2.39 (4H, m, PCH2 and 7CH2), 3.50 (2H, m, ÔCH2 ), 4.08 
(2H, m, aC H  and CHCHg) and 7.42 (IH , s, NH); Ôc (74.76 MHz; C2H 3O2H) 16.05 
(CH3), 23.89 (7CH2), 29.43 (pCHi), 46.48 (ÔCH2), 52.33 (ÇHCH3), 60.70 (aCH ),
169.21 (ÇOCHCH3) and 172.78 (CONH); m/z (El) 168 (M+, 43%), 140 (18, [M - 
NHCH3 + 2H]+), 125 (35, [M - NHCHCHsl+l, 97 (34, [M - CONHCHCHs]+) and 70 
(100, [C4HgN]+).
iV-BenzyloxycarbonyI-glycyI-(2S)-prolme methyl ester (57)
To a solution of A^-benzyloxycarbonyl-glycine (33) (2.09 g, 10 mmol) in dry THF 
(20 cm3) was added iV-methylmorpholine (1.12 cm3, 10 mmol) and the solution 
cooled to -15 °C. wo-Butyl chloroformate (1.36 cm3, 10 mmol) was added with 
stirring and the solution left stirred at -15 °C for 2 min. A solution of (25)-proline 
m ethyl ester hydrochloride (2 1 ) ( 1 .6 6  g, 1 0  mmol) and A -m ethy lm orpho line  
(1.12 cm3, 10 mmol) in dry DMF (5 cm3) was then added. The reaction mixture was 
allowed to warm up to room temperature and left to stir for 2 h. The hydrochloride 
salts were filtered off and the solvents removed under reduced pressure. The resultant 
oily residue was dissolved in CH2CI2 (25 cm3) and washed with 0.5 mol dm*3 HCl 
(2 x 1 5  cm3) and 5% sodium carbonate solution (2 x 1 5  cm3). The organic phase was 
then dried (MgS0 4 ) and the solvent removed under reduced pressure to give a pale 
yellow oil. The crude material was purified by silica column chromatography using 
ethyl acetate/ light petroleum ( 1 :1) as the eluent to give the product as a clear oil 
(2.42 g, 76%), m/z  (Found: [M + H]+, 321.1453. Calc, for C 16H 21N 2O 5 : 321.1450); 
[ a ] g  -68.1 (c 1.0 in MeOH); (thin film)/cm-‘ 3336 (NH), 1732 (ester CO), 1711 
(carbamate CO), 1652 (amide CO) and 736 & 699 (aromatic CH); 0^(200 MHz; 
C^HClg) 1.81-2.33 (t & c, 4H, m, gCHg and 7CH2) 3.35-3.69 (t & c, 2 H, m, ÔCH2), 
3.73 (t, 3H, s, OCH3), 3.76 (c, 3H, s, OCH3), 4.02 {t & c, 2H, d, J  2.6, COCH2), 4.40 
(r, IH, dd, Ji 4.0, J 2 6 .6 , aCH ), 4.53 (c, IH, dd, Ji 3.8, J 2 7.0, aCH ), 5.12 (t & c, 2H, 
s, CH2Ph), 5.74 (t & c, IH, t, J  2.6, NHCH2) and 7.35 {t & c, 5H, s, aromatic); 
ôc (50.31 MHz; C^HClg) 22.52 (c, 7CH2), 24.97 (r, 7 CH2), 29.33 {t, PCH2), 31.66 (c, 
PCH2), 43.52 (c, OCH3), 43.66 (r, OCH3), 46.20 (f, ÔCH2), 47.00 (c, ÔCH2), 52.68 {t, 
COCH2), 53.15 (c, COCH2), 58.80 (c, aC H ), 59.20 {t, aC H ), 128.28 {t & c ,p a ra  
aromatic), 128.37 (r & ortho aromatic), 128.81 {t & c, meta aromatic), 136.87
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(f & c, quat, aromatic), 156.63 (r & c, CO2CH2PI1), 167.41 (t, CO2CH 2), 167.69 (c, 
ÇO 2 CH2 ), 172.29 (c, CO 2CH3 ) and 172.68 (t, CO 2CH 3); m/z  (Cl) 321 ([M + H]+, 
100%), 230 (10, [M -C H 2P h +  H]+), 213 (28, [M - OCH2PW+), 187 (36, [M - 
C0 2 CH2Ph + 2H]+), 157 (63, [M - C0 2 CH2Ph - OCH 3 + 3H]+) and 91 (41, 
[CH2Ph]+).
iV-Benzyloxycarbonyl-(25)-aIanyl-(25)-proUne methyl ester (58)
QÇ0CH3
This com pound was prepared in  a m anner identical w ith that for the 
A^-benzyloxycarbonyi-glycyl-(25')-proline methyl ester (57), using 7/-benzyloxy- 
carbonyl-(25')-alanine (55) (2.23 g, 10 mmol) instead of jV-benzyloxycarbonyl-glycine 
(33) to give a yellow oil which was purified by silica chromatography using ethyl 
acetate/ light petroleum (1:1) as the eluent to give the product as a clear oil (2.89 g, 
84%), m /z  (Found: [M + H]+, 335.1605. Calc, for C 17H 23N 2 O5 : 335.1606); 
[ a ] g  -86.5 (c 1.0 in MeOH); (Nujol)/cm-i 2982 & 2953 (NH), 1746 (ester CO), 
1716 (carbam ate CO), 1654 (am ide CO) and 669 & 6 6 6  (arom atic CH); 
ÔH (200 MHz; C2HCI3) 1.11 ( f & c ,  3H, d ,7  6 .6 , CHCH3), 1.49-2.02 (t & c, 4H, m, 
PCH2 and yCH2), 3.21-3.45 (t & c, 2H, m, ÔCH2), 3.40 (t & c, 3H, s, O C H 3 ) , 4.24 
(t & c, IH, m, aCH ), 4.26 (t & c, IH, q, J  6 .6 , CHCH3), 4.82 {t & c, 2H, s, CH2Ph), 
5.97 (c, IH, d, J  8 .6 , NH), 6.13 (t, IH, d, 77 .8 , NH) and 7.06 {t & c, 5H, s, aromatic); 
ÔC (50.31 MHz; C^BCh)  18.03 {t, CHÇH3), 19.06 (c, CHÇH3), 22.91 (c, 7CH2), 
25.14 (f, 7 CH2), 29.09 (t, PCH2), 31.47 (c, PCH2), 46.75 (c, ÔCH2), 46.96 (t, ÔCH2),
48.56 (f, ÇHCH 3), 48.77 (c, ÇHCH3), 52.30 (t, OCH3), 53.87 (c, OCH3), 58.97 (t, 
aC H ), 59.29 (c ,aC H ), 66.67 (t, CH2Ph), 67.05 (c, CH2Ph), 128.14 (t & c, ortho 
aromatic), 128.68 {t & c, para  aromatic), 129.36 (t & c ,m e ta  aromatic), 137.05 
(t & c, quat. aromatic), 155.73 (c, C0 2 CH2Ph), 156.13 (t, C0 2 CH2Ph), 171.65 (f & c, 
ÇOCHCH3), 172.51 (c, CO2CH3) and 172.62 (t, C O 2 C H 3 );  m/z (Cl) 335 ([M + H]+, 
100%), 319 (7, [ M - C H 3 M ,  291 (13, [M - COCH31+), 227 (12, [M - OCH2Ph]+) and 
91 (8 , [PhCH2]+).
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A^-Benzyloxycarbonyl-(2iR)-alanyl-(25)-proline methyl ester (59)
This compound was prepared in a manner identical with that for the methyl ester (58), 
using A/-benzyloxycarbonyl-(2/?)-alanine (56) (2.23 g, 10 mmol) instead o f 
N  benzyloxycarbonyl-(2iS)-alanine (55) to give a yellow oil which was purified by 
silica column chromatography using ethyl acetate/ light petroleum ( 1 :1) as the eluent 
to give the product as a clear oil (2.40 g, 72%), m/z (Found: [M + H]+, 335.1614. 
Calc, for C 17H 23N 2 O5 : 335.1607); [ d ^  -22.9 (c 1.0 in MeOH); v^ax (thin film)/cm-^ 
2982 & 2955 (NH), 1745 (ester CO), 1719 (caibamate CO), 1652 (amide CO) and 
736 & 699 (aromatic CH); gy (200 MHz; C^HClg) 1.27 (c, 3H, d, 77.0, CHCH3 ),
1.33 (t, 3H, d, 7 6 .6 , CHCH3), 1.79-2.33 (r & c, 4H, m, PCH2 and 7 CH2), 3.38-3.62 
(t & c, 2H, m, ÔCH2), 3.70 (t, 3H, s, OCH3), 3.74 (c, 3H, s, OCH3), 4.31 (c, IH , dq,
71 7.0, 72 8.0, CHCH3 ), 4.42 (t, IH, dd, 7% 2.1, 7] 9.1, aCH), 4.54 {t, IH, dq, 7i 6 .6 ,
72  7.6, CHCH3), 4.91 (c, IH, dd, 7i 3.1, J 2 7.3, aCH ), 5.08 (t & c, 2H, s, CH2?h),
5.59 (c, IH, d, 7 8.0, NH), 5.78 (r, IH, d, 7 7.6, NH), 7.31 (c, 5H, s, aromatic) and
7.32 (f, 5H, s, aromatic); 6 c (50.31 MHz; C^HClg) 17.89 (c, CHÇH3), 18.48 {t, 
CHOH3), 22.67 (c, yCH2 ), 24.92 (f, yCHg), 29.22 (f, PCH2), 31.31 (c, PCH2), 46.81 
(c, ÔCH2), 47.00 (f, ÔCH2 ), 48.42 (c, ÇHCH 3), 48.67 (f, CHCH3), 52.25 (f, OCH3),
52.72 (c, OCH3), 59.32 (/, aC H ), 60.46 (c, aC H ), 66.63 (t & c, CHoPh), 128.13 
(r & c, aromatic), 128.64 (t & c, aromatic), 136,93 (c, quat. aromatic), 137.03 (f, quat. 
aromatic), 155.77 (t, C0 2 CH2Ph), 156.37 (c, C0 2 CH2Ph), 171.05 (f, ÇOCHCH3),
171.29 (c ,C 0 CHCH3), 172.53 (ACO 2 CH3) and 172.98 (f ,G 0 2 CH3); m/z (Cl) 335 
([M + H]+, 100%), 230 (5, [M - CH2 Ph - CH3 + 2H]+), 201 (3, [M - C0 2 CH2Ph + 
2H]+), 196 (4, [M - OCH2Ph - OCHsl^) and 169 (6 , [M - C0 2 CH2Ph - OCH3 + H]+).
A^-BenzyloxycarbonyI-glycyl-(25)-prolinamide (60)
To a saturated solution o f am monia in dry methanol (20 cm^) was added 
N-benzyloxycarbonyl-glycyl-(25)-proline methyl ester (57) (1.60 g, 5 mmol). The 
solution was placed in a tightly stoppered vessel and left at room temperature. When 
the reaction was complete as judged by TLC (9 days), the stoppered vessel was 
cooled to 0 °C, opened and nitrogen gas bubbled through at room temperature for 
5 min. The solvent was then removed under reduced pressure to give a white solid 
which was recrystallised from methanol/ diethyl ether to give the product as a white 
solid (1.24 g, 81%), m.p. 148-9 °C; (Found: C, 59.15; H, 6.4; N, 13.8. Calc, for 
C 15H 19N 3O4 : C, 59.0; H, 6.3; N, 13.75%); m/z (Found: [M + H]+, 306.1459. Calc, 
for C 15H20N 3O4 : 306.1454); [a |^  -60.1 (c 1.0 in MeOH); Omax (NujoI)/cm-* 3394 &
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3213 (NH), 1687 (carbam ate CO), 1671 (tertiary amide CO), 1639 (prim ary 
amide CO) and 753 & 701 (aromatic CH); 6 ^ (200 MHz; ^e-DMSO) 1.67-2.34 (t & c, 
4H, m, 7 CH2 and PCH2), 3.31-3.69 (t & c, 2H, m, ÔCH2), 3.79 (c, 2H, d, J  5.8, 
COCH2), 3.86 it, 2 H, d, J  5.8, COCH2), 4.21 (r, IH, dd, 7] 5.8, J2  7.6, aC H ), 4.35 (c, 
IH, dd, 7i 2.6, 7 2  8.2, aC H ), 5.01 (t & c, 2H, s, CH2PI1), 7.01 (t, IH, s, |C 0 NH2), 
7.28 (c, IH, s, ^ 0 NH2), 7.32 (t, IH, s, 5CONH2), 7.38 (t & c, 5H, s, aromatic) and 
7.61 (c, IH , s, ICONH2); ÔC (50.31 MHz; C^HgO^H) 23.62 (c, 7CH2), 25.90 (t, 
yCH2), 31.05 (t, PCH2), 33.69 (c, PCH2), 44.35 (t, 6 CH2), 44.46 (c, ÔCH2), 47.83 (t, 
COCH2), 48.61 (c, COCH2), 61.26 (c, aC H ), 61.86 (t, aCH), 68.01 (t & c, CH2 PI1), 
129.16 (t & c ,p a ra  aromatic), 129.28 {t & c, ortho aromatic), 129.74 (f & c, meta  
aromatic), 138.43 {t & c, quat. aromatic), 159.30 (r & c, Ç O 2CH 2PI1), 170.58 (t, 
ÇOCH2) , 170.72 (c , ÇOCH2), 177.49 (c, CONH2) and 174.94 [t, CONH 2); 
m/z (Cl) 306 m  + H]+, 33%), 198 (100, [M - OCH2PW+), 172(11, [M - C0 2 CH2Ph 
+ 2H]+), 155 (38, [M - CO2CH2PI1 - NH2 + H]+), 139 (15, [M - CO2CH 2PI1 - NH2 - 
NH]+) and 91 (22, [CH2PW+).
iV-BenzyIoxycarbonyl-(25)-alanyl“(25)-proHnamide (61)
T his com pound was p repared  in a m anner iden tica l w ith  that for 
A^-benzyloxycarbonyl-glycyl-(25')-prolinamide (6 0 ), starting from  the N -tert-  
butoxycarbonyl-(25)-alanyl-(25')-proline methyl ester (58) (0.67 g, 2 mmol) to give an 
off-white solid which was recrystallised from methanol/ diethyl ether to give the 
product as colourless crystals (0.51 g, 79%), m.p. 167-9 °C; (Found: C, 60.5; H, 6.75; 
N, 13.3. Calc, for C 16H 21N 3O4 : C, 60.2; H, 6.65; N, 13.2%); m/z (Found: [M + H]+, 
320.1612. Calc, for C 16H22N 3O4 : 320.1610); [ a g  -81.3 (c 1.0 in M eOH); 
't)max (Nujol)/cm-i 3402 & 3323 (NH), 1668 (carbamate CO), 1653 (tertiary amide 
CO), 1646 (primary amide CO) and 754 & 696 (aromatic CH); Ôh (200 MHz; 
7ô-DMSO) 1.20 (3H, d, 77.6, CH3), 1.62-2.18 (4H, m, pCHg andyCHz), 3.58 (2H, m, 
6 CH2), 4.22 (IH , dd, 7i 7.5, J2 2.7, aC H ), 4.32 (IH , m, CHCH3), 5.01 (2H, s, 
CHzPh). 6 .8 8  (IH , s.jCON Hj), 7.22 (IH , s, jCONHj), 7.35 (5H, s, aromatic) and 
7.51 (IH , d, 7 7.6, NH); 5c (74.76 MHz; C ^ sO ^ H ) 17.63 (t. CH 3 ), 18.28 (c, CH3),
23.52 (c, 7 CH2), 26.42 (f, 7CH2), 31.17 (f, PCH2), 33.36 (c, PCH2 ), 48.93 (f & c.
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ÔCH2 ), 50.36 (t, CHCH3), 50.72 (c, ÇHCH3), 61.86 (t, aCH ), 62.05 (c, aCH ), 68.11 
{t, CH 2Ph), 68.73 (c, CH2Ph), 129.32 {t & c, ortho aromatic), 129.49 (r & c ,p a ra  
aromatic), 129.94 {t & c, meta  aromatic), 138.66 (t & c, quat. aromatic), 158.66 
(t & c, ÇO 2 CH2PI1), 174.45 (t & c, ÇOCHCH3), 176.93 (c, CONH2) and 177.54 {t, 
CONH2); m/z (CI) 320 ([M + H]+, 100%), 303 (20, [M - NH 2]+), 291 (21, [M - CO]+), 
276 (19, [M - CONH2 + H]+), 227 (34, [M - PI1CH2 + H]+), 212 (38, [M - PhCH2 0 ]+), 
91 (40, [PhCH2]+) and 70 (23, [C4HgN]+).
iV-Benzyïoxycarbonyl-(2/î)-alanyl-(25)-prolinamide (62)
This com pound was prepared in a m anner identical w ith that for the 
A^-benzyloxycarbonyl-(25)-alanyl-(25)-prolinamide (61), using iV-benzyloxycarbonyl- 
(2/?)-alanyl-(25^)-proline m ethyl ester (5 9 )  (1.60 g, 5 m m ol) instead  of 
A^-benzyloxycarbonyl-(2tS)-alanyl-(25)-proline methyl ester (58) to give the product 
as a cleai* oil (1.57 g, 98%), m/z (Found: [M + H]+, 320.1606. Calc, for C 16H22N 3 O4 :
320.1610); [oc]^-19.8 {c 1.0 in MeOH); (thin film)/cm-^ 1701 (carbamate CO), 
1683 (tertiary amide CO), 1642 (primary amide CO) and 743 & 699 (aromatic CH); 
6 ^ (200 MHz; C2HCI3) 1.30 (3H, d, 7 6 .8 , CHCH3), 1.70-2.43 (4H, m, PCH2 and 
7 CH 2), 3.22-3.60 (IH , m ,i5 CH2), 3.62-3.97 (IH , m ,j5 CH2), 4.23-4.61 (2H, m, aC H  
and CHCHa), 5.04 (2H, s, CH2 Ph), 5.79 (IH , s ,ÎN H 2), 6.10 (IH , d, J  6 .6 . 
NHCHCH3 ), 6 .8 6  (IH , s, &NH2) and 7.32 (5H, s, aromatic); 8 c (50.31 MHz; 
C^HjO^H) 17.44 (r, CH3), 18.12 (c, CH3), 23.96 (c, 7CH2), 25.89 (f, 7CH2), 31.08 (f, 
PCH2), 33.77 (c, PCH2), 48.42 (c, 8 CH2), 48.75 (t, 8 CH2), 50.04 (r & c, CH CH 3), 
62.03 (c, aC H ), 62.29 (r, aCH ), 67.87 (c, CH2PI1), 68.13 (r, CHzPh). 129.24 (f & c. 
para  aromatic), 129.37 (t & c, ortho aromatic), 129.95 (t & c, meta aromatic), 138.46 
{t & c, quat. aromatic), 158.56 (c, C0 2 CH2Ph), 158.68 (t, C0 2 CH2Ph), 174.36 (t, 
ÇOCHCH3), 175.02 (c, ÇOCHCH3), 177.24 (c, CO2NH2) and 177.39 (t, CO2NH2); 
m/z (Cl) 320 ([M + H]+, 100%), 303 (32, [M - NH2]+), 291 (15, [M - CO]+), 276 (22, 
[M - CONH2 + H]+), 230 (31, [M - Ph - CH3 + 3H]+), 186 (36, [M - C0 2 CH2Ph + 
2 H]+), 91 (52, [PhCH2l+) and 70 (18, [C4HgN]+).
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(8aS)-2,3,6,7,8,8a“Hexahydropyrrolo-[l,2-a]-pyrazîne-l,4-dione (64)
_  .NHO
To a solution o f iV-benzyloxycarbonyl-glycyl-(25)-prolinamide (60) (0.610 g, 
2 mmol) in methanol (50 cm^) was added 10% palladium on activated charcoal 
(30 mg) and the vessel flushed with hydrogen. The resultant suspension was stirred 
vigorously under an atmosphere of hydrogen for 12 h. The mixture was filtered 
thi'ough a celite pad and the solvent removed under reduced pressure to give white 
solid which was recrystallised from methanol to give the product as colourless 
crystals (0.29 g, 93%), m.p. 205-8 °C (lit.,240 208-10 °C); (Found: C, 54.45; H, 6 .8 ; 
N, 18.4; M+, 154.0747. Calc, for C7H 10N 2O2 : C, 54.5; H, 6.65; N, 18.3%; M+, 
154.0742); [otfg -184.3 (c 0.5 in MeOH) (lit..MO . 1 9 6 .5  (c 0.5 in M eOH)}; 
Pmnx (Nujol)/cm‘> 3162 & 3110 (NH), 1681 (tertiary amide CO) and 1652 (secondary 
amide CO); 5^ (300 MHz; C^HsO^H) 2.03-2.38 (3H, m, 7CH2 and îpCHa), 2.45-2.64 
(IH , m, ipCHz), 3.73 (2H, m, 8 CH2), 3.93 (IH , d, J  16.8, jCOCHj), 4.30 (IH , d, 
J  16.8,5C0CH2) and 4.42 (IH , dd, J\ 6 .8 , h  6 .8 , ctCH); 8 c (74.76 MHz; C^HsO^H) 
23.60 (7CH2), 29.68 (PCH2 ), 46.60 (COÇH2 ), 47.29 (8 CH2), 60.15 (aCH ), 166.74 
(ÇOCH2) and 172.27 (CONH); m/z (El) 154 (M*, 70%), 126 (8 , [M - NHCH2 + H]+), 
111 (81, [M - CONHJ+), 98 (28, [M - CONHCH2 + 2H]+), 83 (100, [M - CO 2 - 
NHCH2 + 2 H]+) and 70 (78, [C4HgN]+).
W-/er/-ButoxycarbonyI-(2S)-alanyl-(25)-proline methyl ester (6 6 )
This com pound was prepared in a m anner identical w ith that for the 
A/-benzyloxycarbonyl-(25)-alanyl-(25)-proline methyl ester (58), starting from  
A/-rerr-butoxycarbonyl-(25')-alanine (65) (1.89 g, 10 nunol) to give a yellow oil which 
was purified by silica chromatography using ethyl acetate/ light petroleum ( 1 :1) as the 
eluent to give the product as a clear oil (2.37 g, 79%), m /z  (Found: [M + H]+, 
301.1769. Calc, for C 14H 25N 2O5 : 301.1764); [ a g  -109.4 (c 1.0 in M eOH); 
■Umax (thin film)/cm-' 3325 (NH), 1748 (ester CO), 1710 (carbamate CO) and 1652 
(amide CO); 8 „  (200 MHz; C^HCls) 1.26 (e, 3H, d, J  6 .6 , CHCH3), 1.33 (f, 3H, d, 
7 6 .6 , CHCH3), 1.40 (f & c, 9H, s, C(CH3)3), 1.82-2.33 (t & c, 4H, m, pCH : and 
7 CH 2 ), 3.50-3.76 (t & c, 2H, m, 8 CH2), 3.70 {t, 3H, s, OCH3 ), 3.74 (c, 3H, s, OCH3),
4.48 (t & c,  2H, m, aC H  and CHCH3) and 5.34 (t & c , IH, d, 7 7.9, NH);
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ÔC (50.31 MHz; C^HCls) 17.86 (f, CHÇH3), 18.96 (c, CHÇH3), 21.94 (c, yCHs),
24.83 {t, 7 CH2 ), 28.20 (t & c, € ( ^ 3)3), 28.78 {t, PCH2), 31.14 (c, PCH2), 46.26 
(c, ÔCH2 ), 46.60 (t, ÔCH2), 47.60 (t, OCH3), 47.73 (c, OCH3), 51.92 (A CHCH 3 ),
52.52 (c, CHCH3), 58.57 (t, aC H ), 58.95 (c, aCH), 125.88 {t & c, £ ( ^ 3 )3 ), 154.58 
(c, Ç 0 2 ^Bu), 155.06 (f, C O f Bu), 171.44 (t & c, ÇOCHCH3), 172.08 (c, ÇO2CH 3) and 
172.23 (t, CO2CH3); m/z (CI) 301 ([M + H]+, 52%), 245 (100, [M - C(CH3)3  + 2H]+), 
227 (70, [M - OC(CH3)3 ]+), 201 (17, [M - C02C(CH3)3 + 2H]+), 169 (36, [M - 
C0 2 C(CH3)3 - OCH3 + H]+) and 153 (6 , [M - NHC0 2 C(CH3)3 - 0 CH3]+).
W-/er/-ButoxycarbonyI-(2S)-alanyl-(2S)-prolinamide (67)
T his com pound was p repared  in a m anner iden tica l w ith  that for 
Wbenzyloxycarbonyl-(25)-alanyl-(2,S)-prolinamide (61), starting from the N-tert- 
butoxycarbonyl-(2S)-alanyl-(25)-proline methyl ester (6 6 ) (1.50 g, 5 mmol) to give an 
off-white solid which was recrystallised from methanol/ diethyl ether to give the 
product as a white solid (1.11 g, 78%), m.p. 168-70 °C; m/z  (Found: [M + H]+, 
286.1759. Calc, for C13H25N3O4: 287.1764); [ a g - 8 1 .4  (c 0.5 in M eOH); 
'Umax (Nujol)/cm-i 3404 & 3334 (NH), 1701 (carbamate CO), 1670 (tertiary amide 
CO) and 1648 (primary amide CO); 6» (200 MHz; C2HCI3 ) 1.28 (c, 3H, d, 7  7.0, 
CHCH3), 1 .3 3  (A 3H, d, J  6 .8, CHCH3), 1.71-2.23 {t & c, 3H, m, -yCH2 and&pCHz), 
2.28-2.45 (t & c, IH, m,&pCH2), 3.48-3.79 (t & c, 2H, m, 5 CH2 ), 4.15 (c, IH, m, 
CHCH3), 4.21 (c, IH, dd, 7, 1.9, J2 8.0, aCH), 4.48 {t, IH, m, CHCH3), 4.61 (f, IH, 
dd, 7i 2.6, 72 7.8, aCH), 5.20 (c, IH, d, 7 7.4, NHCHCH3), 5.35 (t, IH, d, 7 7.2, 
NHCHCH3), 5.54 it, IH, s,jC O N H 2), 5.79 (c, IH, s, ÎCONH2), 6.82 (f, IH, s, 
jC0N H2) and 7.43 (c, IH, s,jCONH 2); 5c (50.31 MHz; C^HClg) 18.29 (t, CHCH3), 
18.42 (c, CHCH3), 22.54 (c, 7CH2 ), 25.52 (t, yCH2), 28.84 (f & c, C (£H 3)3 ), 28.88 it. 
PCH2), 32.13 (c, PCH2), 47.33 (c, 8CH2), 47.73 it, SCH;), 48.39 (f, CHCH3), 49.00 
(c, CECH3), 60.23 it & c, aCH), 79.99 (f, C(CH 3)3), 80.38 (c, £ ( ^ 3)3), 155.90 
it & c, C 0 2 *Bu), 173 31 (1 & c, £ 0 CHCH3) and 174 94 it & c, CONH2); mJz (Cl) 286 
([M-^ H]+, 100%), 230 (52, [M - C(CH3)3 + 2H]+), 212 (3, [M - OClCHglg]*), 186 (5, 
[M - C 0 2 C(CH3)3 + 2H]+) and 143 (3, [M- C0 2 C(CH3)3 - CONH2 + 3H]+).
Glycyl-(25)-prolinamide hydrochloride (6 8 )
Hydrogen chloride gas was bubbled through a solution of N-ferr-butoxycarbonyl- 
glycyl-(25)-prolinamide (23) (0.81 g, 3 mmol) in ethylacetate (30 cm^) for 20 min at
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0 °C. The solvent was then removed under reduced pressure to give the product as a 
hygroscopic white solid (0.60 g, 97%), m.p. 143-5 °C; m/z (Found: M+, 172.2063. 
Calc, for C7H 14N 3O2 : 172.2065); [ a g  -52.5 (c 0.2 in MeOH); (Nujol)/cm-i 
1662 (tertiary amide CO) and 1652 (primary amide CO); Ôh (200 MHz; C^HgO^H) 
1.73-2.47 (t & c, 4H, m, gCHg and 7 CH2), 3.42-3.76 (t & c, 2H, m, ÔCH2 ), 3 .9 3  
( t & c ,  2H, s, COCH2 ), 4.49 (t, IH, dd, 7% 7.5, J 2  11.8, aC H ) and 4.56 (c, IH, dd, 
7i 4.1, 72  15.2, aCH ); ôc (50.31 MHz; C^HgO^H) 23.91 (c, 7CH2 ), 26.03 (/, 7 CH2),
31.48 (t, PCH2), 33.83 (c, PCH 2), 42.07 (c, C O £H 2), 42.48 (t, COÇH2), 48.40 
(t, ÔCH2), 48.96 (c, ÔCH2), 61.29 (c, aCH ),  61.74 (t, aC H ), 167.08 (c, CONH2),
167.43 (f, CONH2), 176.68 (c,C O C H 2) and 178.51 (r, ÇOCH2); m/z (Cl) 172 (M+, 
15%), 155 (100, [M - NH3]+), 111 (8 , [M - NH3 - CONH21+) and 70(11, [C4HgN]+).
(2S)-Alanyl-(2S)-prolinamide hydrochloride (69)
This compound was prepared in a manner identical with that for the glycyl-(25')- 
prolinam ide hydrochloride (6 8 ), using A^-r^rr-butoxycarbonyl-(25)-alanyl-(2.5)- 
prolinamide (67) (2.43 g, 5 mmol) instead of iV-rerf-butoxycarbonyl-glycyl-(25')- 
prolinamide (23) to give the product as a hygroscopic white solid (1.06 g, 96%), 
m/z (Found: [M + H]+, 186.1244. Calc, for C8H 16N 3O2 : 186.1242); [ a g  -9.8 (c 0.1 
in MeOH); D^ax (Nujol)/cm*^ 1668 (tertiary amide CO) and 1652 (primary amide 
CO); ÔH (200 MHz; % 2 0 ) 1.38 (c, 3H, d, 7 7.0, CHCH3), 1.43 (t, 3H, d, 7 7.0, 
CHCH3), 1.72-2.08 (t & c, 3H, m,&pCH2 and 7 CH2), 2.24 (t & c, IH, m, 1PCH2), 
3.42-3.71 (t & c, IH, q, 7 7.0, CHCH3) and 4.34 (t & c, IH, dd, 7i 6 .8 , h  8 .6 , aCH ); 
ÔC (50.31 MHz; % 0 )  15.86 (t, CHÇH3), 16.44 (c, CHÇH3), 22.64 (c, 1C H 2), 25.56 
(U 7CH 2), 30.38 (t, P C H 2 ), 32.78 (c, PCH2), 48.41 (c, ÔCH2), 48.56 (t, ÔCH2), 48.66 
(t, ÇHCH3), 48.88 (c, Ç H C H 3), 60.57 (c, aC H ), 61.17 (t, aC H ), 170.07 (t & c, 
ÇOCH3), 176.82 (c, CONH2) and 177.30 (t, CONH2); m/z (El) 186 ([M + H]+, 4%), 
168 (8 8 , [M - NH3]+), 140 (14, [M - NH3 - C 0 ]+ ), 125 (56, [M - NH3 - C H 3 - CO]+), 
97 (69, [M - NH3 - CH3 - 2CO]+) and 70 (100, [C4HgN]+).
iV-Benzyloxycarbonyl-sarcosine (71)
To a vigorously stirred solution of sarcosine (70) (2.05 g, 23 mmol) in 1 mol dm'^ 
NaOH (80 cm3, 80 mmol) was added dropwise benzylchloroformate (5.4 cm^, 
37 mmol) at 0 °C. The resultant cloudy solution was stirred vigorously for 4 h at 
room temperature and then washed with diethyl ether (50 cm^). The aqueous phase
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was acidified to pH 3 with 1 mol dm-^ HCl and then extracted with diethyl ether 
(3 X 50 cm3). The ethereal extracts were washed with 1 mol dm-3 HCl (50 cm^) and 
saturated NaCl solution (50 cm^), dried(M gS0 4 ), and the solvent removed under 
reduced pressure to give the product as a clear oil (2.14 g, 96%), m/z  (Found: M+, 
223.0853. Calc, for C 11H 13NO4 : 223.0845); (Nujol)/cm-^ 1701 (acid CO) and 
1662 (carbamate CO); §„ (200 MHz; C^HCb) 3.03 {t & c, 3H, s, NCH3), 4.04 (c, 2H, 
s, COCH2 ), 4.10 {t, 2 H, s, COCH2), 5.15 (c, 2 H, s, CH2Ph), 5.17 {t, 2 H, s. CH2Ph),
7.32 (c, 5H, s, aromatic), 7.37 (f, 5H, s, aromatic) and 10.02 {t & c, IH, s, CO2H); 
ÔC (50.31 MHz; C2HCI3) 35.76 (c, NCH3) 36.41 (f, NCH3), 50.64 (c, COÇH2 ), 50.91 
(r, COCH2), 68.23 (c, CH2Ph), 68.30 (t, CH2Ph), 128.56 (c, para  aromatic), 128.63 
(t,para  aromatic), 128,24 {c, ortho  aromatic), 128.33 {t, ortho aromatic), 128.91 
(c, meta aromatic), 129.02 (t, meta aromatic), 136.74 {t & c, quat. aromatic), 157.05 
(c, ÇONCH3), 157.70 (r, CO N CH 3), 173.46 (c, CO2H) and 173.62 {t, CO2H); 
m/z (El) 223 (M+, 6 %), 134 (4, [M - PhCH2 + 2H]+), 108 (39, [PhCH2 0 H]+) and 91 
(100, [PhCH2 ]+).
W-Benzyloxycarbonyl-sarcosyl-(2S)-proline methyl ester (72)%
NCBZ CH3
This com pound was prepared in a m anner identical w ith that for the 
A^benzyloxycarbonyl-(25')-alanyl-(25')-proline methyl ester (58), starting from  
Æ benzyloxycarbonyl-sarcosine (71) (2.23 g, 10 mmol) to give a yellow oil which was 
purified by silica column chromatography using ethyl acetate/ light petroleum ( 1 :1) as 
the eluent to give the product as a clear oil (2.56 g, 77%), m/z  (Found: [M + H]+, 
335.1599. Calc, for C 17H 23N 2O5 : 335.1606); [ a g  -78.3 (c 1.0 in M eOH); 
Dmax (Nujol)/cm-^ 2954 (N-CH3), 1747 (ester CO), 1710 (carbamate CO), 1663 
(amide CO) and 734 & 699 (aromatic CH); 0» (200 MHz; C^HClg) 1.68-2.41 
{tt, tc, ct & cc, 4H, m, yCH2 and PCH2), 2.96 (cc, 3H, s, NCH3), 2.97 (tt & tc, 3H, s, 
NCH 3), 2.99 (ct, 3H, s, NCH3 ), 3.22-3.39 (cc, 2H, m, 6 CH2 ), 3.39-3.75 (tt, c t  & tc, 
2H, m, ÔCH2), 3.65 (cc, 3H, s, OCH3), 3.66 {tt, 3H, s, OCH3), 3.68 (ct, 3H, s, OCH3), 
3.69 {tc, 3H, s, OCH3 ), 3.88 {tt, IH, d, J  16.5, iCOCHi), 3.90 {ct, IH, d, J  16.5, 
5COCH2), 3.97 {tc, 2 H, d, J  5.9, COCH2), 3.99 (cc, 2H, d, J  6.0, COCH2), 4.09 (cc, 
IH, dd, 7i = 72 3.2, aCH ), 4.21 {tt, IH, d, 7 16.5,|C0CH2), 4.22 {ct, IH, d, 7  16.5,
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jCOCH 2), 4.41 (tc, IH, dd, Ji = J2 2.9, aCH ), 4.47 (tt & ct, dd, Ji  3.6, J2 5.5, aCH ), 
5.07 (cc, 2H, s, CH2PI1), 5.09 (tt & tc, 2H, s, CH2Ph), 5.10 (cl, 2H, s, CH2Ph), 7.28 
(cc, 5H, s, aromatic), 5.09 (tt & tc, 5H, s, aromatic) and 5.10 (ct, 5H, s, aromatic); 
§c (50.31 MHz; C^HClg) 22.36 (tc & cc, 7 CH2), 25.05 (ct, y 2 H 2), 25.12 (tt, ')CH2), 
29.09 (tt & ct, PCH2), 31.48 (cc, PCH2), 31.58 (tc, PCH2), 35.48 (tt, NCH3), 35.61 
(tc & cc, NCH3 ), 36.28 (ct, NCH3), 46.27 (tt & ct, ÔCHi), 46.81 (tc & cc, ÔCH2),
50.99 (ct, COÇH2), 51.28 (tt, COÇH2), 51.42 (tc & cc, COÇH2), 52.28 (tt & ct, 
OCH3), 52.74 (cc, OCH3), 52.82 (tc, OCH3), 58.70 (cc, aCH), 58.79 (tc, aCH), 59.15 
(tt & ct, aCH ), 67.23 (ct & cc, CH2PI1), 67.34 (tt & tc, CH2Ph), 127.88 (tt, tc, ct & cc, 
para  aromatic), 128.08 (ct & cc, meta aromatic), 128.14 (tt & tc, meta aromatic),
128.40 (tc, ortho aromatic), 128.69 (tt, ct & cc, ortho aromatic), 137.10 (ct&  cc, quat. 
aromatic), 137.16 (tt & tc, quat. aromatic), 156.44 (ct & cc, C O 2CH2PI1), 156.92 
(tt & tc, C0 2 CH2Ph), 167.34 (tt & ct, £O C H 2), 167.69 (tc & cc, £ 0 CH2), 172.43 (cc, 
ÇO 2 CH3), 172.58 (tc, CO2CH3), 172.66 (ct, ÇO 2CH3) and 172.74 (tt, ÇO 2CH3); 
m/z (Cl) 335 ([M + H]+, 100%), 291 (12, [M - CH3 - OCH3 + 3H]+), 226 (5, [M - 
OCH3 - Ph]+), 201 (6 , [M - CO2CH2PI1 + 2H]+) and 91 (7, [PhCH2]+).
iV-BenzyIoxycarbonyl-sarcosyl-(25)-prolinamide (73)
This com pound was prepared in a m anner identical w ith that for the 
A^-benzyloxycarbonyl-(25')-alanyl-(2,S')“prolinamide (61), starting from N-benzyloxy- 
carbonyl-sarcosyl-(25)-proline methyl ester (72) (1.67 g, 5 mmol) to give the product 
as a clear oil (1.42 g, 80%), m/z (Found: [M + H]+, 320.1613. Calc, for C16H22N 3O4 :
320.1610); [a ]“ +3.0 (c 0.1 in MeOH); (thin film)/cm-i 3326 & 3195 (NH), 
1701 (carbamate CO), 1668 (tertiary amide CO), 1652 (primary amide CO) and 737 
& 699 (aromatic CH); 6^(200 MHz; C^HClg) 1.66-2.32 (tt & ct, 4H, m, PCH2 and 
7CH 2 ), 3.06 (ct, 3H, s, NCH3), 3.07 (ft, 3H, s, NCH3), 3.20-3.73 (ft & ct, 2H, m, 
COCH2), 4.01 (ct, 2 H, m, 8 CH2), 4.04 (ft, 2 H, m, SCH2). 4.58 (ft & ct, IH, dd, 7, 2 .6 , 
J2  8.3, aCH ), 5.15 (tt & ct, 2H, s, CH2Ph), 5.91 (ct, IH, s, 5CONH2), 6.00 (ft, IH, s, 
ÏCONH2 ), 6.92 (ct, IH , s,&CONH2), 6.99 (ft, IH , s, ÎCONH2 ), 7.32 (cf, 5H, s, 
aromatic) and 7.36 (tt, 5H, s, aromatic); (50.31 MHz; C^HClg) 22.41 (tc & cc, 
yCH2), 24.84 (tt & ct, yCH2), 28.76 (ct, pCHz), 29.03 (tt, PCH2), 32.33 (tc & cc, 
PCH2), 35.77 (tt & tc, NCH3), 36.32 (ct & cc, NCH3), 46.51 (tt & ct, ÔCH2), 47.15 
(tc & cc, 6 CH2), 50.91 (ct & cc, COÇH2 ), 51.37 (tt & tc, COCH2), 60.05 (ct & cc, 
aC H ), 60.18 (tt & tc, aCH ), 67.25 (ct & cc, CH2Ph), 67.35 (tt & tc, CH2Ph), 127.60 
(ct & cc, para  aromatic), 127.69 (tt & tc ,para  aromatic), 127.81 (ct & cc, ortho  
aromatic), 128.03 (tt & tc, ortho aromatic), 128.52 (tt, tc, ct & cc, meta aromatic).
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136.64 {tt & tc, quat. aromatic), 136.69 (ct & cc, quat. aromatic), 156.38 (ct & cc, 
quat. aromatic), 156.38 (cf & cc, CO2CH2PI1), 157.01 (tt & tc, COaCHaPh), 167.96 
(tt & tc, NCOaPh), 168.07 (ct & cc, NCOgPh), 174.53 (ct & cc, CONH2) and 174.80 
(tt & tc, CONH2 ); m/z (Cl) 320 ([M 4- H]+, 42%), 186 (6 , [M - C 0 2 CH2Ph + 2H]+), 
113 (93, [M - CO2CH2PI1 - COCH2NCH31+), 97 ([100, [C4 HgNCO]+) and 70 (70, 
[C4 HgN]+).
(8a5)-2-Methyl“2,3,6,7,8,8a-hexahydropyrrolo-[l,2-a]-pyrazine-l,4-dione (74)
0H3
This com pound was prepared in a m anner identical w ith that for the 
hexahydropyrro lo -[l,2 -a]-py raz ine-l,4 -d ione (64), using A/-benzyloxycarbonyl- 
sarcosyl-(25')-prolinamide (73) (0.64 g, 2 mmol) to give the product as a clear oil 
(0.31 g, 90%), m/z (Found: M+, 168.0901. Calc, for C 8H 12N 2O2 : 168.0899); 
[ a ] ^  +4.9 (c 0.1 in MeOH); Dmax (thin f i l m ) / c m - t  1675 (tertiary amide CO) and 1652 
(secondary amide CO); 6 » (200 MHz; 0 ^ 3 0 % ) 1.81-2.12 (3H, m, 7 CH2 and 
îPCH2), 2.13-2.49 (IH , m .ipC H ;), 2.99 (3H, s, NCHj), 3.42-3.73 (2H, m, SCH:), 
3.83 (IH , d, J  16.8,jCOCH2), 4.23 (IH , m, aCH ) and 4.30 (IH , d, J  16.8, jCOCHi); 
5c (50.31 MHz C % 3 0 % )  23.64 (^CHa), 30.21 (pCHz), 33.95 (NCH3), 46.54 (ÔCH2),
54.40 (COCH2), 60.38 (aCH), 165.62 (CONCHs) and 169.74 (£ 0 CH2); m/z (El) 168 
(M+, 45%), 156 (18, [Af - CH3 + 3H]+), 140 (15, [M - NCH3 + H]+), 127 (12, [M - 
CH 2NCH3 + 2H]+), 100 (47, [M - COCH2NCH3 + 2H]+) and 84 (100, [M - CO2 - 
CH 2NCH3 4-  3H]+).
/V-BenzyIoxycarbonyl-(25)-alanyl-(2S)-proIine methylamide (75)
NHCHa
NHCBZ
To a saturated solution o f methylamine in dry methanol (30 cm^) was added 
A^-benzyloxycarbonyl-(25)-alanyl-(2iS)-proline methyl ester (58) (1.67 g, 5 mmol).
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The solution was placed in a tightly stoppered vessel and left at room temperature. 
When the reaction was complete as judged by TLC (12 h), the stoppered vessel was 
cooled to 0 °C, opened and nitrogen gas bubbled through at room temperature for 
5 min. The solvent was then removed under reduced pressure to give the product as a 
clear oil (1.62 g, 97%), m/z  (Found: [M + H]+, 334.1772. Calc, for C 17FI24N 3O4 : 
334.1767); [ a ]g  -38.3 (c 1.0 in MeOH); (thin film)/cm-' 3312 (NH), 1717 
(carbamate CO), 1668 (tertiary amide CO), 1652 (methylamide CO) and 735 & 699 
(aromatic CH); Ôh(200 MHz; C2HCI3) 1.26 (c, 3H, d, J  8.0, CHCH3), 1.32 (t, 3H, d, 
J  8.0, CHCH3), 1.77-2.38 {t & c, 4H, ra, 7CH 2 and PCH2), 2.72 (t, 3H, d, J  4.8, 
NHCH3), 2.78 (c, 3H, d, J  4.8, NHCH3), 3.41-3.74 (t & c, 2H, m, ÔCH2), 4.26 (t &c, 
dd, Ji 4.5, J2  6.2, aCH), 4.57 (c, 2H, d, J  8.2, CH2?h), 4.78 (t, 2H, d, J  6.4, CH2Ph), 
5.79 (t & c, IH, d, J  8.0, NHCHCH3), 6.82 (t & c, IH, m, NHCH3), 7.26 (c, 5H, s, 
aromatic) and 7.31 (f, 5H, s, aromatic); (50.31 MHz; C2HCI3) 17.45 (c, CHCH3),
18.59 (t, CHCH3), 22.47 (c, YCH2), 25.48 (f, yCH2), 26.63 (t, NHCH3), 26.96 (c, 
NHCH3), 28.48 (f, PCH2 ), 32.07 (c, pCH]), 47.40 (f, 8 CH2), 47.71 (c, 6 CH2), 48.83 
(f, ÇHCH3), 49.50 (c, CHCH3), 60.34 (t, aCH ), 61.31 (c, aC H ), 67.18 (t, CH2Ph),
67.31 (c, CH2Ph), 128.47 (t & c, para  aromatic), 128.58 {t Sl c, ortho aromatic),
128.94 (f & c, meta aromatic), 136.68 (c, quat. aromatic), 136.79 (f, quat. aromatic),
156.22 (t, C 0 2 CH2?h), 156.89 (c, £ 0 2 CH2Ph), 171.80 (c, ÇOCHCH3), 172.31 (f, 
ÇOCHCH3) and 172.78 (t & c, ÇONHCH3); mfz (Cl) 334 ([M + H]+, 23%), 229 (8 , 
[M - CH2 Ph - CH3 + 2H]+), 200 (3, [M - COgCHzPh + 2H]+), 179 (13, 
[PhCH2C0 2 NHCH2 CH3]+) and 70 (100, [C4HgN]+).
iV-BenzyIoxycarbonyl-(2/?)-alanyl-(25)-prolme m ethylam ide (76)
This compound was prepared in a manner identical with that for the methylamide
(75), starting from Wbenzyloxycarbonyl-(2i?)-alanyl-(25')-proline methyl ester (59) to 
give the product as a clear oil (1.56 g, 93%), m/z (Found: [M + H]+, 334.1770. Calc, 
for C 17H24N 3O4 : 334.1767); [ a g  -32.1 (c 1.0 in MeOH); Umax (thin film)/cm-t 3330 
(NH), 1701 (carbamate CO), 1647 (tertiary amide CO), 1638 (methylamide CO) and 
740 & 699 (aromatic CH); 5h (200 MHz; C^HCls) 1.48 (3H, d, J  6 .8 , CHCH3 ), 2.14 
(3H, m, 7CH2 and&pCH;), 2.48 (IH , m, ICHz), 2.84 (3H, d, 7 4.8, NHCHs). 3.59 
(IH , m, ÎÔCH2 ), 3.99 (IH , m ,|5 CH2), 4.56 (IH , m, CHCH3), 4.70 (IH , m, aCH ),
5.24 (2H, s, CH2?h), 6.10 (IH , m, NHCH3 ), 7.20 (IH , d, J  2.4, NHCHCH3) and 7.48 
(5H, m, aromatic); 8 c (74.76 MHz; C^HClg) 16.25 (f, CHCH3), 17.51 (c, CHCH3 ),
2 2 .2 2  (c, 7CH2), 24.02 (f, 7CH2 ), 25.83 (1 & c, NCH3 ), 28.87 (1, PCH2), 31.83 (c, 
PCH2), 46.76 (f & c, 8 CH2), 48.04 (c, CHCH3), 48.61 (r, £H C H 3), 60.46 (t & c.
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aC H ), 66.35 (t & c, CH2Ph), 127.59 (t & c, ortho aromatic), 127.88 ( t& c ,  para  
aromatic), 128.31 (t & c, meta aromatic), 136.35 ( t& c , quat. aromatic), 155.98 (c, 
Ç 0 2 CH2 Ph), 156.49 (t, Ç 0 2 CH2Ph), 171.24 (c, ÇOCHCH3), 171.87 (t, ÇOCHCH3), 
172.10 (t, CONHCHs) and 172.32 (c, ÇONHCH3); m/z (CI) 334 ([M + H]+, 15%), 
244 (24, [M - CH2PI1 + 2H]+), 212 (8 8 , [M - OCHgPh - CHs]+, 200(11 , [M - 
C0 2 CH2Ph + 2H]+), 97 (100, [C4HgNC0 ]+) and 70 (13, [C4HgN]+).
(2S)-AlanyI-(25)-proline methylamide (77)
To a solution of 7/-benzyloxycarbonyl-(25)-alanyl-(25')-proline methylamide (75) 
(0.67 g, 2 mmol) in methanol (30 cm^) was added 10% palladium on activated 
charcoal (30 mg) and the vessel flushed with hydrogen gas. The resultant suspension 
was stirred vigorously under an atmosphere of hydrogen for 12 h. The mixture was 
then filtered through a prewashed celite pad and the solvent removed under reduced 
pressure to give a white solid which was recrystallised from methanol to give the 
product as a clear oil (0.39 g, 97%), m/z  (Found: [M + H]+, 200.1402. Calc, for 
C9H 18N 3O2 : 200.1399); [ a g  +7.0 (c 0.1 in MeOH); Umax (thin film)/cm-i 3307 (NH), 
1666 (tertiary amide CO) and 1652 (secondary amide CO); 6^(200 MHz; C^HsO^H)
1 .2 1  (c, 3H, d, J  6 .8 , CHQH3), 1.28 (t, 3H, d, J  6 .8  CHCHs), 1.82-2.40 (t & c, 4H, m, 
PCH2 and 7CH2), 2.74 (t, 3H, s, NHCH3), 2.78 (c, 3H, s, NHCH3 ), 3.54-3.81 (t & c, 
3H, m, ÔCH2 and CHCH3) and 4.37 (t & c, IH, dd, Ji 4.6, J 2  8.0, aC H ); ôc (50.31 
MHz; C^HgO^H) 20.69 (c, CHCH3), 20.80 (t, CHÇH3), 23.66 (c, yCHz), 26.19 (t, 
7 CH 2), 26.66 (t, NHCH3 ), 26.91 (c, NHCH3), 30.95 (t, PCH2), 33.47 (c, PCH2), 48.52 
(t, ÔCH2 ), 49.60 (c, ÔCH2), 61.70 (c, aCH ), 61.92 (t, aCH ), 175.09 (c, COCHCH3),
175.33 (t, COCHCH3), 176.91 (t, ÇONHCH3) and 177.47 (c, ÇONHCH3); m/z  (Cl) 
200 ([M + H]+, 12%), 169 (23, [M - NHCHs]-*-), 156 (31, [M - NHCH3 - CH3 + 2H]+), 
142 (7, [M - CONHCH3 + H]+), 126 (13, [M - CONHCH3 - CHslO  and 70 (100, 
[C4HgN]+).
(2/f)-AIanyl-(2S)-proline methylamide (78)
This compound was prepared in a manner identical with that for the (25, 25) 
methylamide (77), using N-benzyloxycarbonyl-(27?)-alanyl-(25)-proline methylamide
(76) (0.67 g, 2 mmol) to give the product as a clear oil (0.41 g, 98%), m/z (Found: 
[M + H]+, 200.1397. Calc, for C9H 18N 3O2 : 200.1399); [ a g  -64.7 (c 1.0 in MeOH); 
Umax (thin film)/cm'^ 3291 (NH), 1642 (tertiary amide CO) and 1638 (secondary
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amide CO); 5^(200 MHz; C^HClj) 1.25 (3H, d, / 6 .8 , CHCHs), 1.76-2.22 (3H, m, 
ipCHz and -yCHj), 2.22-2.55 (IH , m, ipC H 2), 2.74 (3H, d, 74 .8 , NHCHj), 3.42 (2H, 
m, 8 CH 2), 3.67 (IH , m, CgCHa), 4.47 (IH , dd, 7 , 2 .4 ,7 ; 7.8, aC H ) and 7.14 (IH , m, 
NHCH3); 5c (50.31 MHz; C % 3 0 % ) 20.11 (c, CHCH3), 20.31 (t, CHCH3), 23.75 (c, 
7CH 2), 25.80 (1, ■>CH2), 26.75 (f, NHCH3), 26.88 (c, NHCH3), 31.10 (t, pCHa), 33.39 
(c, PCH2), 48.41 (Ï & c, ÔCH2), 49.72 { t& c ,  CHCH3), 61.85 (c, aC H ), 62.07 {t, 
aC H ), 175.11 (c ,£O C H C H 3 ), 175.19 (/,COCHCH 3), 176.59 (/, ÇONHCH 3) and
177.02 (c, ÇONHCH3); m h  (Cl) 200 ([M + H]+, 8 %), 168 (18, [M - NH2CH3]+), 140 
(8 , [M - 2 NH2CH3 + 3H]+), 1 1 2  (10, [M - CONHCH3 - NH 2CH 3 + 2 H]+), 70 (78, 
[C4 HgN]+) and 44 (100, [NH2CH3CH]+).
iV-Benzyloxycarbonyl-sarcosyl-(25)-proIine methylamide (79)%NHCHg O
CBZ' 'OH3
This com pound was prepared in a m anner identical w ith that for the 
A^-benzyloxycarbonyl-(25)-alanyl-(25)-proline methylamide (75), starting from  
7/-benzyloxycai*bonyl-sarcosyl-(25)-proline methyl ester (72) (1.67 g, 5 mmol) to give 
the product as a clear oil (1.59 g, 96%), m/z (Found: [M + H]+, 334.1761. Calc, for 
C 17H 24N 3O4 : 334.1766); [ a f  -58.0 (c 1.0 in MeOH); w„ax (thin film)/cm-' 3328 
(NH), 1701 (carbamate CO), 1672 (tertiary amide CO), 1663 (methylamide CO) and 
733 & 699 (aromatic CH); 0^ (200 MHz; C^HClg) 1.58-2.23 (tt, c t& tc ,  3H, m, 7CH2 
and 1PCH2), 2.23-2.49 («, ct  &  tc, IH, m, îpCHz), 2.62 {ct, 3H, d, 7 4.8, NHCH3),
2.72 {tt, 3H, d, 7  4.8, NHCH3), 2.81 {tc, 3H, d, 7 4.8, NHCH3), 3.03 {ct, 3H, s, 
CH 2NCH3), 3.05 {tt & tc, 3H, s, CH2NCH3), 3.15-3.68 {tt, ct & tc, 2H, m, SCH2),
3.99 {ct, 2 H, s, COCH2), 4.00 (tt, 2 H, s, COCH2), 4.02 {tc, 2 H, s, COCH2 ), 4.29 {tc, 
IH, dd, 7i 1.9, 72  7.9, aCH), 4.53 (tt & ct, IH, dd, 7 , = J2 6.0, aC H ), 5.10 {ct, 2H, s, 
CHaPh), 5.13 (tt & tc, 2H, s, CH2PI1), 6.91 {tc, IH, m, NHCH3 ), 7.01 (tt & ct, IH, m, 
N ECH 3), 7.26 {tc, 5H, s, aromatic), 7.30 (cf, 5H, s, aromatic) and 7.34 {tt, 5H, s, 
aromatic); 5c (50.31 MHz; C^HClg) 22.29 {tc, 7CH2), 24.67 (tt & ct, 7CH 2), 25.96 (cf, 
NHCH3), 26.03 {tt, NHCH3 ), 26.21 {tc, NHCH3 ), 28.29 (cf, PCH2), 28.63 {tt, PCH2), 
32.12 {tc, PCH2), 35.72 (tt & tc, CH2NCH3), 36.17 (cf, CH2NCH3), 46.40 {tt & cf, 
5 CH 2), 46.96 (fc, 5 CH2), 50.80 (cf, COCH2), 50.97 (fc, COCH2), 51.30 {tt, COCH2),
59.84 (fc, aCH ), 60.10 (cf, aCH), 60.26 (tt, aCH ), 66.99 (cf & fc, CH2Ph), 67.13 {tt.
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CH 2Ph), 127.37 {et & tc ,para  aromatic), 127.46 {it, para  aromatic and ct & tc, ortho 
aromatic), 127.86 (tt, ortho aromatic), 128.36 (tt, ct & tc, mct« aromatic), 136.45 (tt, 
quat. aromatic), 136.56 (ct & tc, quat. aromatic), 156.20 (ct, COCH 2Ph), 156.39 (tc, 
COCH2Ph), 156.81 ( t t ,  œ C H 2Ph), 167.79 ( tc ,  ÇOCH 2NCH3), 167.92 (ct, 
ÇOCH2NCH3), 167.96 (tt, C O C H 2NCH3), 171.96 (ct, Ç O N H C H 3), 172.06 (tt, 
ÇONHCH 3) and 172.16 (tc, CONHCH3); m h  (Cl) 334 ([M + H]+, 100%), 229 (5, [M 
- OCH2PI1 + 3H]+), 211 (3, [M - OCHzPh - CH3]+), 200 (8 , [M - CO2CH2PI1 + 2H]+) 
and 91 (4, [CH2PI1I+).
Sarcosyl-(2S)-proline methylamide (80)
This compound was prepared in a manner identical with that for (25')-alanyl-(25')- 
p ro line  m ethylam ide (77), using A /-benzyloxycarbonyl-sarcosyl-(25')-proline 
methylamide (79) (0.67 g, 2 mmol) instead of 77-benzyloxycarbonyl-(25')-alanyl-(25')- 
prolinam ide (75) to give the product as a clear oil (0.38 g, 95%), m/z (Found: 
[M + H]+, 200.1403. Calc, for C9 H 18N 3O2 : 200.1399); [ a g  -75.1 (c 1.0 in MeOH); 
Umax (thin film)/cm-i 3307 (NH), 1668 (tertiary amide CO) and 1652 (secondary 
amide CO); (200 MHz; C2HCI3) 1.62-2.55 (4H, m, pCH] and yCH2 ), 2.47 (3H, s, 
CONHCH3), 2.54-3.05 (2H, m, ÔCH2), 2.73 (3H, s, CH2NHCH3), 2.91 (IH , m, 
CH2NHCH3), 3.21-3.70 (2H, m, COCH2), 4.54 (IH , dd, Ji 1.9, J2  7.0, aC H ) and 7.17 
(IH , m, CONHCH3); ô c (50.31 MHz; C2HCI3) 22.20 (cc, 7CH2 ), 22.49 (tc, 7CH2),
24.70 (tt, 7CH 2), 25.01 (ct, yCH2), 26.15 (tt & tc, CONHÇH3), 26.30 (c t & cc, 
CONHÇH3), 28.01 (ct, PCH2), 28.63 (tt, PCH2), 31.68 (cc, PCH2), 32.17 (tc, PCH2),
35.88 (tc, CH2NHCH3), 36.05 (tt, CH2NHÇH3), 36.79 (cc, CH2NHCH3), 37.29 (ct, 
CH2NHÇH3), 46.42 (tt, ÔCH2), 46.84 (cc, ÔCH2), 46.93 (tc, ÔCH2), 47.03 (ct, ÔCH2), 
52.50 (tc, COÇH2), 52.83 (tt, COÇH2), 53.73 (cc, COÇH2), 53.86 (ct, COÇH2), 56.90 
(tc, aCH ), 57.73 (cc, aCH ), 60.00 (ct, aC H ), 60.13 (tt, aCH), 169.99 (cc, £O C H 2),
170.29 (tt & ct, ÇOCH2), 170.79 (tc, COCH2), 172.21 (tt & ct, ÇONHCH3), 172.31 
(tc, CONHCH3) and 172.43 (cc, ÇONHCH3); m h  (Cl) 200 ([M + H]+, 29%), 186 (40, 
[M - CH3 + 2H]+), 156 (62, [M - NHCH3 - CH3 + 2H]+), 142 (6 , [M - CONHCH3 + 
H]+), 128 (10, [M - CONHCH3 - CH3 + 2H]+) and 70 (100, [C4HgN]+).
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(9aS)-3-Methyl-2,3,7,8,9,9a-hexahydropyrrolo-[2,l"d]"l»2,5-[6H]-triazepine-l,5-
dione (81)
2 NH
CHs
To a stirred solution of methylhydrazine (0.46 g, 10 mmol) in CH2CI2 (15 cm^) was 
added A''-bromoacetyl-(25')-proline methyl ester (38) (1.25 g, 5 mmol). The mixture 
was refluxed for 30 min, allowed to cool to room temperature and extracted with 
distilled water (2 x 20 cm^). The organic phase was separated, the solvent removed 
under reduced pressure and the residue redissolved in ethanol (15 cm^). 
Methylhydrazine (0.23 g, 5 mmol) was added and the resultant solution refluxed for 
1 h. Removal of the solvent under reduced pressure gave a white solid which was 
recrystallised from methanol to give the product as colourless crystals (0.75 g, 82%), 
m.p. 236-8 °C; (Found: C, 52.3; H, 7.3; N, 22.85. Calc, for C8H 13N 3O 2 : C, 52.45; H, 
7.2; N, 22.95%); [a]g^+118.1 (c 1.0 In MeOH); (Nujol)/cm-i 3101 (NH), 1699 
(tertiary amide CO) and 1597 (secondary amide CO); Sh (200 MHz; C^HaO^H), 
1.76-2.15 (3H, m ,îPC H 2 and'yCH2), 2.33-2.58 (IH , m,ypCH2), 2.69 (3H, s, NCH3 ), 
3.41 (IH , d, J  17.2,JCOCH2), 3.55 (2H, dd, 7, = h  6 .6 , 8 CH2), 3.71 (IH , d, J  17.2, 
1COCH2) and 5.19 (IH , dd, 7; =72 7.1, aC H ); Sc (50.31 MHz; C^HsO^H) 22.63 
(yCH2), 28.05 (PCH2), 44.12 (NCH3), 48.46 (8 CH2), 58.50 (COCH2), 63.55 (aCH ), 
169.77 (COCH2) and 173.36 (CONH); m h  (FAB) 184 {[M + H]+, 100%), 168 (7, 
[M - CH3]+), 154 (19, [M - NCH3]+), 112 (26, [M - CONHNCH3 + H]+) and 70 (63, 
[C4HgN]+).
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(4R, 9a5)-3,4-Dimethyl-2,3,7,8,9,9a-hexahydropyrrolo-[2,l-d]-l,2,5-[6H]-
triazepine-l,5-dione (82)
8----- 9
9a W
s'N' 1
L  2*n h
This compound was prepared in a manner identical with that for the triazepine-1,5- 
dione (81), using A/^-(2S)-chIoropropanoyl-(25)-proline methyl ester (48) ( 1 .1 0  g, 
5 mmol) instead of 7/-bromoacetyl-(25)-proline methyl ester (38) to give the product 
as colourless ciystals (0.83 g, 84%), m.p. 155-8 °C; (Found: C, 54.6; H, 7.85; N, 21.4. 
Calc, for C9H 15N 3O 2 : C, 54.8; H, 7.7; N, 21.3%); m/z (Found: [M + H]+, 198.1244. 
Calc, for C9H 16N 3O2 : 198.1243); [a |^  +104.2 (c 0.1 in MeOH); Umax (Nujol)/cm-^ 
3184 & 3124 (NH), 1695 (tertiary amide CO) and 1600 (secondary amide CO); 
5h (300 MHz; C^HClg) 1.38 (3H, d, 7 6 .6 , CHCH3), 1.67-2.02 (3H, m, yCHa and 
&pCHz). 2.39-2,75 (IH , m ,ipC H 2), 2.58 (3H, s, NCH3), 3.37 (IH , q, J  6 .6 , CHCHj), 
3.35-3.66 (IH , m, j 8 CH2). 3.80 (IH , m ,i8 CH2), 5.10 (IH , dd, 7, 5.5, J 2  7.6, aC H ) 
and 7.69 (IH , s, NH); 8 c  (74.76 MHz; C^HCls) 18.69 (CHCH3), 22.91 (7CH2), 27.01 
(PCH2), 41.80 (NCH3 ), 48.76 (8 CH2), 57.04 (aC H ), 68.64 (CHCH3), 171.69 
(COCHCH3) and 173.09 (CONH); m/z (FAB) 198 ([M + H]+, 100%), 182 (6 , [M - 
CH 3]+), 168 (24, [M - NCH31+), 126 (19, [M - CONHCH3 -H H]+) and 70 (85, 
[C4HgN]+).
(4S, 9aS)-3,4-Dimethyl-2,3,7,8,9,9a-hexahydropyrrolo-[2,l-d]-l,2,5-[6H]- 
triazepine-l,5-dione (83)
This compound was prepared in a manner identical with that for the (4R, 9aS) 
diastereomer (82), using A^-(2R)-chloropropanoyl-(25)-proline methyl ester (49) 
(1.10 g, 5 mmol) to give the product as colourless crystals (0.79 g, 80%), 
m.p. 146-50 °C; (Found: C, 54.6; H, 7.9; N, 21.4. Calc, for C9H 15N 3O2 : C, 54.8; H, 
7.7; N, 21.3%); m/z (Found: [M + H]+, 198.1244. Calc, for C9H 16N 3O2 : 198.1243); 
[ a ] ^  +18.2 (c 0.1 in MeOH); Umax (Nujol)/cm-^ 2926 & 2854 (NH), 1696 (tertiary 
amide CO) and 1601 (secondary amide CO); Ôh (200 MHz; C 2HCI3) 1.31 (3H, d, 
7 7 .0 , CHCHs), 1.71-2.12 (3H, m ,|pC H 2 and-yCH2), 2.38-2.62 (IH , m, &PCH2), 2.67 
(3H, s, NCH3), 3.60 (2H, m, 8 CH2), 3.65 (IH , q, 7 7.0, CHCH3 ), 5.00 (IH , dd.
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7i = 7% 7.6, aC H ) and 7.24 (IH , s, NH); 8 c (50.31 MHz; C^HCla) 9.21 (CHCH3),
22.70 (yCHz), 27.69 (PCH j), 41.88 (N CH j), 48.57 (8 CH2 ), 58.10 (aC H ), 65.08 
(CHCH3), 170.80 (COCHCH 3) and 172.65 (CONH); m/z  (FAB) 198 {[M + H]+, 
100%), 182 (6 , [M - CH3]+), 168 (24, [M - NCHs]*), 126 (19, [M - CONHCH3 + H]+) 
and 70 (85, [C4HgN]+).
Ai-(ert-Butoxycarbonyl-AC-benzyloxycarbonyI-Al-methylhydrazine (86)
OH3 o I
o
To a solution of AT-benzyloxycarbonyl-TZ-methylhydrazine (3.60 g, 20 mmol) in 
wopropanol (25 cm^) was added a solution of ditertiarybutyldicarbonate (4.80 g, 
22 mmol) in CH2CI2 (10 cm^). The mixture was stirred for 4 h, and the solvent 
removed under reduced pressure to yield the product as a pale yellow oil. Purification 
by silica column chromatography using ethyl acetate/ light petroleum (1:4) as the 
eluent gave the pure product as a clear oil (4.94 g, 8 8 %), m/z  (Found: [M + H]+, 
281.1504. Calc, for C 14H 21N 2O4 : 281.1501); Umax (thin film)/cm-i 3307 (NH), 1733 
(CBZ CO) and 1707 (^BOC CO); 0» (200 MHz; C^HClg) 1.29 (9H, s, C(CH3)3), 2.45 
(3H, s, NCH3), 5.12 (2H, s, CH2 ?h), 6.12 (IH , s, NH) and 7.31 (5H, s, aromatic); 
6 c (50.31 MHz; C^HC^) 28.31 (C(CH3)3), 39.25 (NHCH3), 63.98 (CH2?h), 80.74 
(C(CH3)3), 128.15 {ortho aromatic), 128.33 {meta aromatic), 128.78 {para aromatic),
136.43 (quat. aromatic), 155.52 ( C0 2 CH2?h) and 157.11 (C0 2 ^Bu); m/z (Cl) 281 
([M + H]+, 54%), 265 (32, [M - CH3]+), 225 (71, [M - C(CH3)3 + 2H]+), 191 (57, [M - 
C0 2 C(CH3)3 + 2 H]+), 91 (100, [PhCH2]+) and 57 (8 8 , [C(CH3)3]+).
/V-/er/-Butoxycarbony 1-A?^ '-m ethylhydrazine (87)
To a solution of 7/-ferf-butoxycarbonyl-7/-benzyloxycarbonyl-77-methylhydrazine 
(8 6 ) (1.40 g, 5 mmol) in methanol (30 cm^) was added 10% palladium on activated 
charcoal (75 mg) and the vessel flushed with hydrogen gas. The resultant suspension 
was stirred vigorously under an atmosphere of hydrogen for 12 h. The mixture was 
then filtered through a prewashed celite pad, and the solvent removed under reduced 
pressure to give a clear oil which solidified on standing to give colourless crystals of 
the product (0.68 g, 93%), m.p. 46-9 °C; (Found: C, 49.25; H, 9.9; N, 19.2. Calc, for 
C6H 14N 2 O2 : C, 49.3 H, 9.65; N, 19.15%); Umax(Nujol)/cm-i 3320 (amine NH), 3241
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(amide NH) and 1700 (CO); 8 h (200 MHz; C^HCls) 1.33 (9H, s, C ICH ;);), 2.48 (3H, 
s, NHCHs), 3.76 (IH , s, NHCH3) and 6.00 (IH , s, CONH); §c (50.31 MHz; C^HCls)
28.88 (C(CH3)3), 39.69 (NHCH3 ), 80.82 (Q C H sls) and 157.27 (CO^'Bu); m/z (El) 
146 (M+, 15%), 131 (3, [M - CHsl+l, 103 (51, [M - NHNHCH3 + 2H]+), 90 (33, [M - 
C(CH 3)3 + H]+), 73 (27, [OC(CH3)3 ]+) and 57 (100, [C(CH3)3]+).
Al-/crt-Butoxycarbonyl-iV-(iV-chloroacetyI-(2S)-proIyl)-iV-methylhydrazine (89)
Cl
To a solution of A^-chloroacetyl-(25)-proline (8 8 ) (1.92 g, 10 mmol) in dry THF 
(25 cm^) was added A/-methyimorpholine (1.12 cm^, 10 mmol) and the solution 
cooled to -15 °C. wo-Butyl chloroformate (1.36 cm^, 10 mmol) was added with 
stirring and the solution left stirred at -15 °C for 2 min. A solution of N-tert- 
butoxycarbony 1-7/-methylhydrazine (87) (1.46 g, 10 mmol) in dry THF (20 cm^) was 
then added. The reaction mixture was allowed to waim up to room temperature and 
left to stir for 6  h. The hydrochloride salts were filtered off and the solvents removed 
under reduced pressure. The resultant oily residue was dissolved in CH2CI2 (25 cm^) 
and washed with 0.5 mol dm'^ HCl ( 2 x 1 5  cm^) and 5% sodium carbonate solution 
( 2 x 1 5  cm^). The organic phase was then dried (MgS0 4 ) and the solvent removed 
under reduced pressure to give a yellow oil. The crude material was purified by silica 
column chromatography using ethyl acetate as the eluent to give the product as a 
white solid (2.17 g, 6 8 %), m.p. 64-7 °C; m/z (Found: [M + H]+, 320.1373. Calc, for 
C 13H2335CIN3O4 : 320.1376); [ot]“  -11.0 (c 0.5 in MeOH); (Nujol)/cm-l 3227 
(NH), 1730 (carbamate CO), 1695 (methylamide CO), 1678 (tertiary amide CO) and 
771 (C-Cl); 8 h (200 MHz; C^HCls) 1.48 (9H, s, C(CH3 )3), 1.74-2.45 (4H, m, yCH^ 
and PCH2), 3.11 (3H, s, NCH3), 3.63 (2 H, m, ÔCH2), 4.04 (IH , d, J  13.0, 5COCH2), 
4.13 (IH , d, J  13.0,|COCH2), 4.97 (IH,  dd, 7i 5.6, J 2 6.2, otCH) and 7.90 (IH , s, 
NH); ÔC (50.31 MHz; C2HCI3) 25.15 (7 CH2), 28.47 (C(£H 3)3), 28.55 (PCH2), 35.54 
(NCH3), 42.48 (COÇH 2), 47.59 (ÔCH2), 57.32 (aC H ), 81.49 (C(CH3)3), 154.96 
(CONH), 165.31 (ÇONCH3) and 173.73 (ÇOCH2); m/z (Cl) 320 ([M + H]+, 3%), 284 
(100, [M - Cl]+), 240 (91, [M - Cl - C(CH3)3 + H]+), 225 (9, [M - Cl - OC(CH3)3 + 
2H]+), 170 (15, [M - CH2CI - C 0 2 C(CH3)3  + H]+) and 155 (4, [M - CH2 CI - 
NHC0 2 C(CH3)3 +H]+).
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(9a5)-2-MethyI-2,3,7,8,9,9a-hexahydropyrrolo-[2,l-d]-l,2,5-[6H]-triazepine-l,5-
dione (91)
2 N — CH
NH
Hydrogen chloride gas was bubbled through a solution of AT-rerr-butoxycarbonyl-A^- 
(//-chloroacetyl-(2S)-prolyl)-iV -m ethylhydrazine (8 9 ) (1.60 g, 5 mm ol) in 
ethylacetate (30 cm^) for 20 min at 0 °C. The solvent was then removed under 
reduced pressure and the resultant hygroscopic white solid dissolved in water 
(25 cm^) and NaOH solution (1 mol dm"3) added until the solution reached pH 9. The 
solution was then extracted with ethyl acetate (3 x 20 cm^), the combined organic 
fractions were dried (MgSO^) and the solvent removed under reduced pressure to give 
the product as a white solid (0.59 g, 64%), m.p. 75-9 °C; m/z (Found: M+, 183.1001. 
Calc, for C8H 13N 3O2 : 183.1007); [ a g  -40.2 (c 1.0 in MeOH); o„,„ (Nujol)/cm-> 
3440 (NH), 1652 (methylamide CO) and 1637 (tertiary amide CO); Sn (200 MHz; 
C % C l3 ) 1.82-2.38 (A & B, 4H, m, 7CH2 and pCHj), 3.18 (A, 3H, s, NCH3 ), 3.22 (B, 
3H, s, NCH3), 3.69 (A & B, 2H, m, 8CH2 ), 3.91 (A & B, IH, s, NH), 4.03 (A & B, IH, 
d, J  12.4, ÎCOCH2), 4.13 (A & B, IH, d, J  12.4,jCOCH2), 5.39 (B, IH, dd, Jt 3.2, J 2  
8 .6 , aC H ) and 5.47 (A, IH, dd, Ji 3.9, J 2  7.9, aCH ); 5c (50.31 MHz; C^HCis) 22.22 
(B, 7 CH2), 24.52 (A, 7CH 2), 29.07 (A, pCH :), 31.67 (B, pCHz), 38.26 (A, NCH3),
38.43 (B, NCH3), 42.41 (A & B, COCH2), 47.44 (A, 5 CH2), 47.65 (B, 8 CH2), 57.46 
(A, aC H ), 57.88 (B ,aC H ), 164.51 (A, CONCH3 ), 165.13 (B, CONCH3) and 172.97 
(A & B, ÇOCH2); m h  (El) 183 (M+, 45%), 155 (15, {M - NCH3 -H H]+), 139 (65, [M - 
NHNCH3 ]+), 125 (20, IM - CH2NHNCH3 ]+), 111 (40, [Af - CONCHsNH]*) and 70 
(100, [C4HgN]+).
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iV-(2S)-Chloropropanoyl-(2S)-proline methyl ester (94)
" ’hV ” °
Cl
To a solution of N-methylmorpholine (1.12 cm^, 10 mmol) in dry THF (20 cm^) was 
added (25’)-chloropropionic acid (92),228 (1.09 g, 10 mmol) and the solution cooled 
to -15 °C. wo-Butyl chloroformate (1.36 cm^, 10 mmol) was added with stirring and 
the resultant suspension stirred at -15 °C for 2 min. A mixture of (2«S)-proline methyl 
ester hydrochloride (2 1 ) ( 1 .6 6  g, 1 0  mmol) and A-methylmorpholine ( 1 .1 2  cm^, 
10 mmol) in dry DMF (5 cm^) was added. The reaction mixture was allowed to 
warm up to room temperature and left to stir for 3 h. The hydrochloride salts were 
filtered off and the solvents removed under reduced pressure. The resultant clear oil 
was dissolved in CH2CI2 (25 cm^) and washed with 0.5 mol dm"2 HCl ( 2 x 1 5  cm^) 
and 5% sodium carbonate solution (2 x 1 5  cm^). The organic phase was then dried 
(MgSO^) and the solvent removed under reduced pressure to yield a yellow oil which 
was purified by silica chromatography using ethyl acetate/ light petroleum (1 :1) as the 
eluent to give the product as a clear oil (1.56 g, 71%), m /z  (Found: [M + H]+, 
220.0747. Calc, for C9H 1535CINO3 : 220.0742); [a f^  -70.8 (c 1.0 in M eOH);
(thin film)/cm-^ 1746 (ester CO), 1659 (am ide CO) and 1433 (C -0 ); 
ÔH (200 MHz; C2HCI3) 1.62 (3H, d, 7 6.8, CHCH3), 1.85-2.32 (4H, m, yCH2 and 
PCH2), 3.51-3.92 (2H, m, ÔCH2), 3.69 (3H, s, OCH3), 4.47 (IH , dd, Ji 3.4, h  6 .6 , 
aC H ) and 4.49 (IH , q, J  6 .8 , CHCH3); ôc (50.31 MHz; C2HCI3) 20.50 (f, CHÇH3),
21.32 (c, CHÇH3), 21.99 (c ,y C H 2), 24.79 (t, yCH2), 29.05 (f, PCH 2), 31.35 
(c, PCH2), 46.91 {t & c, OCH3 ), 51.17 (r & c, ÔCH2), 52.13 (f, Ç H C H 3 ), 52.48 
(c, ÇHCH3), 59.18 (r, ocCH), 59.28 (c, aC H ), 167.52 (r & c, ÇOCHCH 3), 172.07 
(c, CO2CH3) and 172.23 (r, ÇO 2CH3); miz  (El) 220 ([M + H]+, 7%), 184 (5, [M - 
Cl]+), 170 (54, [M - Cl - CH3 + H]+), 160 (84, [M - C02CH3]+), 128 (58, [M - Cl - 
CO2CH3 + 3H]+) and 70 ( 1 0 0 , [C^HgNl+l.
A^-(2/?)-Chloropropanoyl-(25)-proline methyl ester (95)
This compound was prepared in a manner identical with that for the (25, 25) 
diastereomer (94), using (2Æ)-chloropropionic acid (9 3 ), 2^8 (1.09 g, 10 mmol) to give 
the product as colourless crystals (1.82 g, 83%), m.p. 118-20 °C; (Found: C, 49.2; H,
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6.4; N, 6.4. Calc, for C9H 14CINO3 : C, 49.05; H, 6 .6 ; N, 6.4%); [ocfg -113.9 (c 1.0 in 
M eOH); (N njol)/cm -t 1751 (ester CO), 1656 (amide CD) and 1454 (C-O); 
ÔH ( 2 0 0  MHz; C2HCI3) 1.64 (c, 3H, d, J  6.4, CHCH3), 1 .6 6  (r, 3H, d, J  6 .6 , CHCH3), 
1.80-2.33 {t & c, 4H, m, 7CH2 and PCH2), 3.46-3.70 (r, 2H, m, ÔCH2), 3.74 (r, 3H, s, 
OCH3), 3.77 (c, 3H, s, OCH3), 3.82-3.98 (c, 2H, m, ÔCH2), 4.24 (c, IH , q, J  6.4, 
CHCH3), 4.46 (r, IH, dd, 7i 3.2, ^2 8.4, aC H ) and 4.71 (c, IH , dd, 7% 5.0, J2 5.6, 
aC H ); ôc (74.76 MHz; C2HCI3) 20.82 (r, CHÇH3), 20.94 (c, CHÇH3), 22.78 (c, 
7 CH 2), 25.24 (r, yCH2), 29.41 {t, PCH2), 31.44 (c, PCH2), 47.26 (c, ÔCH2), 47.35 (/, 
ÔCH2), 51.29 (f, OCH3), 51.39 (c, OCH3), 52.62 (f, ÇH CH 3), 53.27 (c, ÇH CH 3), 
59.47 (c ,aC H ), 59.62 (r, aC H ), 167.99 (r, COCHCH3), 168.35 (c, ÇOCHCH3),
172.48 (r, CO 2CH3) and 172.78 (c, ÇO 2CH3); m h  (El) 220 ([M + H]+, 3%), 184 (4, 
[M - Cl]+), 170 (5, [M - Cl - CH3 + H]+), 160 (63, [M - C0 2 CH3]+), 127 (58, [M - Cl - 
CO2CH 3 + 2H]+) and 70 (100, [C^gN ]+).
A -(25)-Chloropropanoyl-(2S)-proline (96)
To a solution of A-(25)-chloropropanoyl-(25)-proline methyl ester (94) (2.20 g, 
1 0  mmol) in methanol ( 2 0  cm^) was added 1 mol dm-3 sodium hydroxide solution 
(22 cm3). The resultant solution was stirred at room temperature for 1 h and then 
1 mol dm'3 HCl solution (10 cm^) added. Methanol was removed under reduced 
pressure and a second portion of 1 mol dm-3 HCl solution (10 cm3) was added. The 
precipitated white solid was filtered and recrystallized from methanol to give the 
product as colourless crystals (1.77 g, 84%), m.p. 164-5 °C; (Found: C, 46.95; H, 
5.95; N, 6.75. Calc, for C8H 12CINO3 : C, 46.75; H, 5.9; N, 6 .8 %); [ a g  -62.1 (c 1.0 in 
MeOH); (Nujol mull)/cm-i 3045 (OH), 1739 (acid CO) and 1624 (amide CO); 
ÔH (200 MHz; C2HCI3) 1.68 (3H, d, 7 6 .6 , CH3), 1.92-2.33 (4H, m, PCH2 and 7CH 2), 
3.64 (IH , m, 1ÔCH2), 3.78 (IH , m,&0 CH2), 4.53 (IH , q, 76 .6 , CHCH3), 4.57 (IH , dd, 
7i = h  5.8, aC H ) and 9.19 (IH , s, CO2H); ôc (50.31 MHz; C^HClg) 20.99 (CH 3),
25.34 (7 CH2), 29.39 (PCH2 ), 47.79 (ÔCH2), 51.67 (CHCH3), 60.11 (aC H ), 169.23 
(NCO) and 175.57 (CO2H); m/z (El) 205 (M+, 14%), 172 (46, [M - Cl + 2H]+), 144 
(6 6 , [M -  CHCICH 3 + 2 H ]+ ), 116 (59, [M - COCHCICH3 + 2H]+), 97 (87, 
[C4 HgNCO]+) and 70 (100, [C4HgN]+).
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iV-(2iî)-ChloropropanoyI-(2S)-proline (97)
To a solution of //-(2^)-chloropropanoyl-(25)-proline methyl ester (95) (2.20 g, 
1 0  mmol) in methanol ( 2 0  cm^) was added 1 mol dm-3 sodium hydroxide solution 
(22 cm3). The resultant solution was stirred at room temperature for 1 h and then 
1 mol dm-3 HCl solution (10 cm^) added. Methanol was removed under reduced 
pressure, a second portion of 1 mol dm*3 HCl solution (10 cm^) was added and the 
solution was extracted with ethyl acetate (3 x 50 cm^). The combined organic 
fractions were dried (MgSO^) and the solvent removed under reduced pressure to give 
the product as a white solid (1.54 g, 79%), m.p. 102-6 °C; m/z (Found; [M + H]+, 
206.0589. Calc, for CgH^^sciNOs: 206.0584); [ a g -110.2 (c 1.0 in M eOH); 
'^ max (N ujol m ull)/cm -l 3344 (OH), 1750 (acid CO) and 1616 (amide CO); 
ÔH (200 MHz; C^HClg) 1.64 (c, 3H, d, /  6.4, CHg), 1.65 (t, 3H, d, J  6 .6 , CH3), 
1.85-2.43 {t & c, 4H, m, PCH2 and 7 CH2), 3.58 (t & c, IH, m,&ôCH2), 3.89 {t & c, 
IH , m, 1ÔCH2), 4.32 (c, IH, q, /  6.4, CHCH3), 4.48 (f, IH, q, J  6 .6 , CHCH3), 4.52 (f, 
IH, dd, Ji 4.3, J 2  6.7, aC H ), 4.72 (c, IH, dd, Ji 4.3, J 2 6.7, aC H ), and 10.25 {t & c, 
IH, s, CO2H); 5c (50.31 MHz; C^HC^) 20.45 {t & c, CH3), 22.37 (c, yCH^), 24.70 (f, 
7 CH2 ), 28.88 (r, PCH2), 30.99 (c, ^ 0 % ), 47.21 (c, ÔCH2), 47.26 (f, ÔCH2), 51.07 
(f & c, ÇHCH3), 59.36 {t & c, aCH ), 168.53 {U NCO), 168.81 (c, NCO), 173.92 {c, 
CO2H) and 174.73 (r, CO2H); m/z (Cl) 206 ([M + H]+, 58%), 170 (100, [M - Cl]+), 
156 (23, [M - Cl - CH3 + H]+), 142 (6 , [M - Cl - CHCHsj^), 113 (12, [M - CHCl - 
C0 2 ]+) and 97 (3, [C4HgNC0 ]+).
iV-/er/-Butoxycarbonyl-iV '-{N-(25)-ehloropropanoyl-(2S)-prolyi)-A^ - 
methylhydrazine (98)
CH3 o
Cl
To a solution of 7/-(25')-chloropropanoyl-(25)-proline (96) (2.06 g, 10 mmol) in dry 
THF (40 cm^) was added iV-methylmorpholine (1.12 cm^, 10 mmol) and the solution 
cooled to -15 °C. wo-Butyl chloroformate (1.36 cm^, 10 mmol) was added with 
stirring and the resultant suspension stirred at -15 °C for 2 min. A solution of N-tert- 
butoxycarbonyl-A-methylhydrazine (87) (1.46 g, 10 mmol) in dry THF (10 cm^) was 
added and the reaction mixture was allowed to warm up to room temperature and left
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to stir for 12 h. The hydrochloride salts were filtered off and the solvent removed 
under reduced pressure. The resultant oily residue was dissolved in CH2CI2 (25 cm^) 
and washed with 0.5 mol dmr^ HCl (2 x 15 cm^) and 5% sodium carbonate solution 
(2 X 15 cm3). The organic phase was then dried (MgSO^) and the solvent removed 
under reduced pressure to yield a yellow oil which was purified by silica 
chromatography using ethyl acetate/ light petroleum ( 1 :1) as the eluent to give the 
product as a white solid (2.31 g, 69%), m.p. 81-3 °C; (Found: C, 50.6; H, 7.25; N, 
12.5. Calc, for C 14H 24CIN3O4 : C, 50.4; H, 7.25; N, 12.6%); m/z (Found: [M + H]+, 
334.1538. Calc, for C 14H2535CIN3O4 : 334.1536); [ a g  -16.7 (c 1.0 in MeOH); 
Dmax (Nujol)/cm-^ 3327 (NH), 1735 (carbamate CO), 1685 (methylamide CO) and 
1646 (tertiary amide CO); 6 » (200 MHz; C^HC^) 1.48 (9H, s, C(CH3 )3 ), 1.64 (3H, d, 
7 6 .6 , CHCH3), 1.82-2.31 (4H, m, 7CH 2 and PCH2), 3.12 (3H, s, NCH3), 3.52-3.89 
(2H, m, ÔCH2), 4.53 (IH , q, J  6 .6 , CHCH3), 4.98 (IH, dd, Ji = 7 2  6.3, aCH ) and 7.87 
(IH , s, NH); ÔC (50.31 MHz; C2HCI3) 21.10 (CHÇH3), 25.20 (7CH 2), 28.64 
(C(CH3)3 ), 28.78 (PCH 2), 35.55 (NCH 3), 47.77 (ÔCH2), 51.68 (Ç H C H 3 ), 57.77 
(aC H ), 81.78 (C (C H 3)3), 155.11 (C 0 2 ^Bu), 168.09 (CONCH3) and 173.86 
(ÇOCHCH3); m/z (Cl) 334 ([M + H]+, 33%), 300 (15, [M - Cl + 2H]+), 278 (100, [M - 
C(CH3)3 + 2H]+), 244 (28, [M - Cl - C(CH3)s + 3H]+), 234 (12, [M - C02C(CH3)b + 
2H]+) and 200 (13, [M - Cl - C0 2 C(CH3)3 + 3H]+).
A-/er/-Butoxycarbonyl-A-(A-(2jR)-chloropropanoyl-(2S)-prolyl)-A '^ 
m ethylhydrazine (99)
This compound was prepared in a manner identical with that for the (25, 25) 
diastereomer (98), using A/-(25)-chIoropropanoyl-(25)-proline (87) (2.06 g, 10 mmol) 
to give the product as a white solid (2.47 g, 74%), m.p. 132-5 °C; (Found: C, 50.6; H, 
7.3; N, 12.5. Calc, for C 14H 24CIN3O4 : C, 50.4; H, 7.25; N, 12.6%); m/z (Found: 
[M + H]+, 334.1539. Calc, for C 14H 2535CIN3O4 : 334.1536); [ a g  -20.3 (c 0.2 in 
MeOH); (Nujol)/cm-> 3209 (NH), 1728 (carbamate CO), 1687 (methylamide 
CO) and 1652 (tertiary amide CO); 5h (200 MHz; C^HCl,) 1.47 (f, 9H, s, ClCHsls),
1.51 (c, 9H, s, C(CH3)s), 1.60 (c, 3H, d, J  6 .6 , CHCÏÏ3 ), 1.65-2.48 (t & c, 4H, m, 
7 CH2 and pCHz), 1.65 (f, 3H, d, J  6 .6 , CHCH3 ), 3.11 (t, 3H, s, NCH3), 3.13 (c, 3H, s, 
NCH3), 3.57 (t & c, IH, m, iSCHj), 3.89 (t & c, IH, m, jSCH ;), 4.49 (f & c, IH, q, 
76 .8 , CHCH3), 4.96 (t & c, IH, dd, 7, 4.2, 7% 7.8, aCH ) and 7.92 (f & c, IH, s, NH); 
5c (50.31 MHz; C^HCb) 20.75 (c, CHCH3), 21.05 (r, CHÇH3), 22.37 (c, 7CH 2), 
24.71 (f, 7CH2), 28.03 (c, C(CH 3)3), 28.39 (t, ClCHsls). 31.37 (c, PCH2 ), 35.17 
((, NCH 3), 36.05 (c, NCH3), 47.37 (c, 6 CH2), 47.50 (t, 6 CH2), 51.15 (t, C H C H 3),
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53.86 {c, ÇHCH 3), 57.25 ( f ,  aC H ), 58.02 (c. aC H ), 81.38 (t & c, £ ( ^ 3)3), 155.17 
{t & c, C O fB u), 167.95 {t & c, ÇONCH3) and 173.86 {t & c, ÇOCHCH3); m/z  (CI) 
334 ([M + H]+, 41%), 300 (11, [M - Cl + 2H]+), 278 (100, [M - C(CH3)3 + 2H]+), 234 
(12, [M - COaC(CH3)3  + 2H]+), 219 (11, [M - NHC0 2 C(CH3)3 + 2H]+) and 185 (8 , 
[M - Cl - CH3 - C0 2 C(CH3)3 + 3H]+).
(4iî, 9a5)-2,4-Dimethyl-2,3,7,8,9,9a-hexahydropyrrolo-[2,l“d]-l,2,5-[6H]- 
triazepine-l,5-dione (102)
2 N—CH3
NH
Hydrogen chloride gas was bubbled through a solution of A^-rer/-butoxycarbonyl-A^- 
(A^-(25')-chloropropanoyl-(25)-prolyl)-A^^-methylhydrazine (98) (1.35 g, 5 mmol) in 
ethylacetate (30 cm^) for 20 min at 0 °C. The solvent was then removed under 
reduced pressure and the resultant hygroscopic white solid dissolved in methanol 
(25 cm^) and A^-methylmorpholine (1.12 cm^, 10 mmol) added. The solvent was then 
removed under reduced pressure and the remaining residue dissolved in water and 
extracted with ethyl acetate (3 x 30 cm^). The combined organic fractions were then 
dried (MgS0 4 ) and the solvent removed under reduced pressure to yield an off-white 
solid which was purified by silica chromatography using ethyl acetate/ methanol 
(95:5) as the eluent to give the product as a white solid (0.61 g, 62% ), 
m.p. 108-10 °C; m/z  (Found: M+, 197.1159. Calc, for C9H15N3O2: 197.1163);
-82.6 (c 0.5 in MeOH); Umax (Nujol)/cm-^ 3336 & 3215 (NH), 1655 (tertiary 
amide CO) and 1641 (secondary amide CO); bn (200 MHz; C2HCI3) 1.66 (3H, d, 
7 6 .6 , CHCH3), 1.83-2.36 (4H, m, 7CH2 and PCH2), 3.18 (3H, s, NCH3), 3.76 (2H, 
m, ÔCH2), 4.54 (IH , q, J  6 .6 , CHCH 3) and 5.48 (IH , dd, Ji  4.6, J 2  8.0, ocCH); 
ÔC (50.31 MHz; C^HC^) 21.14 (CH CH 3), 25.28 (7CH2), 29.69 (PCH2), 39.25 
(NCH3), 47.89 (ÔCH2), 51.97 (ÇHCH3), 57.54 (aCH), 167.80 (ÇONCH3) and 174.08 
(ÇOCHCH3 ); m/z (El) 197 (M+, 15%), 182 (9, [M - CH3]+), 153 (17, [M - CH3 - 
NCH3]+), 139 (5, [M - NHNCH 3 - CH3 + H]+), 127 (15, [M - CHCH3NHNCH3 + 
2H]+) and 70 (100, [C4HgN]+).
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(45, 9a5)-2,4-Dimethyl-2,3,7,8,9,9a-hexahydropyrrolo-[2,l-d]-l,2,5-[6H]-
triazepine-l,5-dione (103)
This compound was prepared in a manner identical with that for the (4R, 9a5) 
diastereomer (102), starting from A/'-ferf-butoxycarbonyl-T/-(A^-(2J?)-chloropropanoyl- 
(25)-prolyl)“A ^-m ethy lhydrazine  (9 9 ) (1.35 g, 5 mmol) instead of N-tert- 
butoxycarbonyl-A/'-(A^-(25)-chloropropanoyi-(25)-prolyl)-A^-methyIhydrazine (98) to 
give the product as a white solid (0.63 g, 64%), m.p. 112-15 °C; m/z (Found: M+, 
197.1159. Calc, for C9 H 15N 3O2 : 197.1163); [ a f  -119.4 (c 1.0 in M eOH); 
Umax (Nujol)/cm-^ 3299 & 3210 (NH), 1652 (tertiary amide CO) and 1634 (secondary 
amide CO); Ôh (200 MHz; C2HCI3) 1.57 (B, 3H, d, 7 6 .6 , CHCH3), 1.62 (A, 3H, d, 
7 6 .8 , CHCH3), 1.78-2.34 (A & B, 4H, m, 7CH2 and PCH2), 3.14 (A, 3H, s, NCH3), 
3.18 {B, 3H, s, NCH 3), 3.59 (A & B, IH, m ,j0 CH2), 3.92 (A & B, IH, m, ÎÔCH2),
4.48 (A & B, IH, 7 6.7, CHCH3), 5.40 (A, IH, dd, 7i 4.4, J2 7.8, aCH) and 5.42 {B, 
IH, dd, 7i 4.4, 72 8 .6 , aCH); ôc (50.31 MHz; C^HCls) 21.03 (A, CHÇH3), 21.14 (B, 
CHÇH3), 22.69 (J5, 7CH2), 25.03 (A, 7CH2), 29.42 (A, PCH]), 32.09 (5 , pCHi), 38.69 
(A, NCH 3), 39.21 (B, NCH3), 47.84 (A &B, ÔCH2), 51.62 (A .ÇH CH 3 ), 51.71 (B, 
ÇHCH3), 57.40 (A, aCH), 58.40 (B, aC H ), 167.49 (A, ÇOCHCH3), 168.33 (5 , 
COCHCH3), 173.45 (A, ÇONCH3) and 173.92 (5, ÇONCH3); m/z (El) 197 (M+, 5%), 
182 (19, [M - CH3]+), 153 (7, [M - CH3 - NCH3]+), 139 (6 , [M - NHNCH3 - CH 3 + 
H]+), 127 (23, [M - CHCH3NHNCH3 + 2 H]+), 97 (37, [C4HgNC0 ]+) and 70 ( 1 0 0 , 
[C4 HgN]+).
A^-PropionyI-(2S)-proline methylamide (104)
This com pound was prepared in a m anner identical with that for the 
A^-benzyloxycarbonyl-(25)-alanyl-(25)-proline methylamide (75), starting from the 
iV-propionyl-(25)-proline methyl ester (0.93 g, 5 mmol) instead of iV-benzyloxy- 
carbonyl-(25)-alanyl-(25)-proline methyl ester (58) to give the product as a waxy 
white solid (0.90 g, 98%), m.p. 49-52 °C; (Found: C, 58.65; H, 8.7; N, 15.35. Calc, 
for C9H 16N 2O2 : C, 58.65; H, 8.75; N, 15.2%); [ a g  -83.1 (c 1.0 in MeOH); 
t^ max (thin fllm)/cm'^ 3311 (NH), 1662 (secondary amide CO) and 1637 (tertiary 
amide CO); 0h(200 MHz; C^HCls) 1.08 (c, 3H, t, 7 8.0, CH2CH3), 1.11 (f, 3H, t, 
7 7.8, CH2CH3), 1.66-2.48 {t & c, 4H, m, 7 CH2 and PCH2), 2.72 (r, 3H, d, 7 4.8, 
NCH3), 2.80 (c, 3H, d, 74.8 , NCH3 ), 3.38 (t & c, IH, m^0 CH2), 3.50 (t & c, IH, m, 
ÎÔCH2 ), 4.29 (c, IH, dd, 7i 5.2, J2 5.8, aC H ), 4.52 (f, IH, dd, 7j 3.4, J2 6 .6 , aC H ), 
6.57 (c, IH, br, NH) and 7.18 (r, IH, br, NH); ôc (50.31 MHz; C2 HCI3) 21.14 (t.
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CH2CH 3), 8.77 (c, CH2CH3 ), 22.52 (c, 'yCH2), 24.56 {t, 7CH2 ), 25.82 (t, ÇH 2CH 3), 
26.02 (c, CH2CH3), 27.14 (c, NCH3), 27.43 (t, NCH3), 28.61 (t, pCHj), 31.98 (c, 
PCH2), 46.55 (c, 8 CH2), 47.12 (t, 8CH2), 59.71 (f, aCH ), 60.61 (c, aC H ), 172.49 (t, 
CONCH3 ). 172.79 (c , ÇONCH3), 173.03 (c , COCH2) and 173.21 (t, COCH2); 
m/z (El) 184 (M*, 10%), 171 (27, [M - CH3 + 2H]+), 154 (63, [M - NHCH3]+), 140 
(55, {M - NHCH3 - CH3 + H]+), 126 (82, [M - CH2CH3 - NHCH3 + H]+) and 70 ( 1 0 0 , 
[C4HgN]+).
(4ff, 9a5)-2,4-Dimethyl-3-phenylthlocarbaniyl-2,3,7,8,9,9a-hexahydropyrralo- 
[2,l-d]-l,2,5-[6H]-triazepine-l,S-dione (108)
^N-CHa 
CH3 1
To a solution of (4/?, 9a5)-2,4-dimethyI-2,3,7,8,9,9a-hexahydropyrroio-[2,l-d]-l,2,5- 
[6H]-triazepine-l,5-dione (102) (0.39 g, 2 mmol) in methanol (10 cm^) was added 
phenyl w<9-thiocyanate (1.35 g, 10 mmol). The resultant solution was stirred at 40 °C 
for 3 h and the solvent then removed under reduced pressure to give a yellow oil. The 
crude material was purified by silica column chromatography using ethyl acetate as 
the eluent to give the product as a white solid (0.51 g, 76%), m.p. 100-3 °C; 
m/z (Found; [M + H]+, 333.1393. Calc, for C 16H 21N4O 2S: 333.1385); [ a f  +29.2 
(c 1.0 in MeOH); Dmax (N ujol)/cm -i 3210 (NH), 1675 (methylamide CO), 1638 
(tertiary amide CO) and 1597 (thiourea CS); ôn (200 MHz; C^HClg) 1.66 (3H, d, 
7 6 .6 , CHCH3), 1.83-2.36 (4H, m, 'YCH2 and PCH2), 3.18 (3H, s, NCH3), 3.35 (IH , 
m, Ï8 CH2), 3.52 (IH , m ,i5 CH2 ), 4.18 (IH , q, /  6 .6 , C H C H 3), 4.57 (IH , dd, 
J\ =72 7.0, aC H ), 6.92 (3H, m, aromatic), 7.42 (2H, d, 7 10.5, ortho aromatic) and 
8.28 (IH , s, NH); ô c (50.31 MHz; C % C l3) 20.80 (CHÇH3), 25.85 (7CH 2), 29.33 
(PCH2), 35.58 (NCH3), 48.02 (ÔCH2 ), 51.51 (ÇHCH3), 57.09 (aC H ), 124.82 {ortho 
aromatic), 126.56 (para aromatic), 129.07 (meta aromatic), 138.88 (quat. aromatic),
168.43 (ÇONCH3), 174.45 (COCHCH3) and 182.07 (CS); m/z (Cl) 333 ([M + H]+, 
15%), 245 (10, [M - NHCS - CH3 - CH3 + 2H]+), 154 (6 , [M - PhNHCSN2CH 3 + 
H]+), 137 (9, [PhNHCHS]+), 127 (7, [M - CHCH3NHNCH3 + 2H]+) and 94 ( 1 0 0 , 
[PhNH3]+).
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(10aS)-2-Methyl-2,3,4,5,8,9,10,10a-octahydropyrrolo-[2,l-d]-l,2,5-triazocine-l,6-
dione (109)
8
NHO
This com pound was prepared in a m anner identical w ith that for the 
h ex ah y d ro p y rro lo -[2 ,l-d ]-l,2 ,5 -[6 H ]-tria zep in e -l,5 -d io n e  (91), using N-tert- 
butoxycarbonyhjV-(N-3-chloropropanoyl-(25)-prolyl)-jV-methylhydrazine (111) 
(1.67 g, 5 mmol) instead of iV-?err-butoxycarbonyl-A^-(A^-chloroacetyl-(25)-prolyl)- 
A^-methylhydrazine (89) to give the product as a white solid (0.58 g, 60%), 
m.p. 129-32 °C; m/z (Found: [M + H]+, 198.1241. Calc, for C9 H 16N 3 O2 : 198.1243); 
[a]^P -93.2 (c 1.0 in MeOH); D^ax (Nujol)/cm*^ 3380 (NH), 1655 (methylamide CO) 
and 1640 (tertiary amide CO); 0h (200 MHz; OHCI3) 1.73-2.30 (4H, m, 7CH2 and 
PCH2), 2.79 (2H, t, J  7.0, CH2NH), 3.14 (3H, s, NCH3), 3.49-3.98 (4H, m, ÔCH2 and 
COCH2), 3.94 (IH , br, NH) and 5.42 (IH , dd, Ji  4.0, J2  7.8, aCH ); 5c (50.31 MHz; 
C2HCI3) 24.92 (7CH2), 25.35 (PCH2), 38.04 (CH2NH), 39.61 (NCH 3), 39.97 
(COÇH2), 48.07 (ÔCH2), 57.13 (aC H ), 168 82 (ÇONCH3) and 174.22 (ÇO CH 2); 
m/z (FAB) 198 ([M + H]+, 53%), 170 (38, [M - NCH3 + 2H]+), 154 (37, [M - 
NHNCH3 + H]+), 142 (73, [M - NCH 3NHCH2 + 3H]+), 126 (54, [M - 
NCH3NHCH2CH2 + H]+) and 70 (100, [C4HgN]+).
A-/ert-Butoxycarbonylr/V'-(A^-3-chloropropanoyl-(25)-prolyl)-7V- 
methylhydrazine (1 1 1 )
This com pound was prepared in a m anner identical w ith that for N-tert- 
butoxycarbonyl-A-(A-(25)-chloropropanoyl-(25)-prolyl)-77-methylhydrazine (98), 
using A-3-chloropropanoyl-(25)-proline (110) (2.06 g, 10 mmol) to give the product 
as a white solid (2.93g, 88%), m.p. 108-11 °C; m/z (Found: [M + H]+, 334.1537. Calc, 
for C 14H 2535CIN3O4 : 334.1536); [a]g^-21.7 (c 1.0 in MeOH); (Nujol)/cm-i 3221
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(NH), 1733 (carbamate CO), 1684 (methylamide CO), 1632 (tertiary amide CO) and 
665 (C-Cl); 5h (200 MHz; C^HClj) 1.44 (9H, s, C ICH ;);), 1.72-2.31 (4H, m, 7CH 2 
and PCH2), 2.78 (2 H, t, J  7.5, CH2CI), 3.05 (3H, s, NCH3), 3.49 (IH , m, jSCH 2 ), 
3.62 (IH , m, ïSCH j), 3.76 (2H, m, COCH2 ), 4.97 (IH , dd, 7, 5.2, J 2  6.4, otCH) and
8.43 (IH , s, NH); §c (50.31 MHz; C^HCls) 24.37 (7 CH2), 28.14 (PCH 2 ), 28.38 
(C(CH3)3), 34.87 (NCH3 ), 47.59 (8 CH2), 56.98 (aC H ), 81.48 (C(CH3)3), 154.92 
(C0 2 ‘Bu), 168.58 (ÇONCH3) and 173.71 (COCH2); m/z (FAB) 334 ([M + H]+, 36%), 
298 (21, [M - Cl]+), 288 (67, [M - CH2CI + 2H]+), 278 (35, [M - C(CH3)3 + 2H]+), 
188 (6 8 , [M - NCH3NHC0 2 C(CH3)3]+), 70 (98, [CaHgNl^) and 57 (100, [C(CH3)3 ]+).
(4/Ü, 9a5)-2,4-Dimethyl-3-(iV-benzyloxycarbonyl-(25)-phenylalanyI)-2,3,7,8,9,9a- 
hexahydropyrrolo-[2,l-d]-l,2,5-[6H]-triazepine-l,5-dione (114)
^N~CH3 
CHa T ur-oo
This com pound was prepared in a m anner identical w ith that for N-tert- 
butoxycarbonyl-A-(A^-chloroacetyl-(25)-prolyl)-A-methylhydrazine (8 9 ), using 
A^-benzyloxycarbonyl-(25')-phenylalanine (1 1 3 )  (1.50 g, 5 mm ol) instead of 
A^-chloroacetyl-(25)-proline (8 8 ) and {AR, 9a5)-2,4-dimethyl-2,3,7,8,9,9a-hexahydro- 
pyrrolo-[2 ,l-d]-l,2 ,5-[6H ]-triazepine-l,5-dione (102) (1.99 g, 5 mmol) instead of 
7/-fgrf-butoxycarbonyl-jV-methylhydrazine (87). The crude material was purified by 
silica column chromatography using ethyl acetate/ light petroleum (7:3) as the eluent 
to give the product as a white solid (1.96 g, 82%), m.p, 82-5 °C; m/z  (Found: 
[M + H]+, 479.2282. Calc, for C26H31N4 O5 : 479.2294); [a%  +0.8 (c 1.0 in MeOH); 
Dmax (Nujol)/cm-^ 3270 (NH), 1717 (carbamate CO), 1695 (methylamide CO), 1659 
(secondary amide CO) and 1645 (tertiary amide CO); 5^ (200 MHz; C^HClg) 1.59 
(3H, d, J  6 .6 , CHCHs), 1.68-2.35 (4H, m, 7 CH2 and PCH2), 2.89 (3H, s, NCH3), 3.09 
(2H, d, J  7 ,6 ,^ H C H 2Ph), 3.14 (2H, d, J  7 .0 ,iCH CH 2Ph), 3.56 (2H, m, 8 CH2), 4.44 
(IH , dd, Jx 7.4, J2  8 .8 , aCH ), 4.47 (IH , q, J  6 .6 , CHCH3), 4.70 (IH , m, CHNH), 5.08
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(2H, d, J  2,2, OCHzPh), 5.51 (IH , d, J  7.2, NH), 7.22 (5H, m, aromatic, CHCHjPh) 
and 7.32 (5H, s, aromatic, OCHzPh); 8c(50.31 MHz; C^HCls) 21.15 (CHÇH;), 25.37 
(7 CH 2), 29.21 (PCH2 ), 35.66 (CHÇH 2PI1), 38.66 (NCH3), 47.90 (8 CH2), 51.99 
(CHCH3), 55.46 (CHNH), 57.13 (aC H ), 67.60 (OCH2Ph), 127.75 (para aromatic),
128.51 (ortho  aromatic) 128.72 (para aromatic), 129.07 (ortho aromatic), 129.30 
(meta  aromatic), 129.96 (ortho aromatic), 136.37 (quat. aromatic), 136.72 (quat. 
aromatic), 156.53 (CONH), 168.26 (ÇONCH 3), 170.90 (ÇOCHCH3) and 173.65 
(EOCHCHîPh); m/z (Cl) 513 ([M + 2 NH3 + H]+, 100%), 479 (19, [M + H]+), 403 (3, 
[M - Ph + H]+), 345 (3, [M - CO2CH2PI1 + 2H]+), 295 (4, [M - 0 CH2Ph - Ph + H]+), 
254 (5, [M - NHCO 2CH 2PI1 - Ph + 3H]+) and 181 (32, [M - COCHCH2 Ph - 
NHC0 2 CH2P h - CH3]+).
Af-Dimethoxyacetyl-(2S)-proline methyl ester (118)%0CH3o
0C H 3
This compound was prepared in a manner identical with that for 7/-bromoacetyi-(25)- 
proline methyl ester (38), using 2,2-dimethoxy-glyoxylic acid (117) (1.20 g, 
10 mmol) instead of bromoacetic acid (37) to give a yellow oil which was purified by 
silica chromatography using ethyl acetate/ light petroleum ( 1 :1) as the eluent to give 
the product as a clear oil (2.10 g, 91%), m/z (Found: [M + H]+, 232.1181. Calc, for 
CioHigNO,: 232.1184); [ a ]g  -73.7 (c 1.0 in MeOH); Umax(Nujol)/cm ' 1748 (ester 
CO), 1659 (amide CO) and 1438 (acetal C-O); 8 „ (200 MHz; C^HCls) 1.76-2.22 
(t & c, 4H, m, PCH2 and 7CH 2 ), 3.27 (c, 3H, s, CHOCH3), 3.32 (c, 3H, s, CHOCH3), 
3.38 (t, 6 H, s, CH(OCH3)2 ), 3.47-3.76 (t & e, 2 H, m, 8 CH2 ), 3.66 (t & c, 3H, s, 
CO2CH 3), 4.44 (t, IH, dd, Jx 4.3, J 2  6.1, aCH ), 4.62 (c, IH, s, CH(OCH3)2), 4.74 (c, 
IH , dd, Jx 2.1, J2  10.1, aC H ) and 4.78 (t, IH , s, CE(O CH 3)2); 8 c (50.31 MHz; 
C2HCI3) 21.49 (c, 'VCH2), 25.18 (t. -yCH2), 28.73 (t, PCH2), 31.33 (c, PCH2), 46.62 (f, 
8 CH2 ), 46.84 (c, 8 CH2 ), 52.12 (t & c, CO2CH3), 53.45 (t, CHOÇH 3), 54.07 (c, 
CHOCH3), 54.12 (f, CHOCH3), 54.53 (c, CHOCH3), 58.70 (c, aCH ), 59.16 (t, aCH ),
100.34 (t, £H (0 CH3)2 ), 102.28 (c, £H (OCH 3)2 ), 165.76 (t, £OCH(OCH 3)2 ), 165.87 
(c, C 0 CH(0 CH 3)2 ), 172.45 (t, Ç O 2CH 3) and 172.96 (c, £ 0 2 CH 3); m/z (Cl) 232 
([M + H]+, 6 8 %), 200 (100, [M - OCHsl^), 172 (49, [M - COzCHjl+l, 128 (6 , [M - 
COCH(OCH3)2]+) and 75 (52, [CH(OCH3)2]+).
160
A?^-Dichloroacetyl-(2S)-proline (122)
OH
Cl
Cl
To a stirred suspension of (25)-proline (46) (1.15 g, 10 mmol) in dry diethyl ether 
(100 cm^) containing solid sodium hydrogen carbonate (5.0 g) was added drop wise 
dichloroacetyl chloride (1.48 g, 10 mmol) at 0 °C. The reaction mixture was stirred 
for 30 min at room temperature, filtered and the solvent removed under reduced 
pressure to give a white solid which was recrystallised from diethyl ether/ light 
petroleum to give the product as colourless crystals (1.43 g, 63%), m.p. 133-5 °C; 
(Found: C, 37.3; H, 3.9; N, 6.15. Calc, for C7H9CI2NO3: C, 37.3 H, 4.05; N, 6.2%); 
m/z (Found: [M + H]+, 226.0043. Calc, for CvHio^^CFNOs: 226.0038); [a]22-84.3 
{c 1.0 in MeOH); Umax (Nujol)/cm-^ 1718 (acid CO), 1624 (amide CO) and 677 
(C-Cl); ÔH (200 MHz; afg-DMSO) 1.68-2.36 (f & c, 4H, m, pCHa and 7 CH2), 
3.31-3.80 {t & c, 2H, m, ÔCH2), 4.28 (f, IH, dd, Ji  3.8, J2 8 .8 , aCH), 4.67 (c, IH, dd, 
7i 2.9, 7 2 6 . 1 , aC H ), 6.72 (c, IH , s, CHCI2 ) and 6.91 {t, IH , s, C H C y ; 
6 c (50.31 MHz; (/^-DMSO) 21.84 (c, "^CH:), 24.72 (f, 7 CH2), 28.85 (f, PCH2), 30.63 
(c, PCH2), 47.11 (t & c, ÔCH2), 59.41 (c, aC H ), 59.80 (f, aCH ), 66.18 (c, CHCH),
66.43 (f, CHCI2), 161.65 (t, ÇOCHCI2), 162.47 (c, COCHCI2 ) and 172.65 (t & c, 
CO 2H); m/z (Cl) 226 ([M + H]+, 100%), 208 (7, [M - 0H]+), 190 (13, [M - Cl]+), 180 
(14, [M - C0 2 H]+), 156 (7, [M - 2 C1 + H]+), 1 1 2  (16, [COCHC^r and 70 (43, 
[C4 HgN]+).
A^-Crotonyl-(2S)-proline (125)
H3C
To a vigorously stirred solution of (25)-proline (46) (1.27 g, 11 mmol) in sodium 
hydroxide solution (80 cm^, 5% w/v) was added dropwise fra/zj-crotonyl chloride 
(124) (1.05 g, 10 mmol) at 0 °C. The reaction mixture was allowed to warm to room 
temperature and stirred for 1 h, before being acidified to pH 1 with concentrated HCl.
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The resulted solution was extracted with ethyl acetate (3 x 30 cm^), dried (MgS0 4 ) 
and the solvent rem oved under reduced pressureto  give a w hite solid. 
Recrystallisation from ethyl acetate gave the product as colourless crystals (1.17 g, 
64%), m.p. 161-3 °C; (Found: C, 59.2; H, 7.2; N, 7.55; M+, 183.0893. Calc, for 
C9H 13NO 3 : C, 59.0; H, 7.15; N, 7.65%; M+, 183.0895); [ a g  +99.3 {c 1.0 in MeOH); 
Umax (Nujol)/cm-i 1713 (acid CO), 1659 (amide CO) and 1583 (C=C); 0h(200 MHz; 
C2HC13) 1.93 (3H, dd, 7i 1.6, J2  7.1, CHCH3), 1.95-2.12 (3H, m, 1C H 2 and iPCH j), 
2.10-2.45 (IH , m, 1PCH2), 3.45-3.85 (2H, m, 6 CH2 ), 4.47 (IH , dd, 7% 3.3, J2  7.9, 
aC H ), 6.34 (IH , dd, 7i 1 .6 , J 2  15.0, CHCHCH3), 6.87 (IH , dd, 7 i 7.1, J2  15.0, 
CHCH3) and 10.4 (IH , s, CO2H); 6 c (50.31 MHz; C^HClg) 18.60 (CHÇH3), 26.02 
(7 CH 2 ), 30.61 (PCH2), 48.51 (6 CH2), 60.67 (aC H ), 124.03 (ÇHCHCH 3), 143.89 
(ÇHCH3), 167.38 (NÇO) and 175.91 (CO2H); miz (El) 183 (M+, 3%), 138 (40, [M - 
C 0 2 H]+), 124 (39, [M - CH3CH=CH - OH + H]+), 96 (19, [C4H?NCO]+) and 70 (100, 
[C4HgN]+).
iV-Crotonyl-(25)-proline m ethyl ester (126)
A boron trifloride methanol (BF3 .MeOH) complex (22 cm^, 100 mmol) was added to 
A-crotonyl-(25')-proline (125) (3.66 g, 20 mmol) and the resultant solution refluxed 
for 2  h, and cooled before the addition of a saturated solution of NaHC0 3  (82 cm^). 
The reaction mixture was then extracted with diethyl ether (3 x 50 cm^), dried 
(MgS0 4 ) and the solvent removed under reduced pressure to give the product as a 
clear oil (2.87 g, 73%), m/z (Found: [M + H]+, 198.1127. Calc, for C 10H 16NO3 : 
198.1130); [ a ] ^  -113.7 (c 1.0 in MeOH); Umax (thin film)/cm't 1746 (ester CO), 1666 
(amide CO) and 1620 (C=C); 6 h (200 MHz; C^HCh) 1.82 (3H, dd, 7i 1.6, J2 7.0, 
CHCH3), 1.85-2.22 (4H, m, 7CH 2 and PCH2), 3.48-3.61 (2H, m, ÔCH2), 3.67 (3H, s, 
OCH3), 4.48 (IH , dd, 7i 3.5, J 2 7.6, aCH ), 6.09 (IH , dd, 7% 1 .6 , J2  15.0, CHCHCH3) 
and 6.90 (IH , dq, 7i 7.0, J2  15.0, CHCH3); 6 c  (50.3 MHz; C2HCI3) 18.45 (CHCH3), 
25.17 (7 CH2), 29.48 (P C H 2 ) , 47.19 (ÔCH2 ), 52.47 (O C H 3 ) , 59.13 (aC H ), 122.77 
(ÇHCHCH3 ), 142.42 (CHCH3), 164.16 (NCO) and 173.22 (ÇO2CH3 ); m/z (Cl) 198 
([M +H ]+, 100%), 184(13, [M -C H 3 + 2 H M , 166(18, [M - OCHgJO, 138 (27, [M - 
C0 2 CH 3]+) and 70 (7, [C4HgN]+).
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Appendix 1
Solid-phase peptide synthesis
The peptides were prepared using a Rainin PS3 automated solid phase peptide 
synthesizer. The resin (Wang-type) and all amino acids (Fmoc protected) were 
purchased from Novabiochem Ltd. PyBOP was used as the coupling reagent and was 
also purchased from Novabiochem. Piperazine in DMF (20%, v/v) was used as the 
deprotection solution and NMM in DMF (0.4 mol dm-3) was used as the activation 
solution. The peptides were prepared on a 0.1 mmol scale with coupling times o f 60 
min used throughout the syntheses. Double couplings were carried out for difficult 
amino acids (Pro, Val, Asn).
The peptides were cleaved from the resin using a mixture of TFA, water and anisole 
(95: 2.5: 2.5 respectively) and left for 6  h at 25 °C. To ensure complete removal of 
non-polar contaminants, the peptides were dissolved in water and acetic acid ( 2 0  cm^, 
9:1) and washed with ethyl acetate (2 x 10 cm^), CH2CI2 (10 cm^) and diethyl ether 
(10 cm3). The aqueous phase was then lyophilized under high vacuum and the dry 
peptides stored at -20 °C.
The purity of the peptides was checked by HPLC. The dry peptide (1 mg) was 
dissolved in water (1  cm^), filtered and injected ( 1 0  jil) onto a C^g column 
equilibrated with water containing TFA (0,1%). The peptides were eluted with 
0-60% acetonitrile over 30 min and monitored at 214 nm.
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Appendix 2
NMR and CD analysis of oligopeptides
NMR spectra were recorded on a Varian VXR6005 600 MHz spectrometer at the 
Edinburgh University Ultra-high field NMR centre. All experiments were performed 
on solutions of 1 0  mg of peptide in 1 cm^ of solvent.
The CD experiments were carried out by Dr. Nick Price and Ms. Sharon Kelly at the 
BBSRC service centre in the departm ent o f biom olecular sciences, Stirling 
University. The machine used was a JASCO J-600 spectropolarimeter and the cell 
path length was 0.02 cm. All experiments were performed at 37 °C on solutions of 
0.5 mg of peptide in 1 cm^ of solvent.
164
Appendix 3
Crystallography data
Table 3 .1 : Bond lengths (Â) and angles (°)for (48)
Br-C(2) 1.963(6) N-C(4) 1.458(8)0(1)-C(3) 1.211(7) C(l)-C(2) 1.485(10)0(2)-C(8) 1.175(8) C(2)-C(3) 1.529(8)0(3)-C(8) 1.334(7) C(4)-C(5) 1.500(10)0(3)-C(9) 1.428(8) C(5)-C(6) 1.443(12)N-C(3) 1.346(7) C(6)-C(7) 1.518(9)N-C(7) 1.453(7) C(7)-C(8) 1.521(9)
C(8)-0(3)-C(9) 116.1(5) N-C(4)-C(5) 102.0(5)C(3)-N-C(7) 117.8(5) C(6)-C(5)-C(4) 108.4(6)C(3)-N-C(4) 128.3(5) C(5)-C(6)-C(7) 105.9(6)C(7)-N-C(4) 113.1(5) N-C(7)-C(6) 103.7(5)C(l)-C(2)-C(3) 113.9(6) N-C(7)-C(8) 111.7(5)C(l)-C(2)-Br 110.0(5) C(6)-C(7)-C(8) 112.4(6)C(3)-C(2)-Br 107.1(4) 0(2)-C(8)-0(3) 124.3(6)0(1)-C(3)-N 121.5(5) 0(2)-C(8)-C(7) 126.0(6)0(l)-C(3)-C(2) 120.2(5) 0(3)-C(8)-C(7) 109.6(5)N-C(3).C(2) 118.3(5)
Table 3.2: Bond lengths (A) and angles (°)for (81)
0(1)-C(1) 1.318(2) C(2)-C(3) 1.538(2)0(2)-C (l) 1.210(2) C(3)-C(4) 1.521(3)0(3)-C(6) 1.251(2) C(4)-C(5) 1.524(2)N-C(6) 1.334(2) C(6)-C(7) 1.478(2)N-C(2) 1.462(2) C(7)-C(8) 1.312(2)N-C(5) 1.478(2) C(8)-C(9) 1.492(2)C(l)-C(2) 1.522(2)
C(6)-N-C(2) 120.28(11) C(4)-C(3)-C(2) 103.95(12)C(6)-N-C(5) 127.63(11) C(3)-C(4)-C(5) 103.58(13)C(2)-N-C(5) 112.08(11) N-C(5)-C(4) 102.99(12)0 (2 )-C (l)-0 (l) 124.52(13) 0(3)-C(6)-N 119.47(12)0(2)-C(l)-C(2) 121.43(13) 0(3)-C(6)-C(7) 122.31(12)0(1)-C(1)-C(2) 113.94(12) N-C(6)-C(7) 118.22(12)N-C(2)-C(l) 113.59(11) C(8)-C(7)-C(6) 122.08(13)N-C(2)-C(3) 103.80(11) C(7)-C(8)-C(9) 125.9(2)C(l)-C(2)-C(3) 110.88(12)
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Table 3.3: Bond lengths (Â) and angles (°)for (82)
0(01)-C(01) 1.224(2) C(03)-C(04B) 1.433(5) N(2)-N(3) 1.421(2)0(02)-C(06) 1.238(2) C(04A)-C(05) 1.460(5) N(2)-C(7) 1.455(3)N(01)-C(02) 1.491(2) C(04B)-C(05) 1.535(5) N(2)-C(8) 1.456(3)N(01)-C(05) 1.476(2) C(06)-C(07) 1.510(3) N(3)-C(l) 1.326(3)N(01)-C(06) 1.330(2) O(02)-H(3) 2.01(3) C(l)-C(2) 1.520(3)N(02)-N(03) 1.428(2) N(03)-H(03) 0.87(2) C(2)-C(3) 1.524(3)N(02)-C(07) 1.449(2) 0(1)-C(1) 1.224(2) C(3)-C(4) 1.517(3)N(02)-C(08) 1.460(2) 0(2)-C(6) 1.243(2) C(4)-C(5) 1.507(3)N(03)-C(01) 1.336(2) N(l)-C(2) 1.490(2) C(6)-C(7) 1.508(3)C(01)-C(02) 1.522(3) N(l)-C(5) 1.471(3) O(2)-H(03) 2.02(2)C(02)-C(03) 1.517(3) 
C(03)-C(04A) 1.529(5)
N(l)-C(6) 1.329(2) N(3)-H(3) 0.89(3)
C(06)-0(02)-H(3) 128.8(7) C(6)-O(2)-H(03) 130.3(6)C(06)-N(01)-C(05) 120.1(2) C(6)-N(l)-C(5) 120.3(2)C(06)-N(01)-C(02) 128.8(2) C(6)-N(l)-C(2) 129,2(2)C(05)-N(01)-C(02) 110.73(15) C(5)-N(l)-C(2) 110.6(2)N(03)-N(02)-C(07) 110.23(14) N(3)-N(2)-C(7) 109.74(14)N(03)-N(02)-C(08) 109.1(2) N(3)-N(2)-C(8) 109.0(2)
C(07)-N(02)-C(08) 112.85(15) C(7)-N(2)-C(8) 113.6(2)H(03)-N(03)-C(01) 121.6(14) H(3)-N(3)-C(l) 120.6(16)H(03)-N(03)-N(02) 113.7(14) H(3)-N(3)-N(2) 119.9(16)C(01)-N(03)-N(02) 118.2(2) C(l)-N(3)-N(2) 119.2(2)0(01)-C(01)-N(03) 122.1(2) 0(1)-C(1)-N(3) 122.7(2)0(01)-C(01)-C(02) 123.5(2) 0(1)-C(1)-C(2) 122.7(2)
N(03)-C(01)-C(02) 114.4(2) N(3)-C(l)-C(2) 114.5(2)
N(01)-C(02)-C(03) 103.7(2) N(l)-C(2)-C(l) 111.33(14)
N(01)-C(02)-C(01) 108.84(14) N(l)-C(2)-C(3) 103.49(15)
C(03)-C(02)-C(01) 113.8(2) C(l)-C(2)-C(3) 113.5(2)
C(02)-C(03)-C(04A) 105.9(2) C(4)-C(3)-C(2) 103.9(2)
C(02)-C(03)-C(04B) 106.0(2) C(5)-C(4)-C(3) 103.7(2)
C(03)-C(04A)-C(05) 105.2(3) N(l)-C(5)-C(4) 104.4(2)
C(03)-C(04B)-C(05) 106.2(3) 0(2)-C(6)-N(l) 120.1(2)N(0I)-C(05)-C(04A) 105.5(2) 0(2)-C(6)-C(7) 117.8(2)N(01)-C(05)-C(04B) 100.9(2) N(l)-C(6)-C(7) 122.1(2)0(02)-C(06)-N(01)
0(02)-C(06)-C(07)
N(01)-C(06)-C(07)
N(02)-C(07)-C(06)
120.8(2)
117.3(2)
121.9(2)
115.0(2)
N(2)-C(7)-C(6) 114.7(2)
Table 3.4: Bond lengths (Â) and angles (°) fo r  (117)
0(1)-C(1) 1.216(3) N(3)-C(l) 1.338(2)
0(2)-C(6) 1.235(2) N(3)-H(3) 0.89(2)
N(l)-C(6) 1.337(2) C(l)-C(2) 1.529(3)N(l)-C(5) 1.473(2) C(2)-C(3) 1.529(3)
N(l)-C(2) 1.484(2) C(3)-C(4) 1.474(4)
N(2)-N(3) 1.422(2) C(4)-C(5) 1.492(4)
N(2)-C(7) 1.461(2) C(6)-C(7) 1.526(2)
N(2)-C(9) 1.466(2) C(7)-C(8) 1.527(3)
C(6)-N(l)-C(5) 120.49(15) N(l)-C(2)-C(l) 107.42(14)
C(6)-N(l)-C(2) 128.22(14) N(l)-C(2)-C(3) 103.0(2)
C(5)-N(l)-C(2) 110.90(14) C(l)-C(2)-C(3) 113.9(2)
N(3)-N(2)-C(7) 110.70(13) C(4)-C(3)-C(2) 106.1(2)
N(3)-N(2)-C(9) 107.6(2) C(3)-C(4)-C(5) 105.2(2)
C(7)-N(2)-C(9) 114.1(2) N(l)-C(5)-C(4) 103.6(2)
C(l)-N(3)-N(2) 119.1(2) 0(2)-C(6)-N(l) 120.8(2)
C(l)-N(3)-H(3) 123.4(15) 0(2)-C(6)-C(7) 117.2(2)
N(2)-N(3)-H(3) 117.5(15) N(l)-C(6)-C(7) 121.91(15)
0(1)-C(1)-N(3) 122.6(2) N(2)-C(7)-C(6) 113.99(13)
0(1)-C(1)-C(2) 124.4(2) N(2)-C(7)-C(8) 109.74(15)
N(3)-C(l)-C(2) 112.9(2) C(6)-C(7)-C(8) 105.9(2)
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